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WHO definition of palliative care 
Palliative care is an approach that improves 
the quality of life 
of patients and their families 
facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering 
by means of early identification and impeccable assessment and treatment of 































WHO provides and WHERE?
All medical and non-medical members of 
teams in institutions where incurable 
patients are treated.
Basic palliative care (80% patient):
All levels of health system 
(hospitals, community health centre, at home, senior homes, hospicih...) 
All.
Specialied palliative care (20%): 
Does not substitute basic palliative care, but it upgrade it for the patients with the most 
difficult and complex problems
Specialized teams (acute palliative care departent, mobile PC team)





FAMILY DOCTOR AND 
DISTRIC NURSE
























































































Hui, D. et al. Concepts and definitions for “supportive care,” “best supportive care, ” “palliative care, ” and 






Temel, NEJM 2010 Bakitas, JCO 2015 Murakami BMC Pall 2015





CAN NOT BE TOO EARLY
PALLIATIVE CARE
Is early too early?
PHASES OF DEVELOPMENT:
2. PALLIPHOBIA
3. PALLILALIA 4. PALLIACTIVE
1. DENIAL
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Hope is like the sun, which, as we journey toward it, 
casts the shadow of our burden behind us.





Prof. Renata Dobrila-Dintinjana, MD. PhD.
Damir Vučinić, MD.
Clinical Hospital Center Rijeka
School of Medicine,  University of Rijeka, Croatia
• Monounsaturated fat, n-3 PUFA, and fat soluble vitamins may have a profound 
influence on the prevention and/or suppression of cancer, whereas saturated fat and 
n-6 PUFA may increase the risk of carcinogenesis
• Monounsaturated fat and n-3 fatty acids should be preferred over animal fats and 
other vegetable fats in the diet
• Malnutrition is an important issue in cancer patients, which should be appropriately 
managed by structured collaboration of MDT
• Pharmacological approach (EPA/MA) to the treatment of anorexia cachexia syndrome 
in cancer patients significantly improves QoL and probably prolongs OS
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IMMUNE-RELATED ADVERSE EVENTS OF 
IMMUNE CHECKPOINT INHIBITORS 
Nežka Hribernik, MD
Institute of Oncology Ljubljana 
2nd Summer School in Medical Oncology
September 2021
Possible mechanisms underlying irAE
Postow MA, et al. NEJM 2018
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Martins F, et al. Nature Clinical Oncology Reviews, 2019
Fatal irAE (cont`d)
• Risk of fatality:
– Myocarditis 40% 
– Hypophysitis, adrenal insufficiency, colitis 2 - 5%
– 10 – 17% for other irAEs
– Older patients at higher risk (impared functional reserve, 
comorbidities)
Wang el al. JAMA ONCO 2018
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Management of irAEs
Champiat S et al.  Ann Oncol 2016
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Special populations that are not presented 
in RCT





– PATIENT & PHYSICIAN EDUCATION
– Management protocols




Melanoma patient with multiple irAE
 - clinical case
Side effects of immunotherapy and the management





●Family history: mother had skin cancer
●Comorbidities: arterial hypertension
●Year 2012: presented with skin lesion on her left thigh, changing in colour
– June 2012 – excision: melanoma, Clark IV, Breslow 2,4 mm, no ulceration
– September 2012 – reexcision of tumor bed + SLNB (Institute of Oncology LJ)




 January 2021 progression of disease (DFI: 9 years)
●January 2021: palpable resistance in her left thigh, loss of 6 kg in 1 month, nausea, 
back pain, night sweats
●Diagnostic procedure:
– Lab: LDH 2.66 ukat/L, S-100 1.250 ug/L, CRP 160 mg/L
– Bx of resistance: melanoma metastasis  → BRAF V600E mutation
– PET/CT: high metabolic uptake in the liver, subcutaneous tissue of left thigh, bones (Th 
4,5,8,11, L1,5, sacrum, pubis, scapula, 10th and 5th rib)




●February 2021: started with comboIT ipilimumab 3 mg/kg + nivolumab 1 mg/kg
- Supportive treatment: Zoledronic acid, vitamin D, CaCO3
- No radiotherapy (1 week after 1st infusion her back pain was gone)
●March 2021: increased appetite, no back pain, reduction in size of subcutaneous resistance 
in left thigh --> continues with 2nd infusion of nivo1/ipi3
–Side effects: pruritus grade II (Th: antihistamine)
●April 2021 – early time-point PET/CT (study QTA): PMR in most localisations, S100 
normalized




●End od April 2021 - Regional hospital admission: hepatitis gr. III, diarrhoea gr. I, arthralgia gr.
• Treatment: steroids i.v. (2mg/kg/d)+Pneumocystis prophylaxis, PPI
● In one week no more liquid stools and no more pain in her joints
● regular lab controls - liver transaminases decreased to gr. I
● Tapering of dexamethasone
●End of May 2021: worsening of sympthoms - skin rash around waist, fatigue, transaminitis gr. 
II I, diarrhoea gr. I → again higher dose of steroids p.o. (2mg/kg/d)
●After improvement of lab and sympthoms, SLOW tapering of dexametasone over 5 weeks
●ACTH test!
●Permanently completed IT due to irAE
6 /
●June 2021: PET/CT: complete metabolic response of all metastatic localisations
●July 2021: normal AST/ALT, bili, S100, LDH, CRP
●August 2021: regular check-up, no signs of progression
24
Side effects of chemotherapy and the
management
Tanja Ovčariček
Oncology institute Ljubljana, 2021
Knowing side effects of certain treatment is basic
knowledge every oncologist should have!
 a number of potential side effects 
 Side effects and long term sequelae of 
chemotherapy major source of concern for 
patients 
 Education of patients is important for












Nurgali K, et al. Front.Pharmacol.2018

























After weeks, months, years
- nail changes
- organ failure (heart failure)
- infertility
- teratogeneticy and 
cancerogeneticy
Timing of chemotherapy side effects 
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GASTROINTESTINAL SIDE EFFECTS OF CHEMOTHERAPY 
 Timing of nausea
 Emetogenic potential of chemotherapy/individual risk
 Patophysiology of CINV and drugs used
What should oncologist know about CINV?
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV)
 the most common and feared side-effects among the patients 
 compromise treatment outcomes
Roila F et al, Ann Oncol 2016
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Cht administration Next cht cycle
Acute CINV: up to 24 h
Delayed CINV: more than 24 h after chemotherapy administration
Anticipatory CINV: before next cycle
 in two phases, the acute and the delayed phase:
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV)
Roila F et al, Ann Oncol 2016








































































1. 5HT3 RA acute CINV





Navari RM, et al. NEJM 2016
Antiemetic arsenal:
 5HT3 RA: granisetron, palonosetron, ondasetron
 NK1 RA: aprepitant, fosaprepitant, netupitant
 D2 RA: metoklopramid
 Multiple R: deksamethasone, olanzepin
 CB1: canabinoids
 Other: benzodiazepines
Navari RM, et al. NEJM 2016
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Roila et. Al. Ann Oncol 2016
CLINICAL CASE
 50 years old women with T3N0M0 urothelial bladder cancer, hematuria, no comorbidities
 Treatment plan: neoadjuvant cisplatin-based chemotherapy
 Worried about nausea and vomiting
High risk
(>90 % patients)
 Acute CINV: NK1 RA (aprepitant 125 mg)+5HT3 RA (granisetron 1 mg)+deksamethason
12 mg
 Delayed CINV: aprepitant 80 mg 2.3 D+deksamethason 8 mg 2.-4. d
 Persisting N/V: breakthrough CINV: 




 inflammatory and/or ulcerative lesions of the oral and/or
gastrointestinal tract
 anatomical distribution: oral mucositis (OM),
gastrointestinal mucositis (GIM, diarrhea), and proctitis
 the incidence of clinically significant mucositis has been
reported to range from 40% (standard dose cht), 60–100%
(high-dose cht)
 Predisposing factors: 
 various mucotoxicity for different cht agents: 5-FU,methotrexate, 
irinotecan, cyclophosphamide, cisplatin, anthracyclines and taxanes
 bolus infusion tends to be more toxic
 in general, if a patient develops mucositis in the first cycle of treatment, the 
probability of the condition recurring in a subsequent cycle is high 
Stein et al, 2010, Kwon et al. 2016
ORAL MUCOSITIS
.
 erythema of the movable mucosa which progress to form painful 
ulcerations often covered by a pseudomembrane
 may be associated with microbial colonization that may remain 
localized or become disseminated, especially in patients with 
severe neutropenia-SEPSIS!!
 first signs appear shortly after administration and usually peak at 
about days 7–14, is usually self-limiting
Stein et al, 2010, Kwon et al. 2016, Peterson DE et al, Ann Oncol 2015
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MASCC and ESMO have developed guidelines whith strategies for managing oral mucositis
 effective preventative and treatment strategies are lacking
 Preventative meassurements: Oral health at the start of and during chemotherapy: general hygiene
standards, dental care, normal saline and baking soda-non-alcochol mouthwashes, regular tooth brush,
dietary and behavioral measures
Peterson DE et al, Ann Oncol 2015
 CID is potentially fatal (5%) due dehidration and electrolyte imbalances
 CHT regimens CID: 5-fluorouracil and irinotecan are associated with rates of CID of up to 80% with one 
third of patients experiencing severe (grade 3 or 4) diarrhea, taxanes
 CID:-uncomplicated (grade 1–2 with no complications) or complicated (grade 3–4 with one or more 
complicating signs or symptoms),
-early onset (<24 h after administration, irinotecan) or late onset (>24 h after administration) 
-persistent (present for >4 weeks) or non-persistent (present for <4 weeks)
 Treatment CID:
1. Modification of diet and re-hydration
2. Loperamide
3. Ocreotide: loperamide refractory diarrhea (48 h), severe diarrhea
4. Tincture of opium: may be considered as a second-line therapy for persistent and uncomplicated diarrhea 
CHEMOTHERAPY INDUCED DIARRHEA (CID)
Peterson DE et al, Ann Oncol 2015, Stein et al. Ther Adv Med Oncol 2010
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 54 years old patient on adjuvant chemotherapy for T3N1M0 BC
 4. cycle of adjuvant chemotherapy, 1. application of docetaxel 100 mg/m2, prior cht
applications without meaningful AE
 Docetaxel was administreted with deksamethasone premedication according to standard 
scheme without acute toxic reaction
 D7: confusion, sleepiness, unable to answer questions; afebrile, RR 100/70, p: 100/min, 
normal ECG, without major neurologic deficit on examination, physical examination
otherwise unrenarkabe
 Heteroanamnesis: profound diarrhea (6-10 stools per day 5 days, last 2 days vomiting) 
without fever
 Lab. Test: profound hyponatremia (Na: 115, K:2.1 mmol/l) elevated creatinin value and urea, 
CRP, PCT  normal, no signs of myelosuppression
 X-ray abdomen and stool cultures: negative
 DIAGNOSIS: acute dehydration and hypovolemic hyponatriemia as a consequence of
diarrhea, nausea and vomiting
 Treated with parenteral saline infusion, loperamide








DEFINITION:an oral temperature of >38.3°C or two consecutive readings of >38.0°C for 2 h and an
absolute neutrophil count (ANC) of <0.5 × 109/l
 FN remains one of the most frequent and serious complications of cancer chemotherapy
 20-30 % pts require hospitalisation, mortality 10%
 Predisposing factors: certain chemotherapeutics regimen-FN risk, age, advanced disease, prior FN, 
mucositis, low PS, CVS disease
PREVENTION:
Chemoprpphylaxis
according to risk for FN 





Klastersky J et al, Ann Oncol 2016




















No pneumonia, stable, no i.v. 
cathethers:
Po/iv antibiotics: amoksicillin









FEVER AND SUSPECTED NEUTROPENIA








 HFS:palmar-plantar erythrodysaesthesia syndrome: redness, marked discomfort, swelling and tingling in the 
palms of the hands or the soles of the feet (5-fluorouracil (5-FU), (6%-34%), capecitabine (50%-60%), 
doxorubicin (22%-29%), PEGylated liposomal doxorubicin (40%-50%), docetaxel [6%-58%; preventative 
mesures are important-10% urea cream significantly reduces the incidence of HFS
 Treatment of HFS: , skin inflammation: high-potency topical corticosteroids], while erosions and ulcerations: 
with antiseptic solutions (silver sulfadiazine 1%), analgesia on painful areas: lidocaine 5% patches
 Skin cooling (e.g. cold gloves or socks) significantly reduce of HFS for ChT given as an infusion( paclitaxel, 
docetaxel and liposomal doxorubicin)
Lacouture ME, et al, Ann Oncol 2020
 Extravasated drugs are classified according to their potential for causing damage as ‘vesicant’, ‘irritant’ and 
‘nonvesicant’ 
VESICANT: blisters/tissue destruction !!!!!












Vinca alkaloids Taxane Vinblastine, Vincristine, 
Vinorelbine, Vindesine
Paclitaxel, Docetaxel
Irritant drugs Alkylating agents
Platinum analogs 












EXTRAVASATION:inadvertent infiltration of chemotherapy into the tissues surrounding the intravenous
site
Fidalgo JA, et al, Ann 
Oncol 2012
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Extravasated vesicant Antidote Treatment
Anthracyclines DMSO Dexrazoxane Topical cooling
Docetaxel Hyaluronidase Topical cooling
Mytomicin DMSO Topical cooling
Mitoxantrone DMSO Topical cooling
Vinca alkaloids Hyaluronidase Topical warming
 DMSO (topical application): is a solvent capable of penetrating tissue, it neutralizes free-radical 
accumulation and encances systemic absorption of the extravasated drug.
 Dexrazosane (intravenously): is approved for anthracycline extravasation treatment, it binds to iron 
and prevents the formation of free radicals which induce extravasation-induced tissue necrosis.
 Hyaluronidase (subcutaneously) degrades hyaluronic acid, breaks down subcutaneous tissue bonds 
promoting drug diffusion and enhances the absorption of injected substances.
Signs and symptoms of vesicant extravasation:
swelling, redness and/or discomfort, resistance during 
drug administration, a slow and sluggish infusion, and 
lack or loss of a blood return from the i.v. cannula,
implanted port or other central venous access device.
Fidalgo JA, et al, Ann Oncol 2012
It is essential to recognize that an extravasation has taken place as quickly as possible!!! 
 40 years BC patients develops sweeling
and redness in the arm where the canula
during doksorubicin infusion is inserted
WHAT WOULD YOU DO?
Fidalgo JA, et al, Ann Oncol 2012
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 chemotherapy-induced cognitive dysfunctions=„chemo-brain“, other: other types of acute encephalopathy: 
ifosfamide-induced acute encephalopathy, increased risk of trombemolic stroke
 incidence of CIPN approximately 38% (up to 90% with oxaliplatin)
 reduce functional capacity and quality of life, the long-term reversibility questionable, symptoms may last 
years after chemotherapy discontinuation
 CIPN: platinum-based agents (cisplatin, oxaliplatin), vinca alkaloids (vincristine, vinorelbine), taxanes
(docetaxel, paklitaksel)
 Oxaliplatin-Induced Peripheral Neuropathy:
 more than 90% of patients developed acute neuropathy (paresthesia, dysesthesia of the hands, feet and 
perioral area induced by cold stimuli in the hours and days ) and 30–50% of patients developed chronic 
neuropathy (paresthesia, numbness, sensory ataxia )
 Taxane, vinca alkaloids neuropathy: sensory neuropathy with a stocking-and-glove distribution over the 
hands and feet
CENTRAL AND PERIPHERAL CHEMOTHERAPY INDUCED NEUROTOXICITY (CIPN)
Kerckhove N, et al. F Phar 2017
Kerckhove N, et al. F Phar 2017
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 no effective agent exists to prevent CIPN
 prevention of CIPN with cryotherapy can be considered according to ESMO, similar recommendation for 
medical exercise for cancer patients (low LoeE/GoR-IIC)
 Management of CIPN:- reducing or discontinuing chemotherapy when CIPN develops 
- treatment of the symptoms of neuropathic pain- only duloxetine was shown to help 
neuropathic pain in established CIPN; any other medications (gabapentin, topical preparations, etc.) are used in 
an off-label fashion
Jordan B, et al. Ann Oncol 2020
True allergic responses vs non-allergic responses
Rosello S, et al, Ann Oncol 2016
39
Rosello S, et al, Ann Oncol 2016
Arrythmias: taxanes





 Use all the knowledge for preventative meassures! 
 Educate the patient!
THANK YOU FOR YOUR ATTENTION!
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2nd Summer School of Medical Oncology, 7/ 9/2021




• activate proteins/autoactivate by 
phosphorylation of tyrosine moiety -
important for signal transduction and cell
cycle regulation
Tyrosine kinase inhibitors:
• Small molecules, oral application
• act mostly by blocking ATP binding site, 
therefore inhibit phosphorylation 






B Raf (serine threonine kinase)
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On- and off- target toxicity
Off-target:
• due to inhibiton of other unintended targets
• „off targets“ share structures or residues with
the intended targets
• sunitib: hematologic toxicity (FLT3 inhibition)
• toxicities can ovelap due to cross interaction of
multiple pathways
CA Cancer J Clin. 2013;63:249-79
https://www.targetedonc.com/publications/targeted-therapies-cancer/2013/december-2013/Toxicities-of-Targeted-Therapies-and-Their-Management
On-target: 
• due to inhibition of the desired target (mechanism based)
• class effect: shared with all agents that inhibit specific target
• VEGFR TKI: hypertension
• EGFR TKI: rash
The good news: toxicity may correlate with
response/better survival
• rash due to EGFR TKI in lung cancer
• hypertension and hypothyroidism due to VEGFR TKI in renal cell carcinoma
Liu S et al. Cancer Treat Rev. 2014; 40: 883-91
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ErbB tyrosine kinase inhibitors
all agents: hepatotoxicity
Shah R et al. Drug Safety. 2019; 42:181-98 
spc of selected drugs
ErbB TKI toxicity: management
• drug interruption, 
lowering of the dose
• life threatening: 
discontinuation of 
treatment
Up to Date 
Shah R et al. Drug Safety. 2019; 42:181-98 
Lacouture M et al. Am J Clin Dermatol. 2018; 19: S31-9
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VEGFR tyrosine kinase inhibitors
VEGFR TKI – management of cardiovascular toxicity
TE: thromboembolic events
CA Cancer J Clin. 2013;63:249-79
Up to Date
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VEGFR TKI – management of toxicity
CA Cancer J Clin. 2013;63:249-79
Rimassa L et al. Can Treat Rev 2019; 77: 20-8





ALL: interstital lung disease
Kassem L et al. Crit Rev Oncol Hematol 2019; 134:56-64
smpc
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ALK TKI – management of toxicity
Kassem L et al. Crit Rev Oncol Hematol 2019; 134:56-64
smpc
http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Crizotinib_monograph_1Sep2014.pdf
MEK 1,2 inhibitors (+ B-RAF inhibitors)
MEK1,2  inhibitors:
• ↓ LVEF, hypertension, 
• retinal pigment epithelial 
detachment/retinal vein occlusion, 
• interstitial lung disease, 
B-RAF inhibitors: 
• QT prolongation (vemurafenib, 
encorafenib), 
• uveitis,
• cutaneus squamous cell carcinoma, 
keratoacantomas, hyperkeratosis,
• pyrexia
CK – creatine phosphokinase





crizotinib: poor light-dark adaptation 
Possible mechanism of MET TKI ocular toxicity: 
• ERK activation is important for photoreceptor survival 
• MEK inhibition results in apoptosis and loss of differentiation during photoreceptor 
development
Kdaud A et al. The Oncologist 2017;22:823-33
smpc
• Toxicity varies between patients.
• Beware of interactions with food and drugs!
• Multidisciplinary management: referral to doctors of other 
specialities.











































SURVIVAL ANALYSIS IN SLOVENIAN
PATIENTS WITH METASTATIC MELANOMA
AND IMMUNE RELATED ADVERSE EVENTS
Vid Čeplak Mencin
assist. prof. Tanja Mesti, MD, PhD
Summer School 2021
Institute of Oncology Ljubljana, sept. 2021
CONCLUSION
• irAE cohort: better treatment outcome, longer time to disease progression, better ORR
• ORR: irAE 57%, NirAE 37%
• PFS: irAE 301,6 days, NirAE 247,3 days
• SP: irAE 80%, NirAE 60%
• Better SP in patients with elevated LDH and irAE M1a/b (TNM classification)
• Worse SP for M1c/d – new type of melanoma?
89
Patient  with BRAF mutated metastatic melanoma
Sequencing, rechallenge, new therapies...  
L.Simetic, K.Blazicevic and D. Herceg




• Should we continue with BRAF MEK therapy or not? Patient was treated 
with 2 lines in metastatic setting  so no other option, except Cht, is 
available in Croatia ( by National regulatory agency for health insurance)
• Do we have „ a joker card”  with previous response to ICI ( lung mets 
regression) ? Rechallenge with mono PD-1 inhibitors or combo ICI? 
• Clinical study/ compassionate use programe:: ICI+ lenvatinib or?
• Something new like Fecal Transplant therapy + ICI?
• Your comments are precious 
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Multidisciplinary team for melanoma treatment
University hospital centre Zagreb; core members
 dermatologist, dermatooncologist: D. Štulhofer (chair), R.Čeović
 plastic surgeon: D. Mijatović, S. Smuđ Orehovec
 head and neck surgeon: M.Jurlina, J.Biloš, D. Leović
 ophthalmologist: N.Vukojević, M. Štanfel
 medical oncologist: D.Herceg, K.Blažičević, L.Simetić
 radiooncologist: F.Šantek
 pathologist: S.Dotlić, I.Ili ć
 nuclear medicine specialist: G.Horvatić Herceg, S. Kusačić Kuna, 
M.Ciglar







Systemic treatment of non-melanoma 
skin cancers - immunotherapy?
92
Squamous cell carcinoma of the skin
 The second most common NMSC (20%)
 The incidence has been growing over the last 30 years(50-200%)
 Head and neck 80-90%
 90% has a good prognosis
 What about the rest 10%?
SCC in transplant patients
36 times higher incidence than usual(BCC: SCC 4: 1)
Aggressive course - poor prognosis
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Red horizontal line and associated number in figurer = median mutations per MB.
CSCC, cutaneous squamous cell carcinoma; LUSC, lung squamous cell carcinoma; Mb, megabase of DNA; SCCHN, Squamous cell carcinoma of the head and neck.
Pickering CR, et al. Clin Cancer Res. 2014;20:6582–6592. 
 Anti–PD-1 and anti–PD-L1 therapy across 27 tumour types1
Tumour mutational burden & objective response rate
1. Yarchoan M, et al. N Engl J Med. 2017; 377: 2500–01; 2. Papadopoulos K, et al. Presentation at 2017 American Society of Clinical Oncology, Chicago,
IL. J Clin Oncol. 2017;35(15_suppl):9503; Adapted from Yarchoan et al, 2017
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Reasons for immunotherapy in CSCC
 High tumor mutation load (TMB) and immunogenic cancer
 High TMB may contribute to increased neoantigen production, which may 
increase tumor antigenicity 1
 Immunosuppression is a well-described risk factor for CSCC (especially in 
organ transplant patients)2
 PD-L1 expression was detected in advanced CSCC3
1. Pickering CR, et al. Clin Cancer Res. 2014;20:6582-92; 2. Euvrard E, et al. N Engl J Med. 2003;348:1681-1691. 
3. Slater NA, et al. J Cutan Pathol. 2016;43:663-70.
Candidates for immunotherapy in
advanced CSCC
 Patients with advanced CSCC
 Locally advanced / metastatic disease
 Patients with recurrences after previous surgeries
 Patients who are not candidates for surgery due to morbidity / potential 
exhaustion or a low level of confidence within clear boundaries
 Patients who are not candidates for radiotherapy
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(nodal and/or distant) 
Locally advanced CSCC
Metastatic CSCC
(nodal and/or distant) 
Cemiplimab 
3 mg/kg Q2W IV*
for up to 96 weeks 
(retreatment optional for 
patients with progression 
during follow-up†)
Tumour imaging 
every 8 weeks 
for the assessment of 
efficacy 
Cemiplimab 
350 mg Q3W IV
for up to 54 weeks 
Tumour imaging 
every 9 weeks 
for the assessment of 
efficacy 
Tumour response assessment by ICR
(RECIST 1.1 for scans: modified 
WHO criteria for photographs)
Key inclusion criteria
• ECOG performance status of 0 or 1
• Adequate organ function
• At least one lesion measurable by RECIST 
1.1 criteria (for scans) or modified WHO 
criteria (for photos)
• CSCC lesion that is not amenable to surgery 
or radiation therapy per investigator 
assessment
Key exclusion criteria
• Ongoing or recent (within 5 years) 
autoimmune disease requiring systemic  
immunosuppression
• Prior anti–PD-1 or anti–PD-L1 therapy
• History of solid organ transplant, concurrent 
malignancies (unless indolent or not 
considered life threatening; for example, basal 
cell carcinoma), or haematologic malignancies
CSCC, cutaneous squamous-cell carcinoma; ECOG, Eastern Cooperative Oncology Group; ICR, independent central review; IV, intravenous; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1; 




†To account for possible pseudoprogression, treatment 
could be continued beyond initial RECIST 1.1-defined 
progression informed by ir-related response criteria
*Cemiplimab is not licensed at this dose for the treatment of CSCC
Migden MR, et al. Presentation at 2019 American Society of Clinical Oncology, Chicago, IL. J Clin Oncol. 2019;37(15_suppl):6015 CSCC, cutaneous squamous cell carcinoma
 Phase II data supporting cemiplimab license (n=193)
EMPOWER-CSCC-1 treatment arms 
Group 1 Group 2 Group 3
CSCC Metastatic Locally advanced Metastatic
Number of patients 59 78 56
Cemiplimab dosing 3 mg/kg Q2W 3 mg/kg Q2W 350 mg Q2W
Data cut-off Sept 20 2018 Oct 10 2018 Sept 20 2018
Median follow-up (months) 16.5 9.3 8.1
Cemiplimab SmPC, available at https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_hr.pdf; accessed January 2020
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 Response rates in three treatment groups
EMPOWER-CSCC-1
CSCC, cutaneous squamous-cell carcinoma; Q2W, every 2 weeks
Group 1 Group 2 Group 3
Metastatic CSCC 
Cemiplimab 3 mg/kg 
Q2W*
N=59
Locally advanced CSCC 




Cemiplimab 350 mg Q3W
N=56
Objective response rate








Complete response† 16.9% 12.8% 3.6%
Partial response 32.2% 30.8% 35.7%
Stable disease 15.3% 35.9% 14.3%
Progressive disease 16.9% 11.5% 26.8%*Cemiplimab is not licensed at this dose for the treatment of CSCC
†Only patients with complete healing of prior cutaneous involvement; for 
locally advanced CSCC, biopsy required to confirm complete response
Cemiplimab SmPC, available at https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_hr.pdf; accessed January 2020
Kaplan–Meier Estimation Overall Survival, Progression-Free Survival, 
and Duration of Response in Advanced CSCC Patients
Median PFS by ICR was 
18.4 months (95% CI: 7.3–
not evaluable)
Median OS has not been reached; 
Kaplan-Meier estimation of OS at 

























































Group 1: Median duration of follow-up = 16.5 mos (range 1.1 – 26.6); Group 2: Median duration of follow-up = 9.3 mos (range 0.8 – 27.9)
Data cut-off date: Sept 20, 2018 (Group 1); Oct 10, 2018 (Group 2)
CI, confidence interval; CSCC, cutaneous squamous cell carcinoma; ICR, independent central review; OS, overall survival; PFS, progression-free survival; 
NR, not reached
1. Guminski et al. J Clin Oncol. 2019:37 (suppl; abstr 9526) [poster presentation]. 2. Migden MR, et al. J Clin Oncol. 2019:37 (suppl; abstr 6015) [poster presentation]. 
Locally Advanced CSCC (Group 2)2
Median PFS NR
K-M Estimated PFS at 12 months 58.1% (95% CI: 43.7–70.0)
Median OS NR
K-M Estimated OS at 12 months 93.2% (95% CI: 84.4–97.1)
Median DOR NR
Metastatic CSCC (Group 1)1
Median DOR not reached
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EMPOWER-CSCC-1:Duration of response K-M estimated
event-free probability by ICR in responding patients
CSCC, cutaneous squamous cell carcinoma; ICR, independent central review.
Data cut-off date: 20 Sep 2018 (Group 1); 10 Oct 2018 (Group 2). 
Median duration of response has not been reached. 
1.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Number of patients at risk
Metastatic CSCC 29 29 28 27 22 22 22 22 15 11 7 0 0 0
















































Serious adverse events 8.6% 5.8%
Immune-related adverse reactions  20.1% 4.4%




Most common irARs 
Hypothyroidism 7.1% 0
Pneumonitis 3.7% 1.9%
Immune-related skin ARs 2.0% 0.3%
Hyperthyroidism 1.9% 0
Hepatitis 1.9% 0.8%
Infusion-related reactions 9.1% 0.3%
irARs, immune-related adverse reactions
Cemiplimab SmPC, available at https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_hr.pdf; accessed January 2020
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Pembrolizumab for Recurrent/Metastatic Cutaneous Squamous Cell
Carcinoma: Efficacy and Safety Results From Phase 2 KEYNOTE-629 
Study
J.-J. Grob et al., KEYNOTE-629 Efficacy and Safety of pembrolizumab in patients with R/M cSCC, Poster presented at ESMO 2019
Studiendesign
CR, complete response; cSCC, cutaneous squamous cell carcinoma; DCR, disease control rate; 
DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status
LA, locally advanced; ORR, objective response rate; OS, overall survival; PFS, progression-free survival
Q3W, every 3 weeks; R/M recurrent and/or metastatic.
aPatients who discontinue treatment after achieving CR may be eligible to receive an additional 
17 cycles of pembrolizumab if disease progression occurs.
Pembrolizumab for Recurrent/Metastatic Cutaneous Squamous Cell
Carcinoma: Efficacy and Safety Results From Phase 2 KEYNOTE-629 
Study
J.-J. Grob et al., KEYNOTE-629 Efficacy and Safety of pembrolizumab in patients with R/M cSCC, Poster presented at ESMO 2019
PFSa in the R/M Cohort OSa in the R/M Cohort
NR, not reached; OS, overall survival; PFS, progression-free survival; R/M, recurrent and/or metastatic.
aFrom product-limit (Kaplan-Meier) method for censored data.
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 Cemiplimab is indicated as monotherapy in adult patients with metastatic 
or locally advanced squamous cell carcinoma of the skin who are not 
candidates for curative surgery or curative first-line radiation.
101
Basal cell carcinoma of the skin
A major cause of BCC is exposure to 
UV radiation
 A major cause of BCC is exposure to 
UV radiation, leading to cumulative 
DNA damage and gene mutations1–5
 Epidemiological data suggest the 
overall incidence of BCC is increasing 
significantly and show marked 
geographical variation1,6–8
 Australia has the highest incidence 
rate of BCC in the world, reporting a 
rate of 1–2% per year1,6
5. Caro I, Low JA. Clin Cancer Res 2010;16:3335–9
6. Diepgen TL, Mahler V. Br J Dermatol 2002;146(suppl):1–6
7. Ting PT et al. J Cutan Med Surg 2005;9:10–15
8. Rogers HW et al. Arch Dermatol 2010;146:283–7
80% occur on the head and neck
15% occur on the trunk
5% occur on the arms, legs or other sites
Most sporadic cases of BCC arise 
from chronic sun-exposure1,2
1. Rubin AI et al. N Engl J Med 2005;353:2262–9
2. Wong CSM et al. Br Med J 2003;327:794–8
3. Roewert-Huber J et al. Br J Dermatol 2007;157:47–51
4. Lear JT et al. J R Soc Med 1998;91:585–8
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Advanced basal cell carcinoma
23
Locally advanced basal cell carcinoma (lnBCC)
Aggressive disease with local tissue damage
Frequent recurrences after surgery
The operation would cause deformation
Metastatc BCC (mBCC)
Rare but serious form of BCK
It involves the presence of metastases (e.g., lymph 
nodes, bones, lungs, liver 1
Weak outcome (median survival: 8-14 months2-3





1. Ting PT et al. J Cutan Med Surg 2005;9:10–15
2. von Domarus H, Stevens PJ. J Am Acad Dermatol 1984;10:1043–60
3. Lo JS et al. J Am Acad Dermatol 1991;24:715–19
4. Wong CSM et al. Br Med J 2003;327:794–8
Treatment of basal cell carcinoma










BCC and Hedgehog signal pathway
 The pathway of cell growth and 
differentiation that controls the 
formation of organs in embryonic 
development
 The Hedgehog signaling 
pathway is inactive in most of 
the tissue of the adult
• Abnormal activation 
(mutation) of the Hedgehog 
signal pathway plays an 
important role in pathogenesis
BCC1
• Hedgehog signaling pathway 
inhibitors provide a new 
treatment option for 
advanced patients BCC  




RR in 1st line treatment - HHI
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An open-label, non-randomized Phase 2 study of cemiplimab in patients with advanced BCC who experienced 
progression on or intolerance to hedgehog pathway inhibitor therapy1-4
31
Phase 2 Study of Cemiplimab in Advanced BCC 
(Study 1620) ‒ NCT031326361-3
*Tumor response assessment by ICR (RECIST 1.1 and/or modified WHO criteria).
BCC=basal cell carcinoma; DOR=duration of response; ICR=independent central review; IV=intravenous; laBCC=locally advanced BCC; N=number of patients; ORR=overall response rate; 
OS=overall survival; PFS=progression-free survival; Q3W=every 3 weeks; Q9W=every 9 weeks; Q12W=every 12 weeks; RECIST=Response Evaluation Criteria in Solid Tumors; WHO=World Health 
Organization.
1. ClinicalTrials.gov/NCT03132636. https://clinicaltrials.gov/ct2/show/NCT03132636. Accessed October 2020. 2. Stratigos AJ, et al. Poster presented at: European Society for Medical Oncology 
(ESMO) Virtual Congress; September 19–21, 2020:LBA47. 3. Lewis KD, et al. Poster presented at: Society for Immunotherapy of Cancer (SITC) Virtual Congress; November 9–14, 2020:Poster 428.
Group 2
Adult patients with laBCC
N=84
Group 1
Adult patients with metastatic 
(nodal and distant) BCC
N=54
Tumor response assessments:
Q9W for treatment cycles 1-5, 
Q12W for treatment cycles 6-9*
350 mg IV Q3W for up to 93 weeks (or until 




• ORR by ICR
Select secondary endpoint
• DOR, PFS, OS, complete 
response by ICR, ORR 
per investigator, and 
safety and tolerability
Patient Eligibility
*Defined as any Grade 3/4 HHI-related AEs, or any of the following Grade 2 HHI-related AEs following ≥3 months of exposure: muscle spasms or myalgias, dysgeusia or anorexia (if 
accompanied by Grade ≥1 weight loss), nausea, or diarrhea (despite medical management). 
BCC=basal cell carcinoma; ECOG=Eastern Cooperative Oncology Group; HHI=hedgehog inhibitor; PD-1=programmed cell death protein-1; PD-L1=programmed death-ligand 1.
1. ClinicalTrials.gov/NCT03132636. https://clinicaltrials.gov/ct2/show/NCT03132636. Accessed October 2020. 2. Stratigos AJ, et al. Poster presented at: European Society for Medical Oncology 
(ESMO) Virtual Congress; September 19–21, 2020:LBA47; 3. Lewis KD, et al. Poster presented at: Society for Immunotherapy of Cancer (SITC) Virtual Congress; November 9–14, 2020:Poster 428.
Select Exclusion Criteria1-3
• Ongoing or recent (within 5 years) autoimmune 
disease requiring systemic immunosuppression
• Prior anti–PD-1 or anti–PD-L1 therapy
• Active brain metastases
• Immunosuppressive doses of steroids 
(>10 mg prednisone daily or equivalent) 
• Concurrent malignancy other than BCC and/or 
history of malignancy other than BCC within 3 years 
of date of first planned dose of cemiplimab, except 
for tumors with negligible risk of metastasis
Select Inclusion Criteria1-3
• Adults (≥18 years) with histologically 
confirmed diagnosis of invasive BCC
• Prior disease progression on HHI therapy, 
or intolerance to prior HHI therapy,* or no 
better than stable disease after 9 months 
on HHI therapy
• ≥1 measurable baseline lesion
• ECOG performance status ≤1 
• Adequate organ function
• Must not be a candidate for radiation 
therapy or surgery
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Data cut-off date: 17 February 2020.
CI=confidence interval; ICR=independent central review; laBCC=locally advanced basal cell carcinoma; NE=not evaluable; PFS=progression-free survival.
Stratigos AJ, et al. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress; September 19–21, 2020:LBA47.
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Estimated median PFS, months: 19.3[95% CI, 8.6–NE]
Estimated 12-month event-free probability: 56.5% [95% CI, 44.3–67.0]
Data cut-off date: 17 February 2020.
CI=confidence interval; ICR=independent central review; laBCC=locally advanced basal cell carcinoma; NE=not evaluable; OS=overall survival
.
Stratigos AJ, et al. Poster presented at: European Society for Medical Oncology (ESMO) Virtual Congress; September 19–21, 2020:LBA47.
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Estimated median OS, months: not reached [95% CI, NE–NE]
Estimated 12-month probability of survival: 92.3% [95% CI, 83.6–96.5]
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 Cemiplimab is the first systemic treatment to show clinical benefit in 
patients with laBCC and mBCC after HHI therapy.
 31% and 21% ORR The safety profile is acceptable for the patient 
population. Consistent with other PD-1 antibodies and previous reports of 
cemiplimab in other tumor types
Merkel cell carcinoma (MCC)
109
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Merkel cell carcinoma (MCC) - Epidemiology
 Each year  ~ 2,500 new cases diagnosed in the EU1 and 1,500 in USA 
 Increasing incidence over the past few decades2
 Unclear whether this trend is due to an aging population or increased awareness and diagnosis
 The highest rates of MCC have been observed in Australia, with an incidence rate of 1.6 per 
100,000 persons reported in Queensland3,4
 ~80% of MCCs are caused by MCV (Merkel cell polyomavirus)
 Each year approximately 1 in 3 patients with Merkel Cell Carcinoma will die from their disease
1. IMMOMEC (European Commission). Merkel cell carcinoma. Available at: www.immomec.eu/project/objectives/background/merkel-cell-carcinoma (accessed July 2017); 2. Saini 
AT, Miles BA. Onco Targets Ther 2015;8:2157–67; 3. Schadendorf D, et al. Eur J Cancer. 2017;71:53–69; 4. Youlden DR, et al. JAMA Dermatol 2014;150:864–72.
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MCC – Signs, Symptoms and Risk Factors
Typical presentation






• Head and neck (~50%)
• Upper extremities 
(~16%)





• Median age  ~76 




• Firm, red to purple 
papule/nodule
• Asymptomatic/lack of 
tenderness
• Rapidly Expanding
• Mets at an early stage
MCC on a cheekMCC on the lip
1. Merkel Cell Carcinoma. National Cancer Institute. Available at: www.cancer.gov/types/skin/patient/merkel-cell-treatment-pdq (accessed December 20163. Image 
credit: Klaus D. Peter, Gummersbach, Germany. Available at: commons.wikimedia.org/wiki/File:Merkel_cell_cancer.jpg – attribution required for re-use; 4. Nutan FNU et al. 




Where does MCC occur on the body?
Solid circles depict MCC tumors that arose on the 
skin:
86% of these cases.
O Open circles indicate MCCs that presented in 
lymph nodes 
without an associated “primary lesion” : 14% of 
cases
• MCC primarily occurs on 
highly sun-exposed skin, but 
it can occur anywhere on
the body, including sun-
protected areas such as the 
buttock or the scalp under
hair.
Treatment
 Treatment is generally based on stage of the disease and many issues that 
are highly variable between patients.
 It is best to obtain care from a multi-disciplinary team of physicians with
significant MCC experience who take into consideration many clinical 
factors.
Major treatments
1) surgical excision of the primary lesion or lymph node,
2) radiation therapy, and
3) systemic therapy including immunotherapy and chemotherapy.
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Reason for use of immunotherapy in
mMCC
 PD-L1 is expressed in MCC tumor cells and infiltrates of adjacent immune cells1
 Dysfunction of MCPyV-specific T cells2
-Levels of CD8 T cells increase with a higher tumor load
-Exhausted phenotype (PD-1 +, Tim-3 +)
 MCPyV-negative tumors have a higher burden on mutations and neoanthigens3








A phase II, open-label, multicenter trial to investigate the clinical activity and 
safety of avelumab (MSB0010718C) in subjects with Merkel cell carcinoma





• ECOG PS 0–1
Avelumab 10 mg/kg IV 
(1-h infusion) every 2 
weeks
until disease progression, 
clinical deterioration, 
unacceptable toxicity or 




• Best Overall Response
SECONDARY ENDPOINTS:
• DoR, PFS, OS, safety, 





• BOR, DoR, PFS, OS, safety, 
anti-drug antibodies, PK
Part A: patients have 
received at least one line of 
chemotherapy (n=88)2
Part B: patients have not 





Part A cohort, mMCC 2L+: design1




A phase II, open-label, multicenter trial to investigate the clinical activity and 
safety of avelumab (MSB0010718C) in subjects with Merkel cell carcinoma





• ECOG PS 0–1
• Patients received at 
least one line of 
chemotherapy
Avelumab 10 mg/kg IV 
(1-h infusion) every 2 weeks
until disease progression, 
clinical deterioration, 
unacceptable toxicity or 
other criterion for withdrawal
PRIMARY ENDPOINT:
• Durable response*
KEY SECONDARY ENDPOINTS: 
• BOR**, DoR, PFS, OS, safety, 
anti-drug antibodies, PK
**Best Overall Response is defined as complete response, partial response, stable 
disease, or progressive disease, according to RECIST version 1.1 and assessed by 
an independent review committee.
Part A: 
PRIMARY ENDPOINT:
• Best Overall Response
SECONDARY 
ENDPOINTS:




In previously treated patients who received avelumab 52% are still 
alive at 1 year1
1. Kaufman HL et al. AACR 2017. Abstract CT079 (presentation). – ≥ 12 month follow-up
Number 
at risk
Months since initiating treatment

















0 2 4 6 8 10 12 14 16 18 20 22 24 26
Avelumab
OS n=88
Events, n (%) 48 (54.5)
Median, months (95% 
CI) 12.9 (7.5, –)
1-year rate, % (95% CI) 52 (41–62)
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Part B cohort, mMCC –Treatment naïve - 1L: design1
1. NCT02155647. Available at ClinicalTrials.gov (accessed Oct  2017). 2. Kaufman HL et al. Lancet Oncol 2016;17:1374–85. 





A phase II, open-label, multicenter trial to investigate the clinical activity and 
safety of avelumab (MSB0010718C) in subjects with Merkel cell carcinoma





• ECOG PS 0–1




Avelumab 10 mg/kg IV 
(1-h infusion) every 2 weeks
until disease progression, 
clinical deterioration, 
unacceptable toxicity or 





• BOR, DoR, PFS, OS, 
safety, anti-drug 
antibodies, PK
*Durable response is defined as proportion of patients of the total ITT population 
with objective response (CR or PR) according to RECIST v1.1, with a duration of at 
least 6 months.*
*
* By Kaplan Meier Method
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Avelumab in 1L mMCC:
High ORR 62.1% and >80% on-going for at least 6 months CR in 4 patients 
Preliminary Efficacy Data – Treatment naïve – 1L1
1. D'Angelo SP, et al. Efficacy and Safety of First-lineAvelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned
Interim Analysisof a Clinical Trial. JAMA Oncol 2018 Sep 1;4(9):e180077;
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J Clin Oncol 37:693-702. 2019
In this multicenter phase II trial (Cancer Immunotherapy Trials Network-09/Keynote- 017), 50 
adults na¨ıve to systemic therapy for aMCC received pembrolizumab (2 mg/kg every 3 
weeks) for up to 2 years. Radiographic responses were assessed centrally per Response 
Evaluation Criteria in Solid Tumors (RECIST) v1.1.
 ORR to pembrolizumab was 56% (complete response [24%] plus partial response [32%]; 
95% CI, 41.3% to 70.0%), with ORRs of 59% in virus-positive and 53% in virus-negative tumors. 
 Median follow-up time was 14.9 months (range, 0.4 to 36.4+ months).
 Among 28 responders, median response duration was not reached (range, 5.9 to 34.5+ 
months). 
 The 24-month PFS rate was 48.3%, and median PFS time was 16.8 months (95% CI, 4.6 
months to not estimable). 
 The 24-month OS rate was 68.7%, and median OS time was not reached.
 Although tumor viral status did not correlate with ORR, PFS, or OS, there was a trend 
toward improved PFS and OS in patients with programmed death ligand-1–positive 
tumors.
 Grade 3 or greater treatment-related adverse events occurred in 14 (28%) of 50 patients 
and led to treatment discontinuation in seven (14%) of 50 patients, including one 
treatment-related death.
J Clin Oncol 37:693-702. 2019
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J Clin Oncol 37:693-702. 2019
In patients with aMCC receiving first-line anti– programmed cell death-1 
therapy - Pembrolizumab demonstrated durable tumor control, a generally 
manageable safety profile, and favorable OS compared with historical data 
from patients treated with first-line chemotherapy.






Safety and tolerability, ORR in metastatic patients, 
surgery delay rate
SECONDARY ENDPOINTS
Change in immune cells of viral-specific T-cells; 
change in immune activation/inhibitory molecules 
of viral-specific T-cells; PFS; OS
Non-comparative, two-cohort, single-arm, open-label, 
Phase I/II study of nivolumab (BMS-936558) in subjects with 






Tumor types: MCC, gastric or GEJ carcinoma, 
nasopharyngeal carcinoma, SCC of cervix, vagina or vulva, SCCHN
• NCT02488759. Available at: ClinicalTrials.gov (accessed December 2016).
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*By RECIST v1.1, investigator assessed 














*By RECIST v1.1, investigator assessed 
1. Topalian SL et al. AACR 2017. Abstract CT074 
(presentation).
Immunotherapy
 Phase II of the JAVELIN Merkel 200 trial studied Avelumab in patients with metastatic MCC 
either as 1st line therapy1 or in chemotherapy-refractory MCC2-3. In patients with no prior 
systemic therapy, after a median follow-up of 5.1 months (range 0.3-11.3 months), the overall 
response rate was 62.1%, and 83% of patients had a duration of response of at least 6 
months1. In patients treated with avelumab after progression on chemotherapy, the overall 
response rate was 33.0% after a minimum follow up of 12 months. At the time of data cut-off, 
72.4% of responses were ongoing3
 A different phase II trial studied patients with advanced MCC treated with pembrolizumab4; 
- after a median follow up of 33 weeks (range 7-53 weeks) the overall response rate was 56%, 
with a response duration ranging from 2.2-9.7 months. 
 The ongoing CHECKMATE 358 phase I/II trial is studying nivolumab in patients with resectable
MCC5. In pts treated with nivolumab prior to surgery, 80% had tumour regression and 65% had 
a major pathologic response including 8 CR. 
1.D'Angelo SP, et al. Efficacy and Safety of First-lineAvelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim 
Analysisof a Clinical Trial. JAMA Oncol 2018 Sep 1;4(9):e180077; 2.Kaufman HL, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell 
carcinoma: a multicentre, single-group, open-label, phase 2 trial.Lancet Oncol 2016 Oct;17(10):1374-1385; 3. Kaufman HL, et al. Updated efficacy of avelumab in
patients with previously treated metastatic Merkel cell carcinoma after >/=1 year of follow-up: JAVELIN Merkel200, a phase 2 clinical trial. J Immunother Cancer 
2018 Jan 19;6(1):x. 4.Nghiem PT, et al. PD-1 Blockade withPembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 2016 Jun 30;374(26):2542-2552.
5.Topalian SL, Bhatia S, Kudchadkar RR, Amin A, Sharfman WH, Lebbe C, et al. Nivolumab (Nivo) as neoadjuvanttherapy in patients with resectable Merkel cell 
carcinoma (MCC) in CheckMate 358. JCO 2018;36(15):9505.
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Anti PD-1/PD-L1 in advanced MCC
 ORR 1st line 56-73%
2nd line 33-50%
 PFS 1st line 17 mo (median)
2nd line 3 mo (median)
 OS   1st line median not reached
2nd line 13 mo (median)
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Summary MCC
 NMSC - the most common cancer
 Incidence is rising
 Numerous mutations in UV-induced cancer
 Surgery is a standard therapy for non-complicated cases
 Limited role of radiotherapy despite radiosensitivity in MCC
 anti-PD-1/PD-L1 should be applied as first-line treatment
 ChT should be postponed to 2nd line
 Previous ChT impairs outcome of anti-PD-1/PD-L1
Summary NMSC
 There is no clear benefit of chemotherapy
 Targeted therapy in BCC patched / SMOi is effective (RR 58%, CR 20-30%)
 Imunoterapies (PD-1 and PD-L1 antibodies) are effective in MCC and SCC, 
they also promise a great deal of potential for  BCC
120
Our experience & 
interesting cases
Maša Sever, Janja Ocvirk
Vismodegib in Routine Clinical Practice in Slovenia
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 Although basal cell carcinoma (BCC) is the most common malignancy 
among Caucasians, the incidence of advanced forms is relatively rare 
and therefore there is little data in the literature on treatment of locally 
advanced BCC (laBCC) or metastatic BCC (mBCC) by systemic therapy. 
Vismodegib is a Hh signaling pathway inhibitor and was approved by 
the European Medicines Agency for the treatment of adults with mBCC, 
or with laBCC inappropriate for surgery or radiotherapy. 
 A retrospective analysis was conducted to provide vismodegib long-
term efficacy and safety data in a real-world setting in Slovenia.
Methods
 Evaluation of efficacy and safety of vismodegib (V) was done in a 
retrospective analysis of patients (pts) with laBCC or multiple BCC 
and pts with Goltz-Gorlin Syndrom (G-G Syn) in routine clinical 
practice.
 Baseline characteristics, efficacy data and treatment-related 
adverse events (AEs) were collected from pts who were treated 
with V from November 2012 to January 2021. 
 Efficacy was assessed by objective response rate - ORR (CR + PR), 
disease control rate - DCR (CR + PR + SD) and duration of 





During the 100-month period, 46 pts were diagnosed with laBCC (26 pts), 
multiple BCC (13 pts) or G-G Syn (7 pts), all inappropriate for surgery or 
radiotherapy. Baseline characteristics: median age was 72.8 years in laBCC
+ multiple BCC pts group and 47.4 years in the G-G Syn pts group (Fig.1). 
Fifty-six percent of pts in laBCC +multiple BCC group were females; the 
majority (67%) of pts were previously treated by surgery and/or 
radiotherapy; 51% of pts had one lesion with predominant localization in 
the central face area (eyes, nose, lips, or ears in 76% of pts), 18% had 2-3 
lesions, and 31% more than 3 lesions. Fifty-seven percent of pts in G-G Syn


















































Patients with Goltz-Gorlin Syndrom 
(N=7)





G-G Syn group 
(N=7)
Investigator-assessed objective response rate
(CR+PR); n, %
31 (80%) 6 (86%)
Investigator-assessed disease control rate 
(CR+PR+SD); n, %
37 (95%) 7 (100%)
Duration of treatment (months); median 
(range)
9.9 (1.5-43.1) 19.5 (3.6-94.1)
• At the time of analysis in laBCC or multiple BCC group treatment has 
been interrupted during the treatment course in 23% of pts [in 8 out of 9 
pts due to adverse events (AEs)], 31% of pts are still on treatment. In G-G 
Syn group treatment has been interrupted in 57% of pts (in most cases 
due to adverse events), 43% of pts are still on treatment. Efficacy data 
are presented in Table 1.
Table 1. Response to vismodegib treatment
Efficacy results
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 Serious adverse events were reported in 6 out of 46 patients (13.0%): 
two cases of squamous cell cancer, one case of angiosarcoma, 
melanoma, cholangiocarcinoma and intracerebral hemorrhage each, 
while  one patient died due to other reasons than cancer. AEs of any 
grade were reported in 82% of pts in laBCC or multiple BCC group 
and 71% in G-G Syn group. 
 The majority of AEs in laBCC or multiple BCC group were grade 1 or 2 
(96%) and only 4% of AEs were grade 3: muscle cramps in 3 pts, 
respiratory infection, vomiting and anemia in 1 patient each. The 
majority of AEs in G-G Syn group were also grade 1 or 2 (87%), while 
13% of AEs were grade 3: muscle cramps in 2 pts, weight loss and 
diarrhea in 1 patient each. No grade 4 or 5 vismodegib related AEs 
were reported.
Safety results
Vismodegib has shown meaningful long-term efficacy with 
manageable safety profile in pts with laBCC or multiple BCC 










Quick response to high-dose treatment





 8. 11. 2012
 16. 10. 2014
Patient with Gorlin syndrome
(multiple BCC)
Side effects: alopecia gr.1 






Side effects: alopecia gr. 2, muscle spasms gr.2, change in taste gr.1
14
Man, 87 years old
History:
2001 – Multipl epiteliomas left leg
2001 – Malignant melanoma left leg/excision
2011 – BCC/SCC left leg/
excision, RT → ulcus
BCC right leg →
Not suitable for RT or excision
Others:
2003 – Nefrectomy
2006 – Deep vein thrombosis
2012 – Deep vein thrombosis
2012 – hypertension






August 2020 October 2020
January 2020 May 2020
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After 6 w of 
immunotherapy





 October  2018
 Male 68-year-old, presented with bleeding tumor on right thigh, 
invasions in inguinal lymph nodes, obturator lymph nodes, right 
iliac lymph nodes
 Biopsy - MCC
 TMB decision:  immunotherapy- avelumab
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 before starting immunotherapy
 marked pain occurred
 bleeding from the tumor
 the surgeons decided  for resection of a bleeding tumor on the 
thigh
 complication of treatment for sepsis, wound dehiscence
 he was recovering from complications of surgical treatment in  
January 2019
January 2019
 referred to medical oncologist 
 the patient also has rheumatoid arthritis on methotrexate therapy
 highly motivated for immunotherapy treatment
 he began with immunotherapy (Avalumab) in January 2019
 CT scan in April 2019 - PRCT 
 scan in July 2019 – further response
 CT scan in october  2019 - borderline enlarged lymph node left 
inguinal, no other evident residum of the disease





11.10.2020 2.11.2020 22.2.2021 7.6.2021






After 2 appl and 
post COVID 
pneumonia




Assist. Prof. Tanja Mesti, MD., PhD
2nd Summer school
7 September 2021
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from 
the ESMO Precision Medicine Working Group
◦ ESMO Scale for Clinical Actionability of
molecular Targets (ESCAT)
◦ Advanced lung carcinoma
◦ Metastatic prostate cancer
◦ Metastatic ovarian cancer
◦ Metastatic cholangiocarcinoma
*cancer types without clear standard-of-care
options, such as carcinoma of unknown primary
and other rare tumors




◦ NGS consilium - subgroup of patients with advanced cancer and no standard 
therapeutic options. 
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Systemic treatment of gastric 
carcinoma
Marko Boc, MD
Department for Medical Oncology







Increase R0 resection rate
Treat micrometastatic disease
Improve overall survival
Neoadjuvant and perioperative chemotherapy is more commonly used in non-Asian countries
where tumours are frequently locally advanced and require downstaging prior to successful
resection
NEOADJUVANT AND PERI-OPERATIVE CHEMOTHERAPY
136
5 year OS 45%*
5 year OS 23%*
2002














NEOADJUVANT AND PERI-OPERATIVE CHEMOTHERAPY
*chemotherapy patients; CF, cisplatin + 5-fluourouracil; ECF epirubicin + CF; FLOT. 5-fluororuraci, leucovorin, oxaliplatin, docetaxel 
1. OE02 Trial Group, Lancet 2002.
2. Cunningham D, et al. N Engl J Med 2006. 
3. Ychou M, et al. J Clin Oncol. 2011.
4. Al-Batran S, et al. Lancet 2019.
ADJUVANT CHEMOTHERAPY FOR NON-ASIAN PATIENTS
ADJUVANT CHEMOTHERAPY
Paolettiet al, JAMA. 2010 May 5;303(17):1729-37. 
Although non-Asian adjuvant gastric cancer trials have not shown a survival benefit, this metanalysis can be used to justify use of







Ana Erman, dr. med.
Mentor: doc. dr. Tanja Mesti, dr. med.































• HER2, MSI and NTRK testing
• If sufficient tissue: NGS
• Pembrolizumab for MSI-H/dMMR tumors or TMB-high (>10 mutations/megabase) 
tumors
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Systemic treatment of the Biliary 
tract cancer (BTC)– where we 
stand
Summer School, 8th September 2021
assist.prof. Martina Reberšek, MD, PhD
Current recommendations for systemic treatment of metastatic 
disease
Systemic chemotherapy:
- 1st line: gemcitabine + cisplatin (PS ECOG 0-1), gemcitabine mono (PS ECOG 2)
- 2nd line: mFOLFOX or new standard option Nal-IRI+5FU/LV
Immunotherapy:
- 1st line: MSI-H/dMMR → pembrolizumab
- 2nd line: nivolumab, MSI-H/dMMR/TMB-H → pembrolizumab
Targeted therapy
- 1st line: positive NTRK fusion gene →larotrectinib, entrectinib
- 2nd line: 
→posi:ve NTRK fusion gene → larotrectinib, entrectinib
→ mt BRAF V600 → dabrafenib+trametinib
→ mt IDH1 → ivosidenib
→FGFR2 fusions or rearrangements → pemigatinib
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How to approach GEP NET & NEC
M A R I J A  I G N J A T O V I Ć .
2 N D S U M M E R  S C H O O L  I N  M E D I C A L  O N C O L O G Y
0 8 . 0 9 . 2 0 2 1
NEUROENDOCRINE
NEOPLASMS
(NENs)  Heterogeneous group of malignancies ► arise from  
neuroendocrine cells► release of catecholamines and 
hormones
 Rare malignancies
 Less then 0.5% of all malignancies, only 1%-2% of gastrointestinal 
malignancies
 Growing incidence, especially of localized and regional NENs
 EUR 1.33 – 2.33/100.000; USA: 3.56/100.00
 men > women, men have adverse outcome 
 Sporadic/hereditary
 Younger then < 40 with gastrinoma
 Multiple neuroendocrine neoplasia (MEN)

































GEP-NET  ► 80% - 90%
GEP-NEC ► 10% - 20%
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MANAGEMENT OF PATIENTS WITH 




MANAGEMENT OF PATIENTS WITH 











CONTROL OF HORMONAL 
OVERPRODUCTION
CONTROL OF TUMOUR GROWTH
MENAGMENT OF 







How to approach NET/NEC 
Katja Leskovšek, dr. med.
prof. dr. Janja Ocvirk, dr. med.




 On presentation, Nov 2005
 6 months of diarrhoea, loss of weight (10 kg).
 Family history: positive.
 Past medical history: asthma (2003), discus hernia L4-5 op. (1999).
 PS ECOG 1.
 Therapy: Symbicort.
 Alergies: ketoprofen.
 US: 3 liver metastases Core needle biopsy: NEC metastases; 
origo ignota.
 Laparotomy (Sept 2005): tumor of distal pancreas, invading spleen





 Histopathology report: NEC of pancreas, invading
retroperitoneal fat, hilum of spleen, vascular, peri- and
intraneural invasion, lymphangiosis carcinomatosa; lymph node
status 3/5.
 R1 resection.
 Somatostatin: 10 %.
 Partial liver resection: metastasis of endocrine carcinoma.

Discussion
 NEC of pancreas, liver metastasis, R1.
 On treatment for 15 years.
 Systemic therapy:
 I. line ChT: etoposide + cisplatin;
 II. line ChT: 5-FU + dacarbazine + epidoxorubicin;
 3 x partial liver resection/metastasectomy (12‘, 13‘, 13‘);
 III. line: lanreotide;
 IV. line: lanreotide + everolimus;
 V. line: octreotide + sunitinib;
 6 x TACE (19‘, 20‘, 21‘);
 PRRT ?
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◦ BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; TACE, transarterial chemoembolisation 
1. Yang JD, et al. Nat Rev Gastroenterol Hepatol. 2019;16:589-604
2. Singal AG, et al. J Hepatol. 2020;72:250-61
3. Bruix J, et al. Nat Rev Gastroenterol Hepatol. 2019;16:617-30
3
The fourth most common cause of cancer-related death worldwide1
HCC accounts for >80% of primary liver cancers worldwide1
Chronic HBV and HCV infection are the most important causes of HCC and account for 80% 
of HCC cases globally1
It is estimated that 72% of cases occur in Asia (more than 50% in China)2
Staging of HCC is important to determine outcome and planning of optimal therapy. While 





◦ BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; TACE, transarterial chemoembolisation 
1. Yang JD, et al. Nat Rev Gastroenterol Hepatol. 2019;16:589-604
2. Singal AG, et al. J Hepatol. 2020;72:250-61





Standard of care treatment
Early and intermediate 
HCC
Stage 0-A >5 years Ablation, resection, transplantation
Stage B >2.5 years Chemoembolisation (TACE)
Advanced HCC
Stage C >1 year Systemic therapy
Stage D 3 months Best supportive care
1L FOR ADVANCED 
HCC PATIENTS
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Phase 3 SHARP trial of sorafenib vs 
placebo: study design1
*Not eligible for, or had disease progression after surgical or locoregional therapies.
†Assessed by the Functional Assessment of Cancer Therapy-Hepatobiliary Symptom Index-8 (FSHI-8).
‡Assessed using version 3.0 of the USA National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
BID, twice daily; DCR, disease control rate; EHS, extrahepatic spread; MVI , macroscopic vascular invasion; OS, overall survival;  TTP, time to treatment progression; 
TTSP, time to symptomatic progression.
1. Llovet JM et al. N Engl J Med. 2008;359(4):378-390; 2. Cheng A et al. Lancet Oncol 2009;10:25–34.
Sorafenib 

































Note: same study design 
was used for SHARP-AP2
SHARP: Baseline Patient 
Characteristics
Llovet JM, et al. N Engl J Med. 2008;359:378-390.
BCLC stage (stage B: 18.1% vs. 16.8%; stage C: 81.6% vs. 83.2%; stage D: <1% vs. 
0%) in sorafenib and placebo respective
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SHARP - efficacy data
9























SHARP: sorafenib is generally well 
tolerated in advanced HCC
*Defined by NCI CTC (version 3.0) that occurred in at least 5% of patients; †No grade 4 events reported.
HFSR, hand–foot skin reaction.
Llovet JM et al. N Engl J Med 2008;359:378–90; EASL–EORTC Clinical Practice: Management of hepatocellular carcinoma. J Hepatol 2012;56:908–43; Verslype C et al. ESMO guidelines. Ann 
Oncol 2012;23(Suppl 7):vii41–8.
Adverse event*
Incidence by grade (%)
(N=297)






Abdominal pain 8 2†
Liver dysfunction <1 <1†
Nausea 11 <1†
Vomiting 5 1†
Weight loss 9 2†
Hypertension 5 2†
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Data from SHARP and real-world practice 
support use of sorafenib in intermediate HCC
BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; HR, hazard ratio; OS, overall survival; TTP, time to 
progression
1. Bruix J et al. J Hepatol. 2012;57:821–9; 2. Iavarone M et al. Hepatology 2011;54:2055–63; 3. Ganten TM et al. EMSO 
2012;poster 77; 
4. Lencioni R et al. Eur J Cancer 2011;47 (Suppl 1):abstract 6500 
•Increased OS and TTP with sorafenib (n=54) vs placebo (n=51)
– Median OS: 14.5 vs 11.4 months (HR: 0.72; 95% CI: 0.38–1.38)
– Median TTP: 6.9 vs 4.4 months (HR: 0.47; 95% CI: 0.23–0.96)
SHARP1
BCLC-B subgroup
•Increased OS and TTP with sorafenib (n=86) vs placebo (n=90)
– Median OS: 11.9 vs 9.9 months (HR: 0.75; 95% CI: 0.49–1.14)
– Median TTP: 5.8 vs 4.0 months (HR: 0.57; 95% CI: 0.36–0.91)
SHARP1
previous TACE subgroup
•Good efficacy demonstrated in BCLC-B HCC
– Longer survival in BCLC-B vs BCLC-C patients:
20.6 vs 8.4 months
SOFIA2
•Good efficacy demonstrated in BCLC-B HCC
– Longer survival in BCLC-B vs BCLC-C patients: 
19.6 vs 14.5 months
INSIGHT3





REFLECT (NCT01761266): phase 3, international, 
multicentre, open-label, randomised study in 954 patients 
with hepatocellular carcinoma
Non inferiority assessment of lenvatinib vs. sorafenib for OS
Primary endpoint: OS
Secondary endpoints: PFS, ORR (mRECIST and RECIST v1.1)
Population enrolled: BCLC stage B: 20%; stage C: 80%
13
BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; mRECIST, modified RECIST; 
ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours 
Sources: lenvatinib summary of product characteristics dated June 2020; lenvatinib US prescribing information dated February 2020
14
◦ BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; mRECIST, modified RECIST; 
ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours 





Number of deaths (%) 351 (73) 350 (74)
Median OS in months (95% CI) 13.6 (12.1-14.9) 12.3 (10.4-13.9)
Hazard ratio (95% CI) 0.92 (0.79-1.06)
Progression-free survival (mRECIST)
Number of events (%) 311 (65) 323 (68)
Median PFS in months (95% CI) 7.3 (5.6-7.5) 3.6 (3.6-3.7)
Hazard ratio (95% CI) and P-value 0.64 (0.55-0.75);  <0.001
Objective response rate (mRECIST)
Objective response rate 41% 12%
Complete responses, n (%) 10 (2.1) 4 (0.8)
Partial responses, n (%) 184 (38.5) 55 (11.6)
95% CI (36-45) (10-16)
P-value <0.001
Progression-free survival (RECIST 1.1)
Number of events (%) 307 (64) 320 (67)
Median PFS in months (95% CI) 7.3 (5.6-7.5) 3.6 (3.6-3.9)
Hazard ratio (95% CI) 0.65 (0.56-0.77)
Objective response rate (RECIST 1.1)
Objective response rate 19% 7%
Complete responses, n (%) 2 (0.4) 1 (0.2)
Partial responses, n (%) 88 (18.4) 30 (6.3)
95% CI (15-22) (4-9)
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Sorafenib and lenvatinib safety data in 
HCC patients
15
◦ Sources: sorafenib SmPC; lenvatinib SmPC
Most common adverse reactions (≥20%)
sorafenib-treated patients in 
SHARP trial
Diarrhoea – fatigue – hand-foot skin reaction – weight loss –
anorexia – nausea – abdominal pain
lenvatinib-treated patients in 
REFLECT trial
Hypertension – fatigue – diarrhoea – decreased appetite –
arthralgia/myalgia – decreased weight – abdominal pain –
palmar-plantar erythrodysesthesia syndrome – proteinuria –
dysphonia – haemorrhagic events – hypothyroidism – nausea
IMbrave150 clinical trial
16
AFP, alpha-fetoprotein; BID, twice a day; ECOG PS; Eastern Cooperative Oncology Group performance status; HCC; hepatocellular carcinoma; 
IRF, independent review facility; IV, intravenous; mRECIST, modified RECIST; ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; 
PFS, progression-free survival; PRO, patient-reported outcome; q3w, every 3 weeks; R, randomization; RECIST, Response Evaluation Criteria In Solid Tumours;
VEGF, vascular endothelial growth factor




• IRF-assessed PFS per RECIST 1.1
Secondary endpoints include
• IRF-assessed ORR per RECIST 1.1 and HCC mRECIST
• PROs
Key eligibility criteria
• Locally advanced 
metastatic 
or unresectable HCC
• ECOG PS 0-1
• No prior systemic therapy




• Region: Asia (excluding Japan) or 
rest of world
• ECOG PS 0 or 1
• Presence or absence of 
macrovascular invasion or 
extrahepatic spread















1200 mg IV 
q3w 
+ bevacizumab 




Efficacy results: primary endpoints






Median OS (95% CI), months NE
13.2 
(10.4–NE)




Median PFS (95% CI) per 










Efficacy results: secondary endpoints

















Confirmed ORR per HCC specific 







IMbrave150 clinical trial - safety results
◦ AEs, adverse events






Patients with an AE from any cause 323 (98.2) 154 (98.7)
Grade 3-4 AEs (numbers represents the highest 
grades assigned)
186 (56.5) 86 (55.1)
Grade 5 AEs 15* (4.6) 9** (5.8)
Serious adverse event 125 (38.0) 48 (30.8)
AEs leading to withdrawal from any trial drug 51 (15.5) 16 (10.3)
AEs leading to dose modification or interruption of 
any trial drug
163 (49.5) 95 (60.9)
Dose interruption of any trial treatment 163 (49.5) 64 (41.0)
Dose modification of sorafenib – 58 (37.2)
*Grade 5 events in the atezolizumab–bevacizumab group: 
gastrointestinal haemorrhage (in 3 patients), pneumonia (in 2 patients), 
empyema, gastric ulcer perforation, abnormal hepatic function, liver 
injury, multiple-organ dysfunction syndrome, oesophageal varices 
haemorrhage, subarachnoid haemorrhage, respiratory distress, sepsis, 
and cardiac arrest (in 1 patient each)
**Grade 5 events in the sorafenib group:
death (in 2 patients), hepatic cirrhosis (in 2 patients), cardiac arrest, 
cardiac failure, general physical health deterioration, hepatitis E, 
and peritoneal haemorrhage (in 1 patient each)
IMbrave150 clinical trial - conclusion
◦ IMbrave150 demonstrated a statistically significant improvement in OS and PFS with 
atezolizumab + bevacizumab versus sorafenib in the first-line setting in patients with 
advanced HCC
◦ Times to response were similar in the combination and sorafenib arms
◦ Response rates were significantly higher in the combination arm
◦ The trial was conducted in a patient population that had preserved liver function 
(Child–Pugh class A) and a decreased risk of variceal bleeding. The safety of the 
combination in a broader population warrants further study
20Finn RS, et al. N Engl J Med. 2020;382:1894-905
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Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma 
(HCC): Results from older adults enrolled in IMbrave150 
Key results
Li D, et al. Ann Oncol 2020;31(suppl):abstr O-8
Overall survival





Median OS, mo NE 11.4





































Median OS, mo NE 14.9
HR (95%CI) 0.58 (0.36, 0.92)
Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma 
(HCC): Results from older adults enrolled in IMbrave150
Conclusions
◦ In older patients (≥65 years) with unresectable HCC, atezolizumab + bevacizumab demonstrated 
clinically meaningful benefits with no significant additional toxicities
Li D, et al. Ann Oncol 2020;31(suppl):abstr O-8
AEs occurring in ≥15% of patients treated 





Hypertension 47 (27) 51 (32)
Fatigue 24 (14) 43 (27)
Diarrhoea 28 (16) 34 (22)
Appetite decreased 26 (15) 32 (20)
Pyrexia 29 (17) 30 (19)
Pruritus 35 (20) 29 (18)
Proteinuria 39 (23) 27 (17)
AST increased 39 (23) 25 (16)
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CheckMate 459: long-term efficacy outcomes with nivolumab versus sorafenib as first-
line treatment in patients with advanced hepatocellular carcinoma – Sangro B, et al
Study objective
◦ To evaluate the long-term efficacy and safety of nivolumab as a 1L treatment for patients with 
advanced HCC








• Aetiology (HCV vs. non-HCV)
• Vascular invasion and/or extrahepatic spread (present vs. absent)
• Geography (Asia vs. non-Asia)
Nivolumab 240 mg iv q2w
(n=371)
Key patient inclusion criteria
• Advanced HCC 
• Ineligible for surgery and/or 
for loco-regional therapy or 
PD after surgery and/or 
loco-regional therapy
• Child-Pugh class A
• Systemic therapy naïve




Sorafenib 400 mg po bid
(n=372)
SECONDARY ENDPOINTS
• ORR, PFS, efficacy by PD-L1 status, safety
This talk was presented at the 22nd ESMO WCGC on 1 July 2020 at 18:20
CheckMate 459: long-term efficacy outcomes with nivolumab versus sorafenib as first-
line treatment in patients with advanced hepatocellular carcinoma – Sangro B, et al
Key results






























Primary analysis: June 2019 database lock
Median OS, months (95%CI) 16.4 (13.9, 18.4) 14.7 (11.9, 17.2)
HR (95%CI); p-value 0.85 (0.72, 1.02); 0.0752
Long-term follow-up analysis: April 2020 database lock
Median OS, months (95%CI) 16.4 (14.0, 18.5) 14.8 (12.1, 17.3)
HR (95%CI); p-value 0.85 (0.72, 1.00); 0.0522
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CheckMate 459: long-term efficacy outcomes with nivolumab versus sorafenib as first-
line treatment in patients with advanced hepatocellular carcinoma – Sangro B, et al
Key results (cont.)
Sangro B, et al. Ann Oncol 2020;31(suppl):abstr LBA-3
Overall survival by PD-L1 expression





Median OS, mo (95%CI) 16.1 (8.4, 22.3) 8.6 (5.7, 16.3)





















Median OS, mo (95%CI) 16.7 (13.9, 19.4) 15.2 (12.7, 18.1)















CheckMate 459: long-term efficacy outcomes with nivolumab versus sorafenib as first-
line treatment in patients with advanced hepatocellular carcinoma – Sangro B, et al
Key results (cont.)
aPatients could have had active or resolved HBV or HCV infection as a 
risk factor for HCC Sangro B, et al. Ann Oncol 2020;31(suppl):abstr LBA-3
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CheckMate 459: long-term efficacy outcomes with nivolumab versus sorafenib as first-
line treatment in patients with advanced hepatocellular carcinoma – Sangro B, et al
Key results (cont.)
Conclusions
◦ In patients with advanced HCC, 1L nivolumab continued to demonstrate improvements 
in OS regardless of PD-L1 status or viral aetiology and had a manageable safety profile
Sangro B, et al. Ann Oncol 2020;31(suppl):abstr LBA-3
TRAEs
















































KEYNOTE-240: Pembrolizumab for 
Patients With Previously Treated HCC 
◦ Randomized, double-blind phase III trial of pembrolizumab vs placebo (both with BSC) for pts with advanced HCC with intolerance to or PD on or after sorafenib; Child-Pugh A (N = 413)
◦ Failed to reach prespecified level of statistical significance for OS, PFS in primary analysis (prespecified P = .0174 [OS] and P = .002 [PFS] required) (median f/u 10.6-13.8 mos); updated analysis 
with additional 18 mos f/u
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Median OS, Mos (95% CI) 
13.9 (11.6-16.0)
10.6 (8.3-13.5)
HR (95% CI)             0.77 (0.62-0.96)






Median PFS, Mos (95% CI) 
3.3 (2.8-4.1)
2.8 (1.6-3.0)
HR (95% CI)                0.70 (0.56-0.89)
Nominal P = .0011
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CheckMate 040: Nivolumab + Ipilimumab 
for Advanced HCC
◦ Open-label phase I/II trial of 3 different dosing schemes of nivolumab + ipilimumab for patients 
with advanced HCC and prior sorafenib treatment; Child-Pugh score A5-A6; ECOG PS 0/1
◦ Dosing:
◦ NIVO1/IPI3 Q3W: nivolumab 1 mg/kg + 
ipilimumab 3 mg/kg Q3W (4 doses)
◦ NIVO3/IPI1 Q3W: nivolumab 3 mg/kg + 
ipilimumab 1 mg/kg Q3W (4 doses), 
each followed by nivolumab 240 mg Q2W
◦ NIVO3 Q2W/IPI1 Q6W: nivolumab 3 mg/kg 
Q2W + ipilimumab 1 mg/kg Q6W
























0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
LTFU periodMedian follow-up: 46.5 mos
Median OS, mos (95% CI)
NIVO1/IPI3 Q3W 22.2 (9.4-NA)
NIVO3/IPI1 Q3W 12.5 (7.6-16.4)
NIVO3 Q2W/IPI1 Q6W 12.7 (7.4-30.5)
Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced 
hepatocellular carcinoma: subanalysis of the CheckMate 040 study
Study objective
◦ To evaluate the efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced 
HCC








Nivolumab 1 mg + 
ipilimumab 3 mg q3w x4 
(n=50; 34 Asian)
Key patient inclusion criteria
• Advanced HCC
• Sorafenib naïve or 
progression after or 
intolerant to sorafenib
• Child-Pugh A5 or A6
• HBV, HCV or non-viral HCC








Nivolumab 3 mg + 
ipilimumab 1 mg q3w x4 
(n=49; 27 Asian)
PRIMARY ENDPOINTS
• Safety, ORR (RECIST v1.1, investigator 
assessed), DoR
SECONDARY ENDPOINTS
• DCR, TTR, TTP, PFS, OS
Arm C
Nivolumab 3 mg q2w + 
ipilimumab 1 mg q6w 
(n=49; 29 Asian)
This talk was presented at the 22nd ESMO WCGC on 1 July 2020 at 18:29
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Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced 
hepatocellular carcinoma: subanalysis of the CheckMate 040 study 
Yao T, et al. Ann Oncol 2020;31(suppl):abstr O-5























































































+ IPI1 q6w 
(n=49)
ORR, n (%) 8 (24) 9 (33) 9 (31) 16 (32) 15 (31) 15 (31)





























Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced 
hepatocellular carcinoma: subanalysis of the CheckMate 040 study 
Key results (cont.)
Conclusions
◦ In Asian patients with advanced HCC, nivolumab + ipilimumab demonstrated clinically meaningful responses, 
particularly in the nivolumab 1 + ipilimumab 3 arm
◦ The safety profile was manageable with no new safety signals observed
Yao T, et al. Ann Oncol 2020;31(suppl):abstr O-5
Grade 3/4 TRAEs, 
n (%)























+ IPI1 q6w 
(n=48)
Any 17 (52) 7 (26) 8 (28) 26 (53) 14 (29) 15 (31)
Pruritus 1 (3) 0 0 2 (4) 0 0
Rash 1 (3) 1 (4) 0 2 (4) 2 (4) 0
Diarrhoea 1 (3) 0 0 2 (4) 1 (2) 1 (2)
AST increased 5 (15) 3 (11) 2 (7) 8 (16) 4 (8) 2 (4)
Fatigue 0 0 0 1 (2) 0 0
ALT increased 3 (9) 2 (7) 0 4 (8) 3 (6) 0
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Checkmate 040 : nivolumab in 
advanced hepatocellular carcinoma
◦ Nivolumab 3 mg/kg lead to objective response in 16% of the patients using RECIST 1.1 (15% of 
PR and 1% of CR)
◦ Disease control rate of 68%
◦ Median overall survival of 15 months
◦ Acceptable safety profile
◦ Randomized controlled trial phase 3 comparing sorafenib to ivolumab in advanced HCC 
(Checkmate 459)
El Khoueiry AB, et al. Lancet 2017
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Outcomes for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh 
B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
Study objective
◦ To evaluate the efficacy and safety of cabozantinib in the subgroup of patients with advanced HCC 
whose liver function had deteriorated to Child-Pugh B by Week 8









• Disease aetiology (HBV, HCV, other)
• Geographic region (Asia, other)





Key patient inclusion criteria
• Advanced HCC
• Child-Pugh score A
• Received prior sorafenib
• Progressed after ≥1 prior systemic 
treatment for HCC
• Received ≤2 prior systemic 
regimens for advanced HCC













This talk was presented at the 22nd ESMO WCGC on 1 July 2020 at 19:32
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Outcomes for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh 
B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
Key results








8.5 (7.7, 12.2) 37
Placebo (n=22) 3.8 (3.3, 4.8) 20
Child-Pugh B subgroup
HR 0.32 (95%CI 0.18, 0.58)
Overall





Cabozantinib (n=470) 10.2 (9.1, 12.0) 317







































Outcomes for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh 
B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
Key results (cont.)
Conclusions
◦ In patients with advanced HCC and Child-Pugh B liver function by Week 8, cabozantinib demonstrated 
similar outcomes to those of the overall population and had a manageable safety profile
El-Khoueiry A, et al. Ann Oncol 2020;31(suppl):abstr SO-9
















Multiple VEGF-Targeted Therapies Have 
Activity After Sorafenib: Phase III Data
Regorafenib: multitargeted TKI
Bruix. Lancet. 2017;389:56. Abou-Alfa. NEJM. 2018;379:54. Zhu. Lancet Oncol. 2019;20:282.
RESORCE CELESTIAL REACH-2
Regorafenib vs placebo Cabozantinib vs placebo (N = 707) Ramucirumab vs placebo 




2L, AFP ≥ 400 ng/mL
(N = 292)
Median OS: 10.6 vs 8.0 mos Median OS: 10.2 vs 8.0 mos Median OS: 8.5 vs 7.3 mos
HR: 0.63 (P < .0001) HR: 0.76 (P = .005) HR: 0.71 (P = .0199)
Cabozantinib: multitargeted TKI Ramucirumab: anti-VEGFR2 Ab
OS






OS vs placebo for 












Systemic treatment sequencing for BCLC 
Stage C advanced HCC
◦ Targeted first-line therapies
◦ Combination: atezolizumab (PD-L1 inhibitor) + bevacizumab* (VEGF inhibitor) (US only)
◦ Oral multikinase inhibitors: sorafenib and lenvatinib
◦ Targeted second-line therapies
◦ Multikinase inhibitor: regorafenib
◦ Multikinase inhibitor: cabozantinib
◦ Anti-VEGFR (AFP ≥400 ng/mL) antibody: ramucirumab
◦ PD-1 inhibitors: nivolumab, pembrolizumab
◦ Immune therapy Combination: nivolumab + ipilimumab
47
Bruix J, et al. Nat Rev Gastroenterol Hepatol. 2019;16:617-30
cabozantinib
cabozantinib












ADVERSE EFFECTS OF 
IMMUNOTHERAPY IN 
HEPATOCELLULAR CARCINOMA
- case presentation -
Dimitar Stefanovski, dr.med.
Prof. dr. Janja Ocvirk, dr. med.
2nd International Summer school
OCTOBER 2019
• 83 years old female patient;
• former smoker, no history of alcohol consumption;
• y. 2010 - excision of the submandibular gland (adenoca.),
osteoporosis GERD, AMD;
• PS WHO 1
• pain under the right costal arch;
• abdominal US: tumour formation in the liver;
• moderately differentiated, pseudo glandular HCC.
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• CT thorax + abdomen: hypervascular tumour in the right liver lobe
with A – V fistulas, invasion of the middle hepatic vein, without
cirrhosis, no signs of distant metastasis.
NOVEMBER 2019
• 1st line treatment with Sorafenib
• After 1st application: skin toxicity - erythematous skin with macular 
rash
• Continuing the treatment with dose reduced Sorafenib
• pain in the palms and soles of the feet, macular rash.




• EMBOLIZATION not possible due to the vascular shunt.
• IMbrave 150 tiral results:
Patients with unresectable
hepatocellular carcinoma have
better survival with the
combination of atezolizumab
and bevacizumab than with
sorafenib as first line
treatment.
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• Systemic therapy with Atezolizumab + Bevacizumab.
• CT scans showing stable disease.
JANUARY 2020
JUNE 2021
• oral mucositis (grade 2)
• petechiae, somewhere ulcerated skin with bleeding (grade 1)
• productive cough, non purulent sputum (grade 1)
• temporarily suspended bevacizumab, continuation with atezolizumab
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JULY 2021 - HOSPITALIZATION
• feeling extremely unwell
• cough (grade 2)
• bloody diarrhea (grade 2)
• ecchymosis, somewhere superficially ulcerated skin with bleeding 
(grade 1)
• negative microbiological analyses
• CT scan: PNEUMONITIS
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TREATMENT
• i.v. corticosteroids in high doses 1 mg/kg BW
• i.v. Vit K
• after 1 week of hospitalization, discharged in stable condition
• continuation of corticosteroids therapy p.o. at home
THANK YOU FOR YOUR ATTENTION
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Enrichment of treatment 




Institute for Oncology and Radiology 
of Serbia Belgrade
2nd International Summer School of Oncology
Onkološki Inštitut Ljubljana, 08.09.2021.
Advent of immunotherapy 
supstantially changed initial 
treatment of advanced NSCLC
Factors in choosing initial therapy:
Level of PD-L1(≥50%)
Presence or absence of a driven mutation 
(EGFR, ALK, ROS1, BRAF,etc) 
The extent of disease (number and sites of 
metastases, symptoms)
Squamous vs nonsquamous histology
180
Treatment algorithm for stage IV NSCC, molecular tests 
negative (ALK/BRAF/EGFR/ROS1), ESMO 2020
Check-point inhibitors, specially targeting PD-1 





Decision-making in this space is complex:
the absence of head-to-head prospective comparisons
Paramount for patient selection: 
tumor cell PD-L1 expression and histology
181
Immunotherapy today
*Data not yet made public
1. Carbone, et al. N Engl J Med 2017; 2. Reck, et al. N Engl J Med 2016; 3. Mok, et al. Lancet 2019
4. Rizvi, et al. JAMA Oncol 2020; 5. Spigel, et al. ESMO 2019 (Abs LBA78)
6. Regeneron press release (5 November 2019); 7. Gandhi, et al. N Engl J Med 2018
8. Socinski, et al. N Engl J Med 2018; 9. West, et al. Lancet Oncol 2019
10. Papadimitrakopoulou, et al. WCLC 2018 (Abs OA05.07); 11. Paz-Ares, et al. ESMO IO 2019 (Abs LBA3)
12. Reck, et al. ASCO 2020 (Abs 9501; 13. AstraZeneca press release (28 October 2019)















































Cemiplimab + platinum 
doublet chemotherapy
KEYNOTE-407





Tumor PD-L1 expression ≥ 50%: Initial systemic treatment
(driven mutation absent or unknown) for patients with
squamous or non-squamous NSCLC
Pembrolizumab superior in OS over platinum doublet (KN024)
Atezolizumab superior in OS over platinum doublet (IMpower 110)
Cemiplimab superior in OS over platinum doublet (EMPOWER-Lung1)
An exception, combination doublet chemotherapy with concurrent 
pembrolizumab : high tumor burden or rapidly progressive disease in which 
early PD might preclude the option of chemotherapy in 2nd line setting, due 
to functional decline
Contraindication for immunotherapy (a histology-appropriate platinum 
doublet): allograft recipiens, myastenia gravis, severe IBD or vasculitis
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Cochrane Meta-analysis 2020: data from 7 clinical trials 
comparing the efficacy of PD-L1/PD1 inhibitors to that of 
chemotherapy in patients with advanced NCSLC (n=5893) 
Ferrara et al. Cochrane Database Syst.Rev 12. CD13257 (2020)
Anti PD1/PD-L1 antibodies improved OS in patients  with tumor cell PD-
L1≥50% (n=2111) compred with chemotherapy (HR 0.68, 95%CI 0.60-0.76) 
with a moderate level of certainty
Among never-smokers with PD-L1 expression ≥50%, N=179, no 
stat.significant difference in OS between PD1/PD-L1 Abs and 
chemotherapy; current or former smokers had OS advantage with 
immunotherapy over chemotherapy
No statistically significant difference in OS in PD-L1˂1% or ≥1%
Response rate and Survival at Key Timepoints With 
PD-L1 Blockade vs Chemotherapy in PD-L1 Subgroups: 
Meta-analysis of Metastatic NSCLC trials 
J.Man et al. JNCI Cancer Spectrum(2021)5(3):pkabo012
 9810 pts in 27 studies, retrospective analysis, systematic research of MEDLINE/EMBASE
 In treatment naive patients benefits with PD-L1 blockade over CT were seen in 
ORR in pts having PD-L1 ≥50%,  
2yrOS for PD-L1 ≥1%, 
1-yrPFS, 2-yrPFS and 3-yrOS in unselected pts
 First-line PD-L1 blockade  compared with CT:
Higher ORR, 2-yrPFS and 3-yrOS if PD-L1 was 50% or greater
Lower ORR, higher 2-yrPFS and similar 3-yrOS if PD-L1 was 1-49%
Lower ORR, similar 1-yrPFS and lower 2-yrOS if PD-L1 was less than 1%
 In previously treated patients, PD-L1 blockade demonstrated similar or superior 
outcomes in all PD-L1 subgroups
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Outcomes to first-line pembrolizumab 
in patients with non-small-cell lung 
cancer and very high PD-L1 expression
Aguilar EJ. Et al. Ann Oncol 2019.  
Multicentric retrospective analysis 187 patients,
ORR 44.4%, mPFS 6.5mo, mOS NR
 PD-L1 50-89% N=107pts, ORR 32.7%, mPFS 4.1mo, OS 15.9mo
 PD-L1 90-100% N=80pts, ORR 60%, mPFS 14.5mo, OS NR
Implication: treatment selection, clinical trial intepretation and design
Does immuno-chemotherapy and imuno-immunotherapy
provide additional benefit beyond that of pembrolizumab 
or atezolizumab monotherapy in PD-L1≥50% population?
24 months OS:
50% pembrolizumab mono in KEYNOTE 024 trial
52% pembrolizumab+chemotherapy in PD-L1≥50%  subgroup of KEYNOTE189   
48% with nivolumab+ipilimumab in CheckMate227 trial.
Immuno-chemo and immuno-immuno combination are associated with 
predictable but higher risk of toxicities, while mono  anti-PD1/PD-L1 provide 
impressive levels of tolerability compared to chemotherapy
AntiPD1/PD-L1  antibodies as monotherapy for most patients
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Whom we should offer combo immuno-chemotherapy in 
PD-L1≥50% population?
Imminent need for cytoreduction: 
substantial tumor burden, 
rapidly progressive disease and/or 
severe disease related symptoms
Numerically higher ORR than PD-1/PD-L1 monotherapy
Rapid cytoreduction produced by combo might also attenuate the early
decrements in OS seen in patients receiving monotherapies
Only 51% of patients with PD on pembrolizumab in KN024 and 38% in
experimental arm of KN042 received subsequent therapy
Mono vs combo approach
ORR in patients with PD-L1 expression > 50%
Brahmer et al ESMO 2020 KEYNOTE-024 5 year OS update, Gray et al WCLC 2020 KEYNOTE-189 4 year OS update, Cho et al WCLC 2020 KEYNOTE-042 3 year OS update, 





































































Addition of chemo to immunotherapy does not add benefit in nonsquamous
mNSCLC with high expression of PD-L1 (except in patients with no smoking 
history)  S.Peters et al. ESMO Virtual Pnenary, April 8, 2020.
Observational study, Flatitron Health database, 520 pts, PS 0-2, PD-L1≥50%,
pembrolizumab mono (N=351) or plus paclitaxel-carboplatin (N=169)
Mono arm: higher proportion of poor prognostic baseline characteristics (age, extent
of disease)
Median OS 22.1mo vs 21.0mo p=0.63 HR 1.03, PFS 11.5 vs 10.8mo
No smoking population: combo reduced risk by 75%, P=0.02 and 60%,P=0.04
Liver and brain metastases: outcomes were similar
Invited discutant F.Cappuzzo, ESMO 2020.
About 30% of patients in phase III clinical trials have better survival outcome
with chemotherapy than with single-agent CPI.
In most relevant trials mOS with single-agent was less than two years, but more
than two years in combo approach, ORR were also higher
Cost: toxicity – grade 3-5 in appr. 60% with combo, compared to 20% treated with
single agents
Combo certainly in never-smokers
Not all patients with PD-L1 are equall (Pts with≥90% are extremly sensitive to
immunotherapy)
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Mono imunotherapy options in 1L NSCLC
ORR,DoR, PFS, OS in PD-L1 >50% population

















































































































A subset of patients have a paradoxical
acceleration in tumor growth and clinical
deterioration upon initiation of therapy
The incidence of hyperprogression in previously
treated NSCLC ranges from 8 to 21%
In treatment-naive NSCLC receiving anti-PD1/PD-
L1 as monotherapy the incidence was 16%




Up to 2 years in KEYNOTE and CheckMate 227 trials
Indefinite maintenance in IMpower119, IMpower 130 and IMpower150
Results of KN158 randomized study favored longer duration than a 1 year
fixed dose (small sample, lack of alternative fixed dose, such as 2 years)
In KEYNOTE 024 39 of 154 pts (25%) completed 2 years of
pembrolizumab, and 3-year landmark OS from completion was 81%
These data suggest that most patients completing 2 years of
treatment continue to derive long-term benefit, despite therapy
cessation
The decision to discontinue maintenance in the absence of
substantial toxicities or disease progression should be individualized:
whether therapy beyond 2 years improves outcome remains largely
unclear
Post-progression outcome of NSCLC patients with PD-L1
expression ≥50% receiving first-line single-agent
pembrolizumab in a large multicentre real-world study
Cortellini A. et al, Eur J Cancer 2021.
974 patients were included, median follow-up 22.7months
Median OS 15.8 months (95% CI:13.5-17.5; 548 events)
55.9% had not received any further treatment, 52.9% died
Patients who did not receive post-PD therapies were: older (p=0.0011),
with a worse PS (p˂0.0001) and were on corticosteroids prior to
pembrolizumab (p=0.0024);
At disease progression, 29.2% received a switched approach, 14.9%
received pembrolizumab beyond PD, either alone (9.4%) or in combo
with local ablative treatments (5.5%): OS 13.9 vs 7.8mo (p=0.0179)
35.5% received second-line systemic treatment (sign.higher proportion
of age under 70, poorer PS, having CNS and liver mets)
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Real-world study (Cortellini 2021) and KN024: 
Pts with PDL1≥50%
Median OS 15.8mo vs 26.3mo
Not unsuprising: higher proportion of patients with adverse prognostic
factors (PS ≥2, receiving corticosteroids, older than 70years)
Patients in clinical studies are highly selected for lower co-morbidity burden
Inferior outcome: patients with poor baseline PS, particulary if related to
disease burden; 55.9% did not receive any further treatment;
Older pts, PS ≥ 2, receiving systemic corticosteroids are at higher risk of life-
thretening progressive disease – thus, treatment sequencing approach ICI-CT
doublet is unlikely to be completed
Oligoprogression and pembrolizumab beyond PD: the best post-PD outcome:
pembrolizuimab beyond PD + local ablative treatment
Among patients who reach a second-line treatment, PS still remains th major
determinent of clinical outcome
Real-world study (Cortellini 2021) and KN024: 
Pts with PDL1≥50%
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Take home messages –
mNSCLC with PD-L1≥50%
Decision-making in this space is complex: the absence of
head-to-head prospective comparisons
Paramount for patient selection: tumor cell PD-L1
expression and histology
AntiPD1/PD-L1 antibodies as monotherapy for most
patients
Not all patients with PD-L1 are equall: patients with ≥ 90%
are extremly sensitive to immunotherapy, non-smokers
are for combo approach or chemotherapy
The decision to discontinue maintenance in the absence of
substantial toxicities or disease progression should be
individualized: whether therapy beyond 2 years improves
outcome remains largely unclear
Hyperprogression can largely be avoided using first-line 
chemo-immunotherapy combinations 
Toxicity – grade 3-5 in appr. 60% with combo, compared to 20% 
treated with single agents
Take home messages –
mNSCLC with PD-L1≥50%
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Clinical choices in metastatic NSCLC without actionable oncogenic 
driver mutations regardless of PD-L1 status 
Marko Jakopović, MD, PhD
Associate Professor
Zagreb Medical School
Department of Respiratory Medicine
University Hospital Centre Zagreb
Disclosures
Speakers fees: AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Berlin Chemie, 
Sandoz, Novartis, MSD, Novartis Oncology, Abbott




How to choose treatment options in metastatic NSCLC in patients without driver 
mutation?
 Immunotherapy vs chemotherapy?
Nivolumab vs docetaxel in previously treated squamous NSCLC
Brahmer J et al. N Engl J Med 2015;373:123-135.
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Pembrolizumab in treatment-naive highly positive PD-L1 NSCLC 
patients
Reck M et al. N Engl J Med 2016; 375:1823-1833.
Atezolizumab was superior to docetaxel regardless of PD-L1 
expression in NSCLC
Rittmeyer et al. Lancet 2016. 
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Overview
How to choose treatment options in metastatic NSCLC in patients without driver 
mutations?
 Immunotherapy vs chemotherapy?  The winner is immunotherapy!!!!!
 Line of treatment of immunotherapy?  
 Monotherapy vs combination therapy (CT+IO, IO+IO)?  
 Does histology matter?
 Open questions
 Conclusions
Line of treatment of immunotherapy?
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Nivolumab in heavily preatreated patients
Brahmer JR et al. N Engl J Med 2012;366:2455-2465.
Second-line immunotherapy in NSCLC
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KeyNote-024: First-line pembrolizumab 
in PD-L1 highly positive patients
Overview
How to choose treatment option in metastatic NSCLC in patients without driver 
mutations?
 Immunotherapy vs chemotherapy?  The winner is immunotherapy!!!!!
 Line of treatment of immunotherapy?  The winner is first – line immunotherapy!!!!
 Monotherapy vs combination therapy (CT+IO, IO+IO)? 




Monotherapy vs combination therapy (CT+IO, IO+IO)? 
Keynote-042: Pembrolizumab vs Chemotherapy in PD-L1 positive
NSCLC
197
Mok TS et al. Lancet 2019
Keynote-042: Overall survival in ITT population
Overview
How to choose treatment option in metastatic NSCLC in patients without driver 
mutations?
 Immunotherapy vs chemotherapy?  The winner is immunotherapy!!!!!
 Line of treatment of immunotherapy?  The winner is first – line immunotherapy!!!!
 Monotherapy vs combination therapy (CT+IO, IO+IO)? In patients with PD-L1 
expression <50% the winner is combination therapy!!!!







https://bit.ly/2snPEzbJotte R, et al. IMpower131 PFS Analysis. 
IMower131: Study Design 
Atezolizumab 1200 mg IV q3w; carboplatin AUC 6 IV q3w; nab-paclitaxel 100 mg/m2 IV qw; paclitaxel 200 mg/m2 IV q3w. 
a Patients with a sensitising EGFRmutation or ALK translocation must have disease progression or intolerance to treatment with ≥ 1 approved targeted therapies. Testing for EGFR mutation or ALK translocation was not mandatory.




4 or 6 cycles
Atezolizumab
Arm C (control)
Carboplatin + Nab-Paclitaxel 















Stage IV squamous NSCLC
• Chemotherapy naivea
• ECOG PS 0 or 1 
• Any PD-L1 IHC status
Stratification factors:
• Sex
• PD-L1 IHC expression












per RECIST v1.1 





• Investigator-assessed PFS per RECIST v1.1 (ITT)
• OS (ITT)
Secondary endpoints
• PFS and OS in PD-L1 subgroups
• ORR, DOR; safety
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https://bit.ly/2snPEzbJotte R, et al. IMpower131 PFS Analysis. 
INV-Assessed PFS in the ITT Population (Arm B vs Arm C) 
Data cutoff: January 22, 2018. 
INV, investigator. a Stratified HR. 
Minimum follow-up, 9.8 mo






































CheckMate 9LA: NIVO + IPI + 2 cycles of chemo in 1L NSCLC
Overall survival by histology
SQ NSCLCbNSQ NSCLCa








0.69 (0.55–0.87)HR (95% CI)






(95% CI) (13.1–19.4) (7.2–11.6)
HR (95% CI) 0.62 (0.45–0.86)
No. at risk






























NIVO + IPI + chemo
Chemo
Months Months
224 204 170 154 107 62 20 6 0 0 115 102 88 80 73 46 24 13 4 1 0
223 180 152 122 87 53 18 9 0 0 112 96 80 56 44 29 14 8 2 0 0
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Overview
How to choose treatment options in metastatic NSCLC in patients without driver 
mutations?
 Immunotherapy vs chemotherapy?  The winner is immunotherapy!!!!!
 Line of treatment of immunotherapy?  The winner is first – line immunotherapy!!!!
 Monotherapy vs combination therapy (CT+IO, IO+IO)? In patients with PD-L1 
expression <50% the winner is combination therapy!!!!
 Does histology matter? Combination treatment is superior to chemotherapy alone 




I still have to talk about patients wit metastatic NSCLC and driver mutations
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Check-point inhibitors in EGFR mutated lung cancer
Lee CK et al. J Thorac Oncol 2016; in press
*One patient had EGFR exon 19 deletion and also tested ALK positive per central lab; 
†Unstratified HR; Data cut-off: 22 January 2018 Socinski, et al. ASCO 2018 (Abstract 9002); Kowanetz, et al. AACR 2018 (Abstract CT076)
In EGFR/ALK+ NSCLC patients, OS benefit seen with 
combination of bevacizumab + atezolizumab + chemotherapy
26
OS benefit in EGFR/ALK+ patients was observed despite lower PD-L1 expression in these patients
NE17.5 mo
EGFR/ALK+ 
Bev + atezo + CP* vs Bev + CP
17.5 mo 21.2 mo
0
0













































Atezo + CP vs Bev + CP
4 6 8 10 12 16 18 20 24 26 28 4 6 8 10 12 16 18 22 24 28 30
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Mono-immunotherapy vs combination therapy?
Mono vs combination of IO plus chemotherapy – what to choose?
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Overview
How to choose treatment options in metastatic NSCLC in patients without driver 
mutations?
 Immunotherapy vs chemotherapy? 
The winner is immunotherapy!!!!!
 Line of treatment of immunotherapy?  
The winner is first – line immunotherapy!!!!
 Monotherapy vs combination therapy (CT+IO, IO+IO)? 
In patients with PD-L1 expression <50% the winner is combination therapy!!!!
 Does histology matter? 
Combination treatment is superior to chemotherapy alone regardless of histology 
subtype!!!!
 Open questions? In patients with driver mutations combination of IO+bevacizumab+CT is an 
option!!!! 
In patients with PD-L1<50% combination therapy is better option!!!! 




Long-term survival with mono-immunotherapy
Long-term survival with combination therapy
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Systemic treatment of head and neck 
cancer – what's new in the old 
Assist. Professor Cvetka Grašič Kuhar, MD, PhD
Institute of Oncology Ljubljana, Slovenia
Main question: comparing curative locoregional treatment (LRT) with LRT+Cht
Which treatment is the most effective?
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Conclusions regarding systemic treatment in SCHNC
• Cisplatin based CRT remained the standard of care in cisplatin-fit patients
• There is evidence from 2 phase III trials that weekly cisplatin could be delivered instead of 
high dose cisplatin, efficacy is similar, treatment is less toxic
• Addition of cetuximab or ICI does not improve outcome
• Replacing cisplatin with cetuximab or ICI is less effective (less locoregional control)
• Xevinepant may further increase treatment efficacy
• Cisplatin sensitive:
• ICI (Immune checkpoint inhibitor pembrolizumab) in I. line of SCHNC
• with Chemotherapy (CPS≥1) or as monotherapy (CPS ≥ 1/, >20)
• Extreme regimen: CPS<1 or contraindication for ICI
• Cisplatin resistant :  ICI monotherapy, mono-chemotherapy
• Treatment of stage III/IV disease
• Recurrent/metastatic disease
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Updated results of patients with recurrent or metastatic head and neck cancer treated with 
nivolumab between January 2018 and March 2020 in Slovenia 
In total, 27 patients with head and neck cancers were treated with nivolumab in this period. The 
cohort consisted almost entirely of male patients (96%) and the median age was 59 years. Most of 
these patients were smokers (89%), and their performance status was 0-1 in 88.9%. 
The majority had pharyngeal cancer (63%) of which 3 were HPV positive. Almost a third of patients 
were heavily pre-treated, having received three or more lines of systemic therapy. Cetuximab was a 
part of this treatment in 44% of patients. 
There were in total 14 immune-related adverse events occurring in 8 patients in total, of which there 
was only one case of grade 2-3 event (bullous pemphigoid), while other 13 events were all grade 1. 
Only one patient received concurrent radiotherapy (60Gy to parastomal recurrence). 
At the end of the updated observation period there were 22 deaths in total. Median overall survival 
from the first nivolumab application was 10.7 months (95% CI 1.7-19.7) which is comparable to the 
CheckMate 141 results.1 One-year overall survival rate was 48.1% (95%CI 29.3-66.9). 
Univariate analyses of possible predictive variables with log-rank test, namely the impact of 
presence of distant metastases, immune-related adverse events, neutrophil to lymphocyte ratio, and 
impact of concurrent antibiotics treatment on overall survival, found no statistically significant 
correlation. Individual patients’ timelines from diagnosis to death or to last follow up are presented 
in figure 1. 
Overall, we can conclude that treatment with nivolumab has been shown to be safe also in Slovenian 
patients with recurrent or metastatic head and neck cancer. Due to the small number of patients, it 
is difficult to align the outcomes with the results of previous studies, but in general results are 
comparable. 












1.  Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for 
Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856–
67. 
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Outcome of patients with recurrent/metastatic squamous cell head and neck 
cancer treated with platinum-based chemotherapy with or without cetuximab in 
real-world practice
Tina Zupančič, prof.dr. Branko Zakotnik, doc.dr. Cvetka Grašič Kuhar
• A retrospective analysis of patients with R/M SCHNC treated at the Institute of Oncology Ljubljana 
between April 2008 and May 2018.
• A total of 67 patients: 34 patients received the PF (platinum, 5-FU), 33 the PFE (PF + cetuximab).
• Inclusion criteria for the PF and PFE protocols: First-line therapy for R/M SCHNC, PS 0-2, 
adequate haematologic, renal and liver function, approved reimbursement for cetuximab (for PFE 
only).
• Exclusion criteria for the PE and PFE protocols: Patients with nasopharyngeal carcinoma, PS >2.
• Exclusion criteria for PFE only: Infusion reaction to cetuximab grade >2, prior treatment with 
cetuximab, known allergy to bee or wasp venom grade >2,bulky tumour in the oropharynx or 
larynx.
• The primary aim: to compare the PSF and OS in the routine clinical setting with outcomes in a 
randomized trial and to identify possible prognostic factors for PFS and OS. 
• The secondary aim: to assess the tolerability.
Conclusions
• PFE regimen has improved OS (but not PFS) when compared to the PF regimen 
(median PFS 7.1 vs 6.6; median OS 11.5 vs 9.6 months).
• Objective response to therapy, good nutritional status and possible further 
treatment after progression have better prognosis (prognostic factors for OS).
• Our results regarding OS are comparable to the EXTREME study.
• Similar median PFS and OS with PFE were reported by other real-world studies.
• OS of our patients is better than real-world global OS.
• No differences in diarrhoea, hypomagnesaemia, infections and febrile neutropenia.
• High mortality (13.4%).
• PFE still represents the optimal 1st line therapy for fit patients with PD-L1 negative 
R/M SCHNC (20-30%) or with contraindication for anti-PD-L1 inhibitors and as 2nd 
line therapy.
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Management of cancer of 
unknown primary in the 
molecular era




• CUP is biopsy-proven malignancy for which the anatomic origin at the 
time of presentation remains unidentified in spite of a detailed history, 
physical examination and a thorough diagnostic work-up. 
• CUP is a heterogeneous group of metastatic tumors, which share some 
common features: 
• the ability of an early dissemination, 
• clinical absence of the primary site, 
• aggressive behaviour, 
• unpredictable metastatic pattern,
• poor response to conventional systemic cytotoxic therapy.
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
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Basic diagnostic-work-up in CUP
(ESMO guidelines)
• Patient’s history
• history of previous biopsies, spontaneously regressing lesions and family history
• Physical examination
• Including rectal and breast examination. 
• Good quality tissue sample (ESENTIAL!): 
• meticulous immunohistochemistry.
• Basic blood and biochemical analyses.
• CT of the chest, abdomen and pelvis.
• Mammography in women.
Diagnostic strategy should take in account the natural behaviour of the disease and the expected 
duration of survival based on extent of the disease and PS. 
Difficult and time-consuming diagnostic studies should not compromise patients' quality of life.
Ann Oncol 2015; 26(Suppl 5): v133-138.
Additional diagnostic-work-up in CUP (1)
• Additional procedures should be sign-, symptom-, lab. abnormalities guided.
• Breast MRI: in patients with isolated axillary lymph node metastases and 
suspected occult primary breast carcinoma after negative mammography and 
sonography results. 
• Broader use of MRI in CUP diagnostics is questionable. 
• Endoscopy: if the patient has symptoms or relevant signs. 
• FDG-PET imaging in CUP diagnostics:
• in patients with cervical lymphadenopathy of primarily squamous histological subtype. 
• PET-CT is useful (not been prospectively studied): 
• Patients presenting with solitary metastatic disease who are candidates for curative loco-regional 
treatment in purpose to exclude occult metastases before extensive surgery, 
• Patients with known severe iodine dye allergy 
• Patients with predominant bone disease who would otherwise require either multiple MRIs or bone 
scans to evaluate response to therapy. 
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
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Additional diagnostic-work-up in CUP (2)
• Serum tumour markers have no proven prognostic, predictive or 
diagnostic assistance. 
• Increased values of some tumour markers may help in guiding further 
diagnostics: 
• Beta human chorionic gonadotropin (beta-HCG) and alpha-fetoprotein (AFP):
• in patients with midline tumour masses with undifferentiated histology. 
• Prostate Specific Antigen (PSA): 
• in men with adenocarcinoma and predominantly bone disease. 
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
Unfortunately, most tumour markers (CEA, CA125, CA19-9 and CA15-3) are not specific and thus are not 
helpful in searching for the site of primary tumour.
Clinical presentation of patients with 
CUP?
• There is no unique clinical picture. 
• The majority of patients presents with symptoms and signs of metastatic 
disease. 
• There are patients with only or manly liver metastases, with lymph node 
metastases in mediastinal or retroperitoneal region, with axillary lymph 
nodes, with cervical lymph nodes, with peritoneal disease, with malignant 
ascites, with lung disease only or pleural effusion only, bone only disease or 
metastases to CNS only, although more often as a part of disseminated 
disease. 
• Clinical presentation depends on number of metastatic lesions and their 
distribution. 
• The majority of patients has metastatic disease in more than one organ, 
the most often in liver, lung, bone and lymph nodes.
Ann Oncol 2015; 26(Suppl 5): v133-138.
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How can pathologist help? (1)
• Challenging work! Direct communication between clinician and pathologist is 
crucial. 
• The trend across all cancer types is personalized medicine (CUP seem ideal 
candidate).
• Core biopsy is preferred over fine needle aspirate specimen. 
• Light microscopy (LM): the tissue specimen (paraffin sections stained with eosin 
and haematoxylin)
• Based on established cytological criteria, the pathologist usually can classify the tumors into 
broad groups: 
• Carcinoma (5% SSC)OR adenocarcinoma (60%), 
• Sarcoma,
• Lymphoma. 
• Some specimens will lack any cytological distinguishing features:
• undifferentiated malignancy (35%). 
Ann Oncol 2015; 26(Suppl 5): v133-138.
How can pathologist help? (2)
• IHC: significant role in the workup of CUP
• Define tumour lineage by using peroxidase-
labelled antibodies against specific tumour 
antigens. 
• Have to be directed in terms of clinical and 
radiological patient's data. 
• Random use of large numbers of tissue 
markers is rarely helpful.
• Staining for different CK (components of 
cytoskeleton of epithelial tissue) may be very 
helpful. 
• Commonly used staining for CK7, 20, 5 and 6. 
• From the pattern of theirs' expression, the most 
likely site of origin can be identified.
The method has limitations:
• the majority of tissue markers are not specific for one organ
• no pattern is 100% specific,
• the absence of markers does not exclude the origin in certain organ/tissue.
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
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How can pathologist help? (3)
• The value of some antibodies, such as AFP, beta-HCG, PSA is well established. 
• Some stainings are organ/tissue specific, such as ER, leukocyte common antigen. 
• The absence of certain marker does not exclude the origin in that organ/tissue. 
• The majority of tissue markers are not specific for one organ. 
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
How can pathologist help? (4)
• Novel molecular approaches in CUP evaluation:
• Gene expression profiling tests (GEP) to identify the tissue of origin (ToO)
• Comprehensive genomic profiling tests (CGP) to find treatable (clinically 
relevant) genomic aberrations (GA)
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
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Gene expression profiling
• Methodology: RT-PCR or microarrays evaluating the expression od 
different genes
• Several assays on the market (evaluating from 10 to 92 and more 
genes)
• Tested in a randomized phase III trial (GEFCAPI 04)
Gene expression tests
• Are molecular cancer classifiers that help identify the site of origin for 
cancers with indeterminate, uncertain, or differential diagnoses.
• CancerTYPE ID® uses real-time RT-PCR to measure the expression of 92 genes 
in the patient’s tumor and classifies the tumor by matching the gene 
expression pattern of the patient’s tumor to a database of known tumor types 
and subtypes, encompassing 50 tumor types (not FDA approved).
• Tissue of Origin Test® is based on Affymetrix microarray. It compares the 
expression for 2000 genes in a patient‘s tumor with a panel of 15 know tumor 
types that were diagnosed according to current clinical and pathological 
practice (FDA approved in  June 2010).
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GEFCAPI 04 (Study description)
• Phase III trial of empiric chemotherapy with cisplatin and gemcitabine (GC) or 
systemic treatment tailored by molecular gene expression analysis in patients 
with carcinomas of an unknown primary (CUP) site
• TOO (Pathwork; n=21) or CancerTYPE ID (Biotheranostics; n=222); N=243
• Primary endpoint: PFS
• Secondary endpoints:
• OS 
• PFS in patients with cancers
likely insensitive to GC
Stratification: PS, LDH level
Ann Oncol30; 2019 (Suppl 5): v851–v934.
GEFCAPI 04 (Results)
• Primary cancers most often reported: pancreatico-biliary (19%), SCC 
(11%), kidney cancer (8%), lung cancer (8%)
• 91/123 (arm B): tailored treatment
• PFS: 5.3 mos (arm A) vs 4.6 mos (arm B); HR 0.95 (0.72-1.25); p=0.7
• OS: 10.0 mos (arm A) vs 10.7 mos (mos) (arm B); HR 0.92 (0.69-1.23)
• 60 pts with suspected cancers likely insensitive to GC 
Conclusion:
In GEFCAPI 04, using a molecular test followed by tailored systemic treatment did 
not improve outcomes of pts with CUP.




• Ongoing CUPISCO trial: A Phase II Randomized Study Comparing the 
Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy 
Versus Platinum-Based Chemotherapy in Patients With Cancer of 
Unknown Primary Site (NCT03498521)
https://clinicaltrials.gov/ct2/show/NCT03498521.
Ross JS et al. The Oncologist 2021;26:e394–e402.
CUPISCO (Study description)
• Aim: to determine the efficacy and safety 
of targeted therapies and cancer 
immunotherapies for patients with a 
subset of CUP syndrome. 
• The selection of therapies is based on 
results from CGP (FMT*)
• N=790; F II, global, 162 sites participate
• After 3 cycles of induction platinum-
based ChT doublets the responders are 
randomized to experimental arm 
(targeted therapy tailored to the 
molecular profile) or continue with 
standard ChT. The non-responders go 
directly to molecular guided therapy. 
https://cup-syndrome.com/en/home/cupisco-study.html
*FMT: Foundation Medicine tissue or liquid Test
• The primary endpoint: PFS or death from any cause. 
• The secondary endpoints: OS, RR, CBR, safety…. 
• Estimated date of competition: 2023.
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• About 20% of CUP patients
• Have histopathology, biomarkers and clinical 
presentation consistent with specific tissue 
of origin
• Should be treated with primary-specific 
therapy corresponding to most likely 
primary site
an unresponsive subset:
poor prognostic subset 
• About 80% of CUP patients
• No type of ChT prolonged survival in 
these patients
Int J Cancer 2014; 135, 2475–81.
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
Favourable prognostic subset 
• Traditionally defined favourable subset:
• women with isolated axillary adenopathy, 
• women with serous papillary peritoneal carcinomatosis,
• squamous cell carcinoma involving mid-high cervical lymph nodes,
• poorly as well as well-differentiated neuroendocrine carcinoma, 
• poorly differentiated and undifferentiated carcinoma (extra gonadal germ cell 
cancers), 
• men with blastic bone metastases and elevated PSA 
• patients with single, small and potentially resectable tumours
• Newly identified favourable CUP subset:
• patients who look like CRC (CK 20 pos, CK 7 neg, CDX pos), should be treated as 
patients with advanced CRC (expected RR around 50% and mOS up to 3 years)
Abeloff’s Clinical Oncology (6th Edition) 2020; Cancer of Undefined Site of Origin 1694-702.
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Unfavourable prognostic subset (1) 
• Sensitivity to chemotherapy is modest. 
• Include the patient in clinical trial (if an option).
• Do the CGP to identify potentially treatable, clinically relevant GA and 
treat accordingly.
• In many countries expensive molecular assays are not available or not covered by 
insurance.
• Targeted drugs and check point inhibitors are not covered by insurance.
• At the time being we have no prove that such approach really influence patients' 
survival. Data from well designed clinical trials are necessary (are ongoing).
Unfavourable prognostic subset (2) 
• The majority of patients from this subset have poor prognosis. 
• At presentation, two-thirds of patients have metastatic lesions in two or 
more visceral sites (most often liver, lung, lymph nodes and/or 
peritoneum).
• Patients are often in poor performance status. 
• For many of these patients BSC is the best option. 
• For selected patients empiric chemotherapy is justified. 
• Cisplatin or taxane-based doublets have been used, with little impact on survival.
• Patients and relatives have to be informed that expected RR to ChT is only 20% to 





• 1. Does site-specific therapy determined by GEP improves outcome in patients with CUP?
• According to the result of GEFCAPI 04 study: NO
• The study has limitations!
• 2. If genomic profiling identifies a targetable mutation in a tissue sample of CUP and the 
patients receives targeted therapy, is the outcome improved compared to standard 
chemotherapy? 
• It seems logical, but it is not necessary. 
• A good lesion in terms of this is BRAF mutation. It can be effectively treated if CUP has metastasized 
from melanoma but not from colon cancer.
• The study is underway.
Summary and assessment algorithm 
(1)
• Does molecular profiling assay increases accuracy of identifying the 
primary site? 
• Most probably yes.
• Does molecular profiling (CGP) help us in directing effective targeted 
treatment? 
• We are not certain yet. Studies are ongoing. 
• Does identification of primary site based on molecular assays (GEP 
tests) and accordingly directed therapy improves patient survival? 
• According to the results we have: NO.
• How to proceed knowing all these in current clinical practice?
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Summary and assessment algorithm 
(2)
• Try to search for primary site: clinically, by IHC, imaging, endoscopy studies.
• Rule out potentially treatable or curable tumours (breast cancer, germ cell 
tumour, lymphoma)
• Select, which clinic-pathological entity the patient belongs to: 
• If to favourable prognostic subset: 
• treat accordingly 
• If to poor prognostic subset: 
• Have a profound discussion with the patient and relatives about the disease
• Evaluate patient performance, bear in mind patient’s condition and preferences
• Choose either empirical ChT or BSC
• Do CGP, look at targetable, clinically relevant GA and treat the patient on the bases of the results of 
this test. Of note: without big evidence so far that this approach is beneficial. 
• The best option: include the patient in a clinical study if available.
Conclusions
• CUP is a heterogeneous disease with poor prognosis. 
• It is mandatory to establish to which prognostic group the patient belongs to.
• In patients belonging to a favourable prognostic subset long-term survival 
can be achieved with appropriate treatment. 
• Patients classified to unfavourable prognostic subset have to be informed 
about benefits and disadvantages of empiric therapy. For many patients with 
widespread disease on first presentation and poor PS BSC is the best option.
• Novel approaches (searching for clinically relevant GA) are promising, 
present a fundamental shift in the paradigm of treatment of cancer patients 
from tissue-specific to individual, patient/tumour customized treatment, 
directed according to tumour specific GAs.
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Systemic treatment of Ewing sarcoma
Where do we stand?
Mojca Unk, MD,MS
Institute of Oncology Ljubljana
Department of medical oncology
2nd Summer School in Medical Oncology
Precision oncology- Are we there yet?




the first Professor of pathology at Cornell University
1921: discovery of a form of bone cancer later named Ewing's sarcoma
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Introduction
• a small, blue, round cell sarcoma (RCS)
gene fusion involving a member of 
the FET family and a member of the ETS family 
of transcription factors (definitive diagnosis)
• the 3rd most common bone sarcoma (incidence: ~0.1/100,000/year)
• children and adolescents (rarely adults)
• median age at diagnosis: 15 y
• male predominance
• extremity bones (50%), pelvis, ribs and vertebra (any bone, soft 
tissue)
Rizk et al. Pharmgenomics Pers Med. 2019
Outcome
• historical series: 5-year survival <10 % (micrometastatic disease)
• current recommended multimodal approaches: 
• Localised disease 5-year survival is ∼60 % - 75 % 
• Metastatic disease 5-y survival ∼20 % - 40 % (metastatic sites, tumour burden)
Schuck et al. Int J Radiat Oncol Biol Phys 2003; Womer et al. J Clin Oncol 2012; Le Deley et al J Clin Oncol 2014.
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Initial systemic treatment
• Intensive chemotherapy: reported long term survival 60-70 %
• No novel agents available
• Different chemotherapy regimens standard in Europe and USA
• Multi-agent regimen: 
• vincristine (V), 
• doxorubicin (D),
• actinomycin D (DTIC) 
• cyclophosphamide (C)/ifosfamide (I) 
• etoposide (E).
Schuck et al. Int J Radiat Oncol Biol Phys 2003; Womer et al. J Clin Oncol 2012; Le Deley et al J Clin Oncol 2014.
Comparison of two chemotherapy regimens in Ewing sarcoma (ES): 
Euro Ewing 2012 randomized trial (EE2012)
• randomised study 
• localised or metastatic ES
• patients aged 5-50 years 
• European regimen of VIDE induction and VAI or VAC (V, actinomycin D 
and I or C) consolidation 
• USA regimen of compressed VDC/IE induction and IE/VC 
consolidation
Brennan et al. J Clin Oncol 2020
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Results
Brennan et al. J Clin Oncol 2020
Conclusion
• The interval-compressed VDC/IE regimen is currently the preferred first-line 
treatment in ES
• up to nine cycles of induction ChT
• local therapy
• consolidation chemotherapy
• The optimal timing for local control:
• primary site, 
• size, 
• response, 
• anticipated morbidity from surgery 
• tolerability. 
• Primary metastatic disease
• the same treatment approach
• worse prognosis 
• local treatment with responding metastatic disease; outcome improvement




• prognostic factor: time to relapse (>2 years from initial diagnosis)
• no standard of care
• multiple regimens used at progression
• little prospective evidence
Stahl et al. Pediatr Blood Cancer 2011; Ferrari et al. Pediatr Blood Cancer 2009; Hunold et al. Pediatr Blood Cancer 2006
rEECur study






McCabe et al. J Clin Oncol 2020
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Results
McCabe et al. J Clin Oncol 2020
Irinotecan&temozolamid is less effective than







Italiano et al. Lancet Oncol. 2020; DuBois et al. Cancer 2010
mPFS 4·4 months (95% CI 3·7–5·6) mOS 10·2 months (95% CI 8·5–18·5)
*2 pts NA
Partial response: 26 % 
Stable disease: 49%
Clinical benefit: 75 %
Progressive disease 21% 
Cabozantinib produced high tumour shrinkage.
MET expression in Ewing sarcoma (negative prognostic factor).
MET inhibition might contribute to the clinical activity of cabozantinib.
Multicentre, single arm, phase II
Regorafenib: REGOBONE study
• randomized, placebo -controlled phase II study 
• efficacy and safety of regorafenib (REG) in pts with Ewing sarcoma
Duffaud et al. ESMO 2020
Regorafenib delays disease progression
Only modest activity- combination therapy???
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Conclusion
• Ewing sarcoma a rare curable cancer 
• Treatment in experienced reference centres 
• Treatment of primary tumour complex and individualised 
• Long term consequences of treatment very significant 
• Recurrence remains frequently fatal 
• Active new agents emerging 
• Testing new strategies requires coordinated international collaboration 
• Many improvements still needed
Thank you for your attention!
Institute of Oncology Ljubljana
a member of EURACAN
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Presentation of Two Patients with 
Localised Ewing Sarcoma
Aleksandra Sokolova
2nd Summer School in Medical Oncology
Institute of Oncology Ljubljana
September 7-10, 2021
Patient 1, December 2016: male, 27 years
First visit 6/1/17
• no previous diseases
• 3 weeks lump above the left lower 
ribs, slightly painful, growing
• no other symptoms
• examination: 6x5 cm palpable lump 
above lower left ribs
• CRP 35; LDH, AF - normal 
US: tumour in left hemithorax
chest CT 21/12/16: 6x7 cm tumour 
arising from destructed anterior part 
of the 6th left rib, infiltrating 
surrounding soft tissues
US guided fine needle aspiration 
biopsy 21/12/16
citology: Ewing sarcoma (FISH 
positive for EWS gene translocation)
bone scintigraphy 4/1/17: no other 
bone lesions
PET/CT 5/1/17: 8 cm tumour of the 
6th left rib (SUV 17.3), infiltration of 
surrounding soft tissues, no 
metastases/pathologic lymph nodes
Multidisciplinary sarcoma tumour 
board
Dec/16: male, 27 years, 
localised Ewing sarcoma of 
6th left rib
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Dec/16: male, 27 years, 
localised Ewing sarcoma of 
6th left rib
INT-0091: ChT + surgery + 
RT (Jan-Oct/17)
January 2017 – October 2017: protocol INT-0091
neoadjuvant ChT




alternating with ifosfamide, 
etoposide)
• after 2nd cycle the tumour 
no more palpable
• CT (Feb/2017): good partial 
regression, no new lesions
surgery
• tumour excision (Apr/2017) -
resection of tumour with 
anterior parts of 6th and 7th 
left ribs
• histology: <5% residual Ewing 
sarcoma, R0 resection, 
narrow margins
adjuvant ChT + adjuvant RT
• 8 cycles VACA/IE at 3-week 
intervals (5th-12th cycle)
• after 9th and 10th cycle 
febrile neutropenia gr. 4 
and anemia gr. 3
• 11th and 12th cycle 75% 
dose
• concomitant RT to the site 
of the surgery (May-
Jul/2017, TD 50 Gy)
Dec/16: male, 27 years, 
localised Ewing sarcoma of 
6th left rib
INT-0091: ChT + surgery + 
RT (Jan-Oct/17)
October 2017 ⇢ today:
Regular checkups (+ lab. + chest X-ray) every 3 months for the first 2 years, 
later every 6 months
Chest CT and bone scintigraphy once a year
After almost 4 years no recurrence of the disease
Follow-up Oct/17 ⇢ today: 
no recurrence
last chest CT from 2 months ago
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Patient 2, August 2018: male, 23 years
first visit 11/9/18 
• previous conditions: psoriasis
• symptoms:
• 9 months pain in left lumbar 
region and left lower ribs
• progressing to both legs with 
tingling, difficulty walking
• Aug/2018: acute paraparesis and 
urine retention
• CRP, LDH, AF – all normal
MRI 22/8/18
9x7x6 cm left paravertebral tumour
(Th11-Th12) arising from posterior 
part of the 12th left rib, spreading 
intraspinally cousing compression of 
medullary cone
Urgent surgery  22/8/18
hemilaminectomy of Th11 and Th12 
and removal of intraspinal part of 
the tumor -> after surgery residual 
mild left lumbar pain and still some 
weakness in legs with tingling
Histology: Ewing sarcoma (fusion 
EWSR1-FLI1)
CT thorax & abdomen and PET/CT –
no distant metastases
Multidisciplinary sarcoma tumour 
board
Aug/18: male, 23 years, 
localised Ewing sarcoma of 
12th left rib
neoadjuvant ChT






• - after 2nd cycle 
complete resolution of 
symptoms
• MRI (Oct/2018): good 
partial regression (9 cm -> 5 
cm), no new lesions
surgery
• tumour excision (Dec/2018) -
posterior spine mobilisation 
with pediculotomy at Th12 
and spine fixation at Th10-L1, 
and resection of tumour with 
left diaphragm and 12th rib 
and posterior parts of 9-11th
ribs
• histology: residual Ewing 
sarcoma with 40-50% tumour 
necrosis, max diameter 5 cm,  
R1 resection
adjuvant ChT + adjuvant RT
• 8 cycles VACA/IE at 3-week 
intervals (5th-12th cycle)
• concomitant RT to the site 
of first and second surgery
(Feb-Mar/2019, TD 58 Gy)
Aug/18: male, 23 years, 
localised Ewing sarcoma of 
12th left rib
September 2018 – June 2019: protocol INT-0091
June 2019 ⇢
regular checkups (+ lab. + chest 
X-ray) every 3 months, chest CT 
every 6 months
INT-0091: ChT + surgery + 
RT (Sep/18-Jun/19)
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Aug/18: male, 23 years, 
localised Ewing sarcoma of 
12th left rib
INT-0091: ChT + surgery + 
RT (Sep/18-Jun/19)
June 2020: deterioration  
Jun/20: metastatic
2nd line ChT (Jun-Nov/20)    
+ RT mediastinum (Feb/21)
dyspnea, cough, right pleuritic chest pain – right pleural effusion, pneumonia; 
↑CRP 200 mg/L, ↑LDH 7 ukat/L, AF norm. 
Chest x-ray and CT – metastases (lungs, pleura, mediastinum)
June 2020: metastatic disease 
→ 2nd line ChT: gemcitabine and docetaxel
(gemcitabine day 1 and 8, docetaxel day 8, at 3-week intervals)
• after 1st cycle – no more symptoms 
• chest X-ray after 3rd cycle: regression
• total 7 cycles (Jun-Nov/2019)
•PET/CT (Dec/2020): almost complete response, only one metabolically active 
residual mass in right upper mediastinum behind right brachiocephalic vein (2 cm, 
SUV 6.4) ➜ RT (Jan-Feb/2021, TD 58.8 Gy)
Aug/18: male, 23 years, 
localised Ewing sarcoma of 
12th left rib
INT-0091: ChT + surgery + 
RT (Sep/18-Jun/19)
Jun/20: metastatic
2nd line ChT (Jun-Nov/20)   + 
RT mediastinum (Feb/21)
March 2021: regular checkup
Follow-up chest X-ray 15/3/2021: progression (lungs, pleura)
mild stabbing pain in right chest and right shoulder, PS 0-1
CT 29/3/2021: progression – large tumour mass on right pleura infiltrating right 
diaphragm and liver + bone metastasis in left iliac bone
3rd line ChT: topotecan and cyclophosphamide
(day 1-5 at 3-week intervals)
•at initiation of therapy (Apr/2021): right chest pain spreading to right shoulder and 
legs, fatigue, no dyspnea or caugh; ↑CRP 200 mg/L, ↑LDH 22 ukat/L, ↑AF 3 ukat/L
•after 1st cycle – disappearance of all symptoms
•April/2021 ⇢ today: 6 cycles, 2-6th cycle 60% dose (3/5 days, fever on day 3)
•CT (Aug/2021): good partial regression




Best survival with neoadjuvant ChT followed by 
surgery/RT if not resectable and adjuvant ChT 
+/- RT.
All patients with radiological signs of sarcoma 
should be referred to the reference centre for 
bone sarcomas. 
Biopsy and further treatment should be 
descussed at multidisciplinary sarcoma tumour 
board and carried out in sarcoma reference 
center.
We should monitor cured patients for long 
term toxicities and secondary malignancies >10 
years after treatment.
Patient 1: male, 27 years, 
localised Ewing sarcoma of 6th 
left rib
Patient 2: male, 23 years, 
localised Ewing sarcoma of 12th 
left rib




4. adjuvant RT + ChT
5. follow-up – after 4 years no 
recurrence
1. urgent surgery due to spine 
compression
2. dignosis from resected part of 
the tumour
3. neoadjuvant ChT
4. second surgery (R1)
5. adjuvant RT + ChT
6. early recurrence 1 year after 
completment of treatment, 
currently on 3rd line of ChT
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Systemic treatment of prostate cancer –
standards and perspectives
Borislav Belev
Dpt of Medical Oncology
Clinic of Oncology








• 2 main trends in prostate cancer treatment:
• Tendency to earlier systemic aproach
• Genetic profiling being more important
• New treatment options should prolong OS in prostate cancer
• Personalized treatment more important and dictate optimal
treatment
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Advances in Systemic Treatment
of Renal Cell Carcinoma (RCC)
Boštjan Šeruga, MD, PhD
Division of Medical Oncology
Institute of Oncology Ljubljana and University in Ljubljana
2nd Summer School in Medical Oncology
Ljubljana, September 9, 2021
Topics
 Adjuvant systemic therapy in RCC
‒ Anti-VEGF agents
‒ Immune checkpoint inhibitors (ICIs)
 Combined 1st line systemic therapy for advanced RCC
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Adjuvant phase III trials in RCC
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There is no role of adjuvant anti VEGF therapy
Eur Urol Oncol 2019
There is no role of anti VEGF therapy after radical metastasectomy
Similar results in ECOG-ACRIN E2810 
study, which evaluated pazopanib in 
this setting
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Drug Atezolizumab Nivolumab Pembrolizumab Nivolumab + ipilimumab
Histology
Clear-cell ± sarcomatoid 
histology
RCC of any histology
Clear-cell ± sarcomatoid 
features





2 doses prior to surgery 
and adjuvant nivolumab 
for 9 mos
1 yr 6 mos
Risk 
classification
T2 grade 4, T3a grade 3/4, 
T3b/c any grade, T4 any 
grade, or TxN+ any grade
Clinical stage ≥ T2 or 
any N+
pT2, grade 4; pT3/4, any 
grade; N+ M0; M1 NED




DFS RFS at 5 yrs DFS DFS
BICR Yes Yes Yes Yes
Status Active, recruiting Active, recruiting Active, recruiting Active, recruiting
1. Uzzo. ASCO 2017. Abstr TPS4598. 2. Harshman. ASCO 2018. Abstr TPS4597. 
3. Choueiri. ASCO 2018. Abstr TPS4599. 4. Bex. ESMO 2018. Abstr 927TiP.
KEYNOTE-564: DFS (Primary Endpoint)
*Crossed P value boundary for statistical significance of .0114. 
Slide credit: clinicaloptions.comChoueiri. ASCO 2021. Abstr LBA5. Reproduced with permission.
HR: 0.68 (95%: 0.35-0.87)
P = .0010*
Pembro 22.0 NR (NR-NR)
Placebo 30.3 NR (NR-NR)
Median follow-up: 24.1 mo (14.9-41.5)
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KEYNOTE-564: DFS by Subgroup (ITT)
Slide credit: clinicaloptions.comChoueiri. ASCO 2021. Abstr LBA5. Reproduced with permission.
Subgroup Events/Patients, n/N Favors: HR (95% CI)
Overall 260/994 0.68 (0.53-0.87)
























Region  North America
 European Union


















*Did not cross P value boundary for statistical significance of .0000093 for 51 OS events; final OS analysis to occur after ~200 OS events. 
Slide credit: clinicaloptions.comChoueiri. ASCO 2021. Abstr LBA5. Reproduced with permission. 
HR: 0.54 (95%: 0.30-0.96)
P = .0164*
Pembro 3.6 NR (NR-NR)
Placebo 6.6 NR (NR-NR)
Median follow-up: 24.1 mo (14.9-41.5)
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Take home message (adjuvant therapy)
 No role of anti-VEGF adjuvant therapy in locoregional RCC 
after nephrectomy and after "radical" metastasectomy
‒ Conflicting results for DFS, does not improve OS, 
‒ Toxic treatment, deterioration of QoL
 ICIs promising new adjuvant therapy in RCC  
Heng. JCO. 2009;27:5794.
 Clinical
‒ KPS < 80% (P < .0001)
‒ Time from diagnosis to tx < 1 yr (P = 
.01)
 Laboratory
‒ Hemoglobin < LLN (P < .0001)
‒ Calcium > ULN (P = .0006)
‒ Neutrophil count > ULN (P < .0001)
‒ Platelet count > ULN (P = .01)
IMDC (Heng) Prognostic Criteria











Favorable: 0 risk factors; intermediate: 1-2 risk factors; 
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‒ KPS < 80% (P < .0001)
‒ Time from diagnosis to tx < 1 yr (P = .01)
 Laboratory
‒ Hemoglobin < LLN (P < .0001)
‒ Calcium > ULN (P = .0006)
‒ Neutrophil count > ULN (P < .0001)
‒ Platelet count > ULN (P = .01)
IMDC (Heng) Prognostic Criteria











Favorable: 0 risk factors; Intermediate: 1-2 risk factors; 
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Favorable
75% to 80% of patients with mRCC have ≥ 1 of these 
risk factors (intermediate or poor risk)
Intermediate
Poor


















Phase III clinical trials in the 1st line therapy
Trial Comparison Primary endpoint (s)
CheckMate 214
Motzer et al, NEJM, 2018
Ipilimumab+Nivolumab
vs. Sunitinib
OS, ORR, PFS in patients with
intermediate and poor prognosis
Keynote 426




OS in PFS in the ITT populations (all-
comers)
Javelin Renal 101
Motzer et al, NEJM, 2018
Avelumab+Axitinib
vs. Sunitinib
OS in PFS in PD-L1+ patients
Immotion 151





OS in the ITT population
CheckMate 9ER
Choueiri et al, ESMO 2020
Nivolumab+Cabozantinib
vs. Sunitinib
PFS in the ITT population
Clear




PFS in the ITT population
Results of phase III trials in the 1st line 
Trial Comparison Results
CheckMate 214
Motzer et al, NEJM, 2018
Ipilimumab+Nivolumab
vs. Sunitinib
ORR: 42% vs. 27%, PFS: 11.6 vs 8.4 mo
(HR 0.82-ns), OS: at 4 yrs HR 0.65 
Keynote 426




PFS: 15.1 vs. 11.1. mo (HR 0.69), at OS: 2 
yrs 74% vs 66% (HR 0.68)
Javelin Renal 101
Motzer et al, NEJM, 2018
Avelumab+Axitinib
vs. Sunitinib
PFS (PD-L1+): 13.8 vs 7.2 mo (HR 0.61). 
OS: HR 0.82 (ns-immature)
Immotion 151




PFS (PD-L1+): 11.2 vs 7.7 mo (HR 0.74)
OS (ITT): HR 0.93 -ns
CheckMate 9ER




PFS (ITT): 16.6 vs. 8.3 mo (HR 0.51)
OS (ITT) @ 12 mo: 85.7% vs 75.6%
Clear




PFS (ITT): 23.9 vs. 9.2 mo (HR 0.39) for
P+L, OS (ITT): HR 0.66 for P+L
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Phase III clinical trials in the 1st line therapy
Trial Comparison ORR (CR)  (%)
CheckMate 214
Motzer et al, NEJM, 2018
Ipilimumab+Nivolumab
vs. Sunitinib
42% vs. 27% 
(9% vs 1%)
Keynote 426




59.3% vs. 35.7% 
(5.8% vs. 1.9%)
Javelin Renal 101
Motzer et al, NEJM, 2018
Avelumab+Axitinib
vs. Sunitinib
51.4% vs. 25.7% 
(3.4% vs. 1.8%)
Immotion 151




37% vs. 33% 
(5% vs. 2%)
CheckMate 9ER
Choueiri et al, ESMO 2020
Nivolumab+Kabozantinib
vs. Sunitinib
55.7% vs. 27.1% 
(8% vs. 4.6%)
Clear




71% vs. 53.5% vs. 36.1% 
(16.8% vs. 9.8 vs. 4.2%)
Long-term control of disease with ICIs
≈ 70%
+20%





Motzer RJ et al, J Immunother Cancer, 2020 
Checkmate 214
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60 56 52 49 47 45 43 37 32 30 29 22 10 5 1 0
52 48 36 32 29 23 22 19 18 17 15 15 9 3 1 0






Events, n (%) 31 (52) 39 (75) 







































Which combination works earlier?
Porta C, ESMO, 2020
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KEYNOTE  426










≥ 1% 90% 78%




IMDC denotes International Metastatic Renal Cell Carcinoma Database Consortium
Rini et al, NEJM, 2019
Δ 12%
Δ 14%
Take-home Messages (advanced disease)
 Combined therapy which involves ICIs is a new 1st line 
standard of treatment in patients with advanced RCC (for
all?)
 With combination therapy durable remission can be 
achieved also in patients with poor prognosis disease
 Combination of ICI and anti VEGF preferable 1st line therapy
in patients with symptomatic disease
254
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Bladder cancer systemic treatment
Milena Gnjidić, UHC Zagreb, Croatia
9.2021
Is something new going on?
~ 3% of all new cancer
~ 550 000 new cases per year worldwide
~ 200 000 death annually (2018)
Bray F at al. GLOBOCAN. CA Cancer J Clin. 2018.
~ Until the advent of immunotherapy 2015. there
was no new treatment options for decades
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ABC meta analysis. Eur Urol. 2005
Cisplatin-combinations better than mono Cis
Neoadjuvant chemotherapy
Kim I et al. Int J Mol Sci. 2021.
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Neoadjuvant immunotherapy
Kim I et al. Int J Mol Sci. 2021.
Neoadjuvant therapy
Kim I et al. Int J Mol Sci. 2021.
259
Neoadjuvant therapy
Kim I et al. Int J Mol Sci. 2021.
Neoadjuvant therapy
Kim I et al. Int J Mol Sci. 2021.
Could neoadj CPIs replace neoadj chemo?





Kim I et al. Int J Mol Sci. 2021.
Adjuvant immunotherapy





DFS 20.8 ~ 10.8mo
HR 0.70 HR 0.55
CheckMate 274
Adjuvant Nivolumab
1. PD-L1 expression > 1% !
2. Neoadjuvant chemotherapy !
3. Urinary bladder !
Subgroup analysis
Bajorin DF et al. N Engl J Med. 2021.
CheckMate 274
Overall survival ?!
Follow-up 20 mo disease recurrence = 48.2% ~ 57.3%
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• Less extensive surgery
• Response monitoring
• Primary tumor=more antigens
• Delaying cystectomy























Setting Regimen ORR mOS





First line Cisplatin ineligible Gemcitabine+
Carboplatin4-6
36-56% 7-9 months





1.Loehrerer JCO 1992, 2. Van der Masse JCO 2000, 3. Bellmunt JCO 2012, 4. De Santis JCO 2012. 
5. Linardou Urology 2004, 6. Nogue-Aliguer Cancer 2003, 7. Bellmunt NEJM 2017, 8.Bellmunt  JCO 
2009. 9. Petrilac JCO 2015.
mBC: First line - chemotherapy
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mBC: First line - Chemotherpy 50% patients cisplatin ineligible
only PDL1+                    
▪ Pembrolizumab
▪ Atezolizumab
Szabados B, et al. Eur Urol Oncol. 2021.
Chemotherapy is still standard of care!













mBC: First line - Maintenance
22Grivas P, et al. Cancer Treat Rev. 2021.
AVELUMAB
Subgroup analysis
mBC: First line - Maintenance
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- longer duration - PFS
- better tolerability
mBC: Second line - immunotherapy
Setting Regimen ORR mOS


















1.Loehrerer JCO 1992, 2. Van der Masse JCO 2000, 3. Bellmunt JCO 2012, 4. De Santis JCO 2012. 
5. Linardou Urology 2004, 6. Nogue-Aliguer Cancer 2003, 7. Bellmunt NEJM 2017, 8.Bellmunt  JCO 
2009. 9. Petrilac JCO 2015.




mBC: Second line and beyond
ERDAFITINIB ( antiFGFR1-4)
ENFORTUMAB VEDOTIN (ADC)
Sacituzumab govitecan ( ADC)
3
Targeted therapy in mBC – today and tomorrow




 New antibody-drug conjugates




 CAR-T cell therapy
 Combinations
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Yoshida T. In J Urol. 2019.
Biomarkers
Predictive biomarkers for immunotherapy
Biomarker Predictive capacity
PD-L1 Increased = improved response
TMB - tumor mutational burden Increased = improved response
STING – stimulator of interferon genes Deficient = reduced response
ASC - apoptosis-associated speck-like protein containing CARD Gene methylation = worse survival
TME - tumor microenvironment High CD4+, CD8+, CD45RO+ T cells = better
survival
PBMCs – peripheral blood mononuclear cells High CD4+, CD8+ T cells = better response
ctDNA – ciculating tumor DNA Increased = worse survival
Exsomes – extracellular vesicles Increased = better response
Cytokines Predict irAEs
Metal chelators Cooper chelating drugs = increase CD8+, NK 
sPD-L1/sPD-1 – soluble PD-L1/PD-1 Low level = better survival
CTCs – circulating tumor cells Presence = poor response
Microbiome Some species = better response





▪ Immunotherapy in the earlier stages is at the door
▪ Perioperative therapy is required; neoadjuvant > adjuvant
▪ Bladder-sparing approach is increasingly being on the mind
▪ Trials with new targeted therapy or combinations are ongoing
▪ Urgent need for better biomarkers to guide the optimal choice of therapy
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Systemic treatment of germ cell tumors 
– could it get better
B R E D A  Š K R B I N C
I N S T I T U T E  O F  O N C O L O G Y  L J U B L J A N A
2 N D  S U M M E R S C H O O L  I N  M E D I C A L O N C O L O G Y
7 - 1 0  S E P T E M B E R  2 0 2 1
FACTS ABOUT GERM-CELL TUMORS (GCT)
• GCT  the most common cancer in men aged 18-35 years 
• Testicular cancer accounts for ~1% of newly diagnosed cancer in men worldwide
Testicular cancer - NATURE REVIEWS | DISEASE PRIMERS 2018
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FACTS ABOUT GERM-CELL TUMORS (GCT)
• GCT  the most common cancer in men aged 18-35 years 
• Testicular cancer accounts for ~1% of newly diagnosed cancer in men worldwide
• Highly curable disease 
• Since 1975 with platinum based chemotherapy - the most curable metastatic solid cancer in males
• Histology 
• 50%seminoma, 40% NSGCT, 10% combined GCT
• Stage of the disease
• 60% of patients present with lokalised disease (stage I)
• Primary tumor location 
• Testicular, retroperitoneal, mediastinal, intracranial
• Level of serum tumor markers AFP, β-hCG, LDH determine the treatment choice
• IGCCCG classification PROGNOSTIC CLASSIFICATION ( y 1997 + updates) 
• Good prognostic group
• Intermediate prognostic group
• Poor prognostic group
Testicular cancer - NATURE REVIEWS | DISEASE PRIMERS 2018
Testicular cancer - NATURE REVIEWS | DISEASE PRIMERS 2018
FACTS ABOUT GERM-CELL TUMORS (GCT)
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Multidisciplinary treatment
FACTS ABOUT GERM-CELL TUMORS (GCT)
FACTS ABOUT GERM-CELL TUMORS (GCT)
• Recidivant disease still curable (probability for cure signifficantly reduced)
• more efficient treatment modalities are needed for this group of GCT patients
Testicular cancer - NATURE REVIEWS | DISEASE PRIMERS 2018
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Presented By Anja Lorch at 2018 ASCO Annual Meeting
Phase I / II studies
Kollmansberger C trastuzumab
HER2/neu expressing 
GCT Ann Oncol 1999
Rick O talidomid
platinum refractory GCT
Eur J Cancer 2006
Feldman DR sunitinib
relapsed or refractory 
GCT
Invest New Drugs 2010
Feldman DR tivantinib
relapsed or refractory 
GCT
Invest New Drugs 2013
Einhorn LH imatinibmesilat
CTX refractory GCT 
expressing KIT J Clin Oncol 2006
Necchi A pazopanib
relapsed or refractory 
GCT Ann Oncol 2017
Fenner M everolimus multiply relapsed GCT
Journal of Cancer 
Research and Clinical 
Oncology, 2018
Adra N pembrolizumab
multiply relapsed GCT, 
no other treatment 
option
Annals of Oncology, 
2018
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the genomes of cancers deficient in MMR contain exceptionally high numbers of 
somatic mutations
sensitivity to immune checkpoint blockade
Le et al., Science 357, 409–413 (2017)
The overall rate of mutations per megabase in cisplatin resistan GCT is low
(< 1 mutation/ MB) J Clin Oncol. 2016, 33:4000-4007.
low sensitivity to immune checkpoint blokade
FACTS ABOUT GERM-CELL TUMORS (GCT)
• Long term survivals 
• risk for 2nd CA  
• neuropathy / hearing loss
• nefropathy




Testicular cancer - NATURE REVIEWS | DISEASE PRIMERS 2018
275
GCT  SURVIVALS
10.1200/JCO.21.00637 Journal of Clinical Oncology 2021
How does treatment with platinum-based chemotherapy or radiotherapy influence the non–testicular 
cancer mortality and causes of death in GTC survivors?
Investigation of cause specific non-GCT mortality with impact on previous treatment with platinum-based 
chemotherapy or radiotherapy
The aim of the study was to assess non-TC mortality and causes of death in relation to TC treatment, including the impact 
of number of cisplatin based chemotherapy cycles, in a population-based cohort with complete information on TC
treatment burden.
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10.1200/JCO.21.00637 Journal of Clinical Oncology 2021
Testicular Cancer in the Cisplatin Era: 
Causes of Death and Mortality Rates in 
a Population-Based Cohort
5707 GCT patients diagnosed with GCT Jan 1st 1980-Dec 31st 2009
identified by the Cancer Registry of Norway
METHODS
• Overall, 5,707 men identified by the Cancer Registry of 
Norway diagnosed with TC from 1980 to 2009 were included 
in this population-based cohort study. 
• By linking data with the Norwegian Cause of Death Registry,
standardized mortality ratios (SMRs), absolute excess 
risks (AERs ; [(observed number of deaths – expected
number of deaths)/person-years of observation] x 10,000), 
and adjusted hazard ratios (HRs) were calculated
10.1200/JCO.21.00637 Journal of Clinical Oncology 2021
Testicular Cancer in the Cisplatin Era: Causes of Death 
and Mortality Rates in a Population-Based Cohort
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10.1200/JCO.21.00637 Journal of Clinical Oncology 2021
Results
• Median follow-up was 18.7 years , during which non-TC death was registered for 665 (12%) men.
 Overall excess non-TC mortality 23%  (SMR, 1.23 - AER, 11.14) compared with the general population, 
 Increased risks after PBCT (SMR, 1.23 - AER, 7.68 )
 Compared with surgery , increased non-TC mortality appeared after 3, 4, and more than 4 cisplatin-based chemotherapy cycles 
after > 10 years of follow-up
 Increased risk after RT (SMR, 1.28 - AER, 19.55). 
• The highest non-TC mortality was in those < 20 years at TC diagnosis (SMR, 2.27 - AER, 14.42). 
• The most important cause of death was non-TC second cancer with an overall SMR of 1.53 - AER, 7.94), with increased risks after 
PBCT and RT. 
• Overall noncancer mortality was increased by 15% (SMR 1.15 - AER, 4.71). 
• Excess suicides appeared after PBCT (SMR 1.65 - AER, 1.39). 
Testicular Cancer in the Cisplatin Era: Causes of Death 
and Mortality Rates in a Population-Based Cohort
10.1200/JCO.21.00637 Journal of Clinical Oncology 2021
Testicular Cancer in the Cisplatin Era: Causes of Death 
and Mortality Rates in a Population-Based Cohort
Conclusions
• GCT surviviors treated with platinum based CTX or RT suffer increased mortality rates compared with the general population.
• The most notable excess mortality was caused by seconnd cancers , 
• measures to avoid delayed SC diagnosis are essential ( extende follow up) 
• Citotoxic treatment ( CTX / RT )  seems to be the main risk factor for increased mortality.
• The increased mortality risk might be reduced by lifestyle improvements, which should be recommended following GTC treatment. 
• It is crucial that GCT surviviors and health personnel involved in the follow-up should be aware of the increased premature mortality risk.
RISK ADAPTED TREATMENT
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• Validation of the 1997 prognostic classification and update of the survival probabilities in a modern 
cohort
• Identification of additional prognostic factors to refine the IGCCCG prognostic classification
J Clin Oncol 39:1563-1574.  2021
J Clin Oncol 39:1563-1574.  2021
• 30 Institutions
• Complete patients database 
1980-2013
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J Clin Oncol 39:1563-1574.  2021
J Clin Oncol 39:1563-1574.  2021
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Without nonpulmonary visceral metastases
J Clin Oncol 39:1563-1574.  2021
Nomograms of the final prognostic model for patients
With nonpulmonary visceral metastases
J Clin Oncol 39:1563-1574.  2021
Nomograms of the final prognostic model for patients
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https://eortc.shinyapps.io/IGCCCG-Update/
• IGCCCG database is the largest dataset on metastatic NSGCT worldwide
• Improved treatment outcomes
• stage migration because of earlier diagnosis and better diagnostic tools, 
• improved supportive care, 
• superiority of cisplatin- and etoposide-based first-line treatment over other combinations, 
• use of upfront dose-intensified regimens, 
• more stringent use and higher quality of postchemotherapy surgery, 
• better salvage strategies in nonresponding or relapsing patients, 
• more stringent guideline adherence,
• centralization of care at experienced expert centers, 
• a combination of these factors
J Clin Oncol 39:1563-1574.  2021
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 In future trials, patients with a particularly favorable prognosis in the nomogram may be 
subjected to de-escalation strategies to further reduce treatment burden in patients likely to be 
cured. 
 In contrast, trials evaluating dose-escalation strategies should be pursued in patients with the 
worst prognosis according to the new IGCCCG update model
J Clin Oncol 39:1563-1574.  2021
The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major
advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated
between 1975 and 1990. 
 To reassess the original International Germ-Cell Cancer Collaborative Group (IGCCCG) classification for seminoma with modern 
treatment data and to screen for additional prognostic variables
J Clin Oncol 39:1553-1562.2021
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J Clin Oncol 39:1553-1562.2021
• 30 Institutions
• Complete patients database 
1980-2013
J Clin Oncol 39:1553-1562.2021
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J Clin Oncol 39:1553-1562.2021
J Clin Oncol 39:1553-1562.2021
• Other variables such as age, extragonadal primary tumor, elevated levels of β-hCG, or the 
presence of lung metastases did not add significant prognostic information in good prognosis 
patients once LDH elevations were considered
• LDH above 2.5 x ULN levels before chemotherapy an additional adverse prognostic factor that 
allowed splitting the good prognostic group further.
• Good prognosis patients with an elevated LDH above 2.5 x ULN before chemotherapy
experienced significantly worse outcomes.
Until the availability of prospective trials results of this analysis do not allow to recommend using intensified
CTX schemes instead of three cycles BEP in good ( according to the original classification ) prognosis patients
who have an LDH level above 2.5 x ULN
285
J Clin Oncol 39:1553-1562.2021
Given 5-year PFS and OS survival probabilities of 88% (95% CI, 87 to 89) and 95% 
(95% CI, 94 to 96), respectively, across all prognostic groups,
metastatic seminoma represents the most curable metastatic cancer in males
numerous challenges and pitfalls in testis cancer care that need to be addressed
Testicular Cancer Biomarkers
• Clinical management greatly relies on sTM measurements
• AFP, β-hCG, LDH – specific cellular proteins secreted into the bloodstream, 
• conventional panel of serum tumor markers of GCT (sTMs)
• standard in GCT  diagnosis and treatment monitoring
• Special S stage in the TNM sistem 
• Poor specificity and sensitivity of clasical sTM (https://doi.org/10.1155/2019/5030349)
• Elevated in seminomas:  bhCG 28% and LDH 29.1% , (AFP never)
• Elevated in NSGCT: bhCG 53%, AFP 60.1%, and LDH 37.8%
• sTMs may be elevated nonspecifically by processes other than GCT and may be normal in the setting of 
radiographically and serologically occult metastatic disease




on horizon there is an important change in the field of GCT sTMs
• In the past decade, nucleic acid–based markers, specifically microRNAs (miRNAs), have garnered attention 
Nat Rev Clin Oncol 2011;8:467–77 
• miRNAs - small noncoding RNA molecules of approximately 22 nucleotides 
• involved in epigenetic regulation of mRNA translation by direct interaction with the larger messenger RNA 
molecules regulating the level of gene expression on a post-transcriptional level
• influencing cellular differentiation and other physiological processes 
as well as
• carcinogenesis, for which they can operate as oncogenes or tumor suppressors
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• Serum miRNA - the most exciting discovery in the GCT field  
• Emerged as promising biomarkers in diagnosing and monitoring of patients with GCT
• Several clusters of miRNA that are expressed in testicular cancer tissue and measurable in the serum have
been identified on historical samples / retrospective studies
• miR-371a-3p specifically exhibited greater accuracy than traditional sTMs in GCT 
https://doi.org/10.1016/j.eururo.2021.06.006 
J Clin Oncol 37:1412-1423; 2019
• to prospectively evaluate the utility of the M371 test in a large and representative patient 
population enrolled from a large number of European institutions 
• to involve various histologies and clinical stages
and in particular
• to evaluate the diagnostic sensitivity and specificity of the test for the primary diagnosis of 
GCT  
• to assess its usefulness for monitoring GCT treatment
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J Clin Oncol 37:1412-1423; 2019
Receiver operating characteristic curves that discriminate controls from
all patients with germ cell tumors, clinical stage (CS) I only or CS II/III only
J Clin Oncol 37:1412-1423; 2019
ROC =  the measure of the
usefulness of any test
(a greater AUC area means a more useful test)
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J Clin Oncol 37:1412-1423; 2019
• The median expression of miR-371a-3p was significantly higher in the entire GCT group and in all the 
CS subgroups compared with the controls
• Patients with CS greater than I had a higher serum level than those with CS I (all P < 0.001) (fig A)
• Seminoma was found to have significantly lower miR-371a-3p values than nonseminoma (fig B)
• difference only detectable in CS I patients
• Teratoma had the lowest expression values of all subtypes (fig C)
J Clin Oncol 37:1412-1423; 2019
Expression of miR-371a-3p in controls and patients with GCT 
recurrence.
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J Clin Oncol 37:1412-1423; 2019
Sensitivity of miR-371a-3p in all GCTs  compared with the classic GCT markers  b-human chorionic gonadotropin (bHCG), a-
fetoprotein (AFP), and lactate dehydrogenase (LDH)  and all three classic markers combined
J Clin Oncol 37:1412-1423; 2019
Sensitivity of miR-371a-3p
compared with the classic GCT 
markers in all GCTs  CS I 
Sensitivity of miR-371a-3p
compared with the classic GCT 
markers in all GCTs  CS II / III
Sensitivity of miR-371a-3p
compared with the classic GCT 
markers in NSGCTs  CS II / III
Sensitivity of miR-371a-3p
compared with the classic GCT markers 
in seminoma GCTs  CS II / III 
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J Clin Oncol 37:1412-1423; 2019
Post-treatment decrease of microRNA (miR)-371a-3p
Decrease of miR-371a-3p expression 
after surgical removal of the primary 
tumor 
in clinical stage (CS) I , CS II, and CS III
Decrease of miR-371a-3p 
serum levels  over the course of 
chemotherapy 
in CS II patients 
Decreas of miR-371a-3p serum 
levels over  the course of 
chemotherapy 
in CS III patients
Decrease of miR-371a-3p 
expression
in recurrent germ cell
tumors (GCTs) after treatment 
J Clin Oncol 37:1412-1423; 2019
This study provides a considerable body of evidence that supports the usefulness of miR-
371a-3p serum levels as a new biomarker of GCTs.
Five features of the M371 test are noteworthy: 
• the test has a 90.1% sensitivity and a 94.0% specificity for establishing the primary 
diagnosis of GCT; 
• it is relevant for the two main histologic subgroups of GCT; 
• miR serum levels correlate with primary tumor size, local stage, and CSs; 
• miR levels mirror treatment-related disease changes;  
• miR levels are elevated in recurrences
• the study strongly confirmed previous data regarding to the usefulness of the M371 test as a 
new serum biomarker of GCT that is informative in both seminoma and nonseminoma; 
• because of its high sensitivity and specificity, M371 test involves the potential of simplifying 
clinical pathways of the management of GCT 
• further validation in an independent cohort is needed
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https://doi.org/10.1016/j.eururo.2021.06.006 
The Lange-Winfild criteria for biomarkers
The ideal TM is a substance that
(1) is produced only by the malignancy itself; 
(2) is secreted into body fluids in such a way that it can easily 
be measured in a reproducible fashion; 
(3) correlates well with the amount of tumor present;
(4) can be detected at an early stage of the disease; 
(5) has a half-life which is short enough so as not to 
accumulate in   body tissues and result in false-positive 
results; 
(6) correlates with the response of the tumor to treatment
Cancer 60:464-472. 1987
• M371 test has the potential of simplifying clinical pathways of the management of GCT 
• further validation in an independent cohort is needed
Systemic treatment of germ cell tumors – could it get any better?
Yes it cann
and 
it should still get better
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Provided that
• GCT patients are treated strictly according the international guidelines on diagnosis and 
treatment of GCT 
• The patients are treated by expirienced physicians dedicated to the treatment of GCT 
patients
• GCT poor prognostic group patients are treated by multidisciplinary teams dedicated to the
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Endometrial cancer (EC) is the most common gynecological cancer in high income countries, 
and the second most common in low income countries (1). In Serbia it is the fourth most 
common cancer in the female population – behind breast, lung and colorectal cancer (2). The 
molecular classification of EC introduced by the Cancer Genome Atlas (TCGA) (3) has ushered 
in a change in the way we view and classify EC. This project used genomic, transcriptomic, and 
proteomic analyses to characterize over 370 ECs. Four molecular subgroups and several 
predictive biomarkers have been defined based on based the genetic architecture of tumor cells. 
The Cancer Genome Atlas (TCGA) Research Network suggested 4 genomic classifications for 
endometrial cancers: 
a) polymerase ε (POLE) ultramutated,  
b) microsatellite instability hypermutated (MSI-H),  
c) copy-number low,  
d) and copy-number high.  
POLE ultra-mutated cancers are relatively rare (5% to 10% of endometrial cancers), highly 
immunogenic, and typically have a favorable prognosis.(3) MSI-H tumors have high rates of 
genomic mutations related to altered or defective DNA repair, including dysfunction in 
mismatch repair (dMMR).(3,4) Approximately 20% to 30% of endometrial cancers exhibit an 
MSI-H phenotype or loss of MMR. Alterations in PI3K/AKT/mTOR signaling are also 
common.Copy-number low tumors, or microsatellite stable (MSS) tumors, represent the majority 
of low-grade endometrioid cancers and have an intermediate prognosis.(3,4) These tumors have 
low mutation rates with few TP53 mutations, but often have mutations in PTEN, CTNNB1, 
PIK3CA, ARID1A, or KRAS.Copy-number high or serous-like tumors are generally high-grade 
with low estrogen and progesterone receptor expression and low mutation rates.(3,4) As the 
name suggests, these malignancies have extensive copy number variations and frequent mutation 
of TP53. 
These groups display distinct prognostic outcomes, clinical and pathological features. 
Although prognosis is favorable for patients with early stage disease, outcomes are poor for 




patients with recurrent or metastatic endometrial cancer, primarily focused on platinum-based 
regimens. Carboplatin in combination with paclitaxel is the option of choice (5). 
Recent years have witnessed the emergence of newer options for progressive disease, including 
bevacizumab, pembrolizumab, lenvatinib, and everolimus/letrozole. These expanded options 
have the potential to improve patient outcomes and provide more individualized care for patients 
with advanced or recurrent endometrial cancer. 
Patients with HER2-positive uterine serous carcinoma should be considered for the addition of 
trastuzumab to platinum-based doublet chemotherapy, while those with low-grade endometrioid 
histology may benefit from the use of hormone therapies. 
 
Targeted Therapy 
Antiangiogenic Therapies.  
In patients with advanced endometrial cancers early research indicated that there is a role for 
bevacizumab in certain subsets of patients, leading to phase 2 trials such as GOG-86P and MITO 
END-2 with the goal of testing the effectiveness of bevacizumab in combination with 
carboplatin/paclitaxel. (6,7). The GOG-86P trial, which also evaluated combinations with 
temsirolimus, did not show a significant PFS benefit for the addition of bevacizumab to 
platinum-doublet chemotherapy.(8). However, the ORR was 60% and median OS was 
significantly increased compared with historical controls from the GOG209 study (HR 0.71; P < 
.039). PFS was not significantly increased in any experimental arm compared to historical 
controls.The MITO END-2 trial failed to demonstrate a significant PFS or OS benefit for 
bevacizumab plus chemotherapy, although the rate of 6-month disease control was significantly 
higher (91% vs 70%).(7) Current NCCN Guidelines® list bevacizumab alone as an option after 
progression on chemotherapy or in combination with platinum-based chemotherapy for advanced 
disease.(5). The multi-targeted tyrosine kinase inhibitors (TKIs) lenvatinib and cediranib have 
also demonstrated efficacy in patients with advanced endometrial cancers.(9,10). 
Inhibitors of HER2 and mTOR. 
Uterine serous carcinomas are an aggressive variant of endometrial cancer and often have 
dysregulated HER2 signaling, leading to investigation of trastuzumab in combination with 
carboplatin/paclitaxel in this patient subset. A randomized phase 2 trial showed a 4.6-month 
improvement in median PFS with the addition of trastuzumab to chemotherapy (HR 0.44; P = 
.005) in patients with HER2-positive uterine serous carcinomas. The PFS benefit was consistent 
in both treatment-naive and pretreated patients, and the combination was well tolerated.(11). The 
phase 2 GOG-3007 trial compared hormone therapy alone with everolimus (an mTOR inhibitor) 
plus letrozole in patients with advanced endometrial cancer and showed an improvement in 
median PFS from 3.8 to 6.3 months.(12) 
PFS benefit from everolimus/letrozole was particularly evident in patients who had received no 




rates of grade 3/4 anemia and hyperglycemia were increased compared with hormone therapy 
alone. 
Immunotherapy 
Several checkpoint inhibitors have demonstrated some efficacy in patients with advanced 
endometrial cancers.(13-20). Pembrolizumab has a tumor-agnostic approval for patients with 
MSI-H or dMMR advanced solid tumors and is listed in current NCCN Guidelines® as an option 
for advanced endometrial cancers. (5,21)  
Another PD-1 inhibitor, dostarlimab (TSR-042), was evaluated in the phase 2 GARNET trial, in 
advanced endometrial cancer.  The ORR was 29.6% overall, but reached 48.8% in patients with 
MSI-H tumors (compared with 20.3% for those with MSS tumors). A total of 85% of patients 
with MSI-H endometrial cancer experienced a reduction in total tumor burden of over 50%. The 
DCR was 63% for MSI-H tumors vs 46.8% for those with MSS tumors.(15) Responses were 
durable in both cohorts, with 50% of responders remaining on therapy longer than 1 year. 
Dostarlimab had a manageable safety profile and was most commonly associated with fatigue, 
diarrhea, and nausea. Grade 3 or higher immune-mediated AEs only occurred in 5.6% of patients 
and included increases in alanine aminotransferase and aspartate aminotransferase, 
hyperglycemia, autoimmune hemolytic anemia, colitis, and infusion-related reaction. 
A phase 2 study evaluated avelumab in patients with dMMR and those with proficient MMR 
proteins.(22) The MMR-proficient cohort was closed early due to futility, while the dMMR 
subgroup demonstrated an ORR of 26.7%. PFS at 6 months was 40%, and responses were 
observed independent of PD-L1 expression. The most frequent any-grade treatment-related AEs 
were fatigue, nausea, hypothyroidism, neutropenia, anemia, and diarrhea. Grade 3 AEs included 
anemia and diarrhea, and no grade 4 toxicities were reported. 
A phase 1b trial recently reported data on the activity of atezolizumab in patients with advanced 
solid tumors, including 15 patients with recurrent or metastatic endometrial cancers. Benefit was 
modest, with an ORR of 13%, median PFS of 1.4 months, and median OS of 9.6 months. Benefit 
was more substantial in patients with high PD-L1 expression (n = 5), with an ORR of 40% and 
median PFS and OS of 4.2 and 38.2 months, respectively.(23) 
Combination regimens. Potential synergy between targeted agents and immunotherapies 
continues to be explored based on the hypothesis that the action of targeted therapies may prime 
the immune system, thus increasing the anti-immune response elicited by immunotherapies.[44] 
Targeted agents may enhance immunotherapy activity by improving the function or activation of 
immune cells, creating neoantigens, or eliciting immune cell infiltration of the tumor 
microenvironment. 
The KEYNOTE-146 trial investigated the co-inhibition of VEGF and PD-1 signaling by 
combining these 2 agents, lenvantinib and  pembrolizumab.(25) Lenvatinib plus pembrolizumab 
had an ORR of 40% and a DCR of 87%. Responses were durable, with 65% having a response 
lasting at least 12 months. The most common any-grade AEs were fatigue, hypothyroidism, 




side effects included hypertension, palmar-plantar erythrodysesthesia syndrome, and fatigue. 
Based on these data, lenvatinib combined with pembrolizumab recently received accelerated 
FDA approval for the treatment of patients with previously treated advanced endometrial 
carcinoma that is not MSI-H or dMMR.(21) Also concidering AE patients should be monitored 
regularly and educated regarding the potential for AEs to protect patient quality of life (QoL) and 
avoid unnecessary treatment delays or interruptions. 
Some others ongoing clinical trials continue to investigate immunotherapeutic combination 
approaches for endometrial cancer, including combinations with chemotherapy such as phase 2 
trial is evaluating pembrolizumab with carboplatin/paclitaxel in patients with advanced 
endometrial carcinoma.(26) The phase 3 RUBY trial is directly comparing carboplatin/paclitaxel 
with placebo or dostarlimab in patients with recurrent or primary advanced endometrial 
cancer.(27) The phase 3 AtTEnd trial is evaluating atezolizumab plus carboplatin/paclitaxel in 
patients with advanced or recurrent endometrial cancer.(28) 
Another area of interest is the potential efficacy of combining immune checkpoint inhibitors with 
inhibitors of poly(ADP-ribose) polymerase (PARP). Ongoing phase 2 trials are investigating 
combinations such as olaparib/durvalumab (DOMEC trial), rucaparib/atezolizumab/bevacizumab 
(EndoBARR trial), and niraparib/dostarlimab in patients with recurrent or metastatic endometrial 
cancers.(29-31) 
Highlights 
Given the molecular subtypes of endometrial cancer outlined by TCGA, optimal patient selection 
for emerging therapies is going to be paramount to ensuring patients receive the most effective 
therapy without compromising safety and QoL.  
Despite randomized phase II trials suggesting that adding bevacizumab to chemotherapy 
carboplatin and paclitaxel in frontline endometrial cancer was feasible and may result in some 
benefit, no randomized phase III trials have been conducted to confirm those results 
Immune checkpoint inhibitors have shown efficacy in patients with recurrent MSI-H/dMMR 
solid tumors, including endometrial cancers, with a prolonged duration of response in those who 
respond 
Single-agent immunotherapy with anti–PD-1 monoclonal antibodies, either dostarlimab or 
pembrolizumab, is approved for patients with recurrent endometrial cancer with MSI-H/dMMR. 
Still, experts suggest that adding lenvatinib to pembrolizumab monotherapy in patients with 
MSI-H tumors is likely to result in added toxicity, but not meaningfully improve response 
Response with single-agent pembrolizumab in MSI-H endometrial cancer in KEYNOTE-158 is 
comparable to that of the combination of lenvatinib plus pembrolizumab in MSI-H/dMMR 
endometrial cancers from KEYNOTE-146 (57.1% vs 63.6%) 




Also have to notice that many of the currently available therapies are associated with AEs that 
can negatively affect patient QoL and lead to early treatment discontinuation. Unique targets 
continue to be identified, and ongoing clinical trials will hopefully elucidate promising therapies 
to improve survival and QoL for patients with advanced disease. 
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The Early and locally advanced hormone dependant 




EARLY BREAST CANCER: WHO NEEDS ADJUVANT ET?
• (almost) All ER+ EARLY BREAST CANCER patients! 
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Genomic features
 Gene expression assays
– 21-gene (Oncotype DX)
– 70-gene (MammaPrint)
PlanB: DFS by Ki-67 [a]
WSG PlanB Trial: DFS by Oncotype RS and Ki-67
Proliferation features
 Ki-67 by immunohistochemistry
– Cutoff values of High vs Low
Nitz. Breast Cancer Res Treat. 2017;165:573.
Identifying Patients at Biological High Risk for 
Recurrence





















































TAILORx: Treatment Assignment and Randomization
 Randomized, parallel-assignment phase III study 
 Primary endpoint: iDFS, secondary primary cancer, or death
 Key secondary endpoints: freedom from breast cancer recurrence at distant site, freedom 





T1c-T2 (high-risk T1b) 
(N = 10,273)
Stratified by RS (11-15, 16-20, 21-
25), menopausal status (pre vs 
post), planned chemotherapy 











Arm A: ET Alone
(n = 1629)
Arm C: ET + Chemotherapy
(n = 3312) 
Arm B: ET Alone
(n = 3399)
Arm D: ET + Chemotherapy
(n = 1389) 
Statistical Design
Noninferiority - iDFS
Hazard Ratio: 1.332 
(90 vs. 87% 5-yr DFS)
Type I 10%, type II 
5%
Full info: 835 iDFS 
events
NCT00310180. Sparano. NEJM. 2018;379:111
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TAILORx: ITT Population—RS 11-25 (Arms B & C) 
 836 iDFS events (after median of 7.5 yr), including 338 (40.4%) with recurrence as 














































Hazard ratio, ET alone vs CT + ET:




























































Hazard ratio, ET alone vs CT + ET:







 Primary endpoint: iDFS
 Key secondary endpoints: OS, distant DFS, local DFI, toxicity, QoL
RxPONDER: Adjuvant ET ± Chemotherapy in HR+/HER2-
EBC With 1-3 Positive Lymph Nodes and RS ≤25
 Randomized phase III trial
Kalinsky. SABCS 2020. Abstr GS3-00.
Adults with HR+/HER2- EBC and 
1-3 positive LN without distant mets*; 
able to receive adjuvant taxane 
and/or anthracycline-based CT†; 
axillary staging by SLNB or ALND; 
RS 0-25‡
(N = 5015)
Chemotherapy Followed by ET
(n = 2509) 
ET Alone
(n = 2506)
*Protocol amended to exclude patients with pN1mic as only nodal disease after 2493 patients 
randomized. †Approved CT regimens: TC, FAC (or FEC), AC/T (or EC/T), FAC/T (or FEC/T); AC alone or 
CMF not allowed. ‡Patients with RS > 25 recommended to be treated with CT followed ET off study.
Stratified by RS (0-13 vs 14-25), menopausal status 







RxPONDER: iDFS (Primary Endpoint)
 In this population of node positive, 
hormone receptor–positive BC with RS 
0-25, RS did not predict relative CT 
benefit for iDFS
‒ HR: 1.02 (95% CI: 0.98-1.06; P = .30)
 CT use and RS independently prognostic 
for iDFS
‒ iDFS events less likely among patients 
who received CT
‒ HR: 0.81 (95% CI: 0.67-0.96; P = .026)
‒ iDFS events more likely among patients 
with higher RS
‒ HR: 1.06 (95% CI: 1.04-1.07; P <.001)
 At median follow-up of 5.1 yr, 447 iDFS 
events were observed (54% of expected 
at final analysis)
Kalinsky. SABCS 2020. Abstr GS3-00. 
iDFS in Overall Population






5-yr iDFS, % 92.4 91.0
Absolute difference, % 1.4










































RxPONDER: iDFS by Menopausal Status 
 Absolute difference in distant recurrence as 
first site: 0.3% (2.3% CT + ET vs 2.6% ET)
 Absolute difference in distant recurrence as 
first site: 2.9% (3.1% CT + ET vs 6.0% ET)
Kalinsky. SABCS 2020. Abstr GS3-00. 
Postmenopausal Premenopausal






5-yr iDFS, % 91.6 91.9
Absolute difference, % NS






5-yr iDFS, % 94.2 89.0
Absolute difference, % 5.2





















































































Chemotherapy for ER+/HER2- BC With 0-3 LN
Kalinsky. SABCS 2020. Abstr GS3-00. Sparano. NEJM. 2019;380:2395. 









RS 0-10 RS 11-15 RS 16-20 RS 21-25 RS ≥26
▲ 3.9% (RS 0-13) ▲ 6.2% (RS 14-25)
▲ 0.2%
▲ 6.5% ▲ 8.7%
▲ 6.4%
ET alone CT + ET CT (discuss OFS + AI as 
alternative)
ADAPT HR+/HER2-: Adjuvant ET ± Chemotherapy in 
Intermediate/High-Risk, HR+/HER2- Luminal EBC
 2-part, prospective phase III trial
‒ Part 1: Current analysis evaluated prognostic impact of RS <26 and Ki-67 decrease after short-
course of preoperative ET in the ET alone arm and is not a randomized comparison
Harbeck. SABCS 2020. Abstr GS4-04.
 Primary endpoint: 5-yr iDFS
‒ Part 1: NI* for pN0-1/RS 12-25/Ki-67post
≤10% vs pN0-1/RS 0-11
Adult patients 
with HR+/HER2-
unilateral luminal EBC; 
cT1-4c, cN0-3; 




CT Followed by ET
(n = 2335) 
ET Alone
(n = 2356)
Baseline biopsy evaluated 
for RS (Oncotype DX) and 
Ki-67 expression; surgical 
specimen evaluated for 
Ki-67 expression† after 
short ET run-in
*cT2 or G3 or Ki-67 ≥15% or <35 yr old or cN+.
†Ki-67post ≤10% = ET response.
 pN2-3
 pN0-1/RS >25
 pN0-1/RS 12-25/ 
Ki-67post > 10%
 pN0-1/RS 12-25/ 
Ki-67post ≤10%
 pN0-1/RS 0-11
 Key secondary endpoints: dDFS, OS, 
translational research
*NI defined as ≤3.3% 1-sided 95% CL of 5-yr iDFS 
difference (α = .05, 80% power; 5% dropouts)
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ADAPT HR+/HER2-: 5-Yr iDFS (Primary Endpoint)
 Primary endpoint met
─ 5-yr iDFS difference: -1.3% 
(95% CI: -3.3% to 0.6%)
─ 95% lower confidence limit of 
-3.3% met prespecified criterion for 
noninferiority of pN0-1/RS 12-25/ 
Ki-67post ≤10% vs pN0-1/RS 0-11
(P = .05)
 5-yr OS rate
─ 97.3% for pN0-1/RS 12-25/Ki-67 
≤10% vs 98.0% for pN0-1/RS 0-11
(P = .160)
Harbeck. SABCS 2020. Abstr GS4-04. 

































Treatment De-Escalation Strategies in HR+/HER2- EBC:
Summary
 TAILOR-x :In LN-negative breast cancer:
‒ Age >50 yr: RS ≤25 have no chemotherapy benefit 
‒ Age ≤50 yr: RS 16-25 may derive chemotherapy benefit 
 RxPONDER: analysis of adj CT for HR+/HER2- EBC with 1-3 positive nodes and RS ≤25, postmenopausal 
women did not benefit, whereas premenopausal women did1
‒ Premenopausal patients experienced a 46% decrease in iDFS events and a 53% decrease in deaths, leading 
to a 5-yr OS absolute improvement of 1.3%
 ADAPT HR+/HER2-: primary endpoint reached: patients with luminal EBC and 0-3 positive nodes, RS 12-25 and 
endocrine response 
(Ki-67post ≤10%)
2 after short preoperative ET had a 5-yr iDFS (92.6%) comparable 
to those with 0-3 LN and RS 0-11 (93.9%)
 Outcome was excellent in both groups with adj ET alone: 5-yr dDFS (95.6% vs 96.3%) and 5-yr OS (97.3% vs 
98.0%)
1. Kalinsky. SABCS 2020. Abstr GS3-00. 2. Harbeck. SABCS 2020. Abstr GS4-04.
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Is There a Role for CDK4/6 Inhibition for 
Early-Stage HR+ Disease?









































0 2 4 6 8 10
Stage I II III
Cheng. Cancer Epidemiol Biomarkers Prev. 2012;21:800.
PALLAS: Phase III Open-Label Study of 
Adjuvant Palbociclib + Endocrine Therapy
 Multicenter, open-label, randomized phase III trial
 Primary endpoint: invasive disease–free survival
Mayer. ESMO 2020. Abstr LBA12. Mayer. Lancet Oncol. 2021;22:212. 
Palbociclib x 2 yr*+ 
Endocrine therapy†
(n = 2883) 
Endocrine therapy†
(n = 2877)
Patients with stage II-III HR+/HER2-
breast cancer; completion of prior 
surgery, ± CT, RT within 12 mo of 
diagnosis or within 6 mo of starting 
adjuvant endocrine treatment; 
FFPE tumor block submitted
(N = 5760)
Stratified by stage (IIA vs IIB/III), chemotherapy 
(yes vs no), age (≤50 vs >50 yr), geographic 
region (N America vs Europe vs other)
*125 mg QD, 3 wk on/1 wk off †Aromatase 
inhibitor or tamoxifen ± LHRH agonist.
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P = .51
Hazard ratio: 0.93 (95% Cl: 0.76-1.15)
PALLAS: Primary Endpoint iDFS
 At a median follow-up of 23.7 mo, no significant difference in either 3-yr iDFS or DRFS was observed
Palbociclib + ET ET Alone
iDFS 88.2% 88.5%
Hazard ratio: 0.93 (95% CI: 0.76-1.15; P = .51)
Palbociclib + ET ET Alone
DRFS 89.3% 90.7%

















































Hazard ratio: 1.00 (95% Cl: 0.79-1.27)
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Mayer. ESMO 2020. Abstr LBA12. Mayer. Lancet Oncol. 2021; 22:212.
monarchE: Adjuvant Abemaciclib + ET in High-Risk, 
Node-Positive, HR+/HER2- EBC
 International, randomized, open-label phase III trial
 Primary endpoint: iDFS
‒ Planned for after ~390 iDFS events (~85% power, assumed iDFS hazard ratio of 0.73, cumulative 2-sided 
α = 0.05)
‒ Current primary outcome efficacy analysis occurred after 395 iDFS events in ITT population
 Key secondary endpoints: iDFS in Ki-67 high (≥20%) population, distant RFS, OS, safety, PRO, PK
Johnston. JCO. 2020;38:3987. Rastogi. SABCS 2020. Abstr GS1-01. 
Women or men with high-risk, 
node-positive, HR+/HER2- EBC; 
prior (neo)adjuvant CT permitted; 
pre- or postmenopausal
no distant metastasis;
≤16 mo from surgery to 
randomization; ≤12 wk of ET after 
last non-ET
(N = 5637)
Abemaciclib 150 mg BID up to 2 yr +
ET per standard of care of physician’s 
choice for 5-10 yr as clinically indicated
(n = 2808)
ET per standard of care of physician’s 
choice for 5-10 yr as clinically indicated
(n = 2829)
Cohort 1
≥4 positive ALN or 1-3 positive 
ALN plus histologic grade 3 
and/or tumor ≥5 cm
Cohort 2
1-3 positive ALN, Ki-67 ≥20% 
per central testing, not grade 
3, tumor size <5 cm
ITT Population (Cohorts 1 + 2)
Stratified by prior CT, menopausal 
status, region
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monarchE: iDFS (Primary Endpoint)















































Median f/u: 19.1 mo in both arms. 
Curves should not be interpreted 
beyond 24 mo due to limited f/u. 





Events, n 163 232




Log-rank P = .51
Differences between the drugs themselves/drug exposure and discontinuations/
level of risk within patient populations?
MonarchE iDFS PALLAS iDFS
Palbociclib + ET ET Alone
3-yr iDFS, % 88.2 88.5

















0 6 12 18 24 30 36
Event, n
Palbociclib + ET  170
ET                         181
Patients at Risk, n
Palbociclib + ET
ET
2883       2634          2563        1946         1257          583           163
2877       2649          2535        1953         1295          574           172
Johnston. JCO. 2020;38:3987. Mayer. ESMO 2020. Abstr LBA12. Mayer. Lancet Oncol. 2021;22:212. 
Why Did MonarchE Succeed Where PALLAS Failed?
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monarchE NAC Subgroup Analysis: Prior NAC Regimen
 NAC subgroup comprised 36% 
of ITT population
 Most patients received standard 
NAC regimen of anthracycline + 
taxane
‒ Use of standard NAC regimen 











903 (88.1) 931 (90.3)
Anthracycline 
without taxane
71 (6.9) 59 (5.7)
Taxane + 
cyclophosphamide
28 (2.7) 23 (2.2)
Other* 23 (2.2) 18 (1.7)
*Includes taxane only, cyclophosphamide only, other CT.
Martin. ASCO 2021. Abstr 517.
monarchE NAC Subgroup Analysis: iDFS 
(Primary Endpoint)
 In the NAC subgroup, abemaciclib + ET 
demonstrated a clinically meaningful 38.6% 
reduction in risk of an iDFS event vs ET alone
 The 2-yr iDFS rate was higher with 
abemaciclib + ET vs ET alone in the NAC 
subgroup (87.2% vs 80.6%; difference: 6.6%)
Martin. ASCO 2021. Abstr 517. Reproduced with permission. 









iDFS events, n 92 148 -- --
HR (95% CI) 0.614 (0.473-0.797; 
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monarchE NAC Subgroup Analysis: Conclusions
 In this preplanned subgroup analysis of the monarchE trial, abemaciclib + adjuvant ET 
demonstrated clinically meaningful improvements in iDFS and distant RFS vs ET alone in 
patients with high-risk HR+/HER2- EBC who received prior NAC1
‒ Reduction in risk: iDFS, 38.6%; distant RFS, 39.1%
‒ Benefits were numerically greater than those observed in ITT population and were maintained 
independent of tumor size at diagnosis and surgery
 Among those treated with ET alone, the NAC subgroup exhibited a lower 2-yr iDFS rate vs 
the ITT population consistent with a higher risk of recurrence1-3
‒ 2-yr iDFS rate comparable to that reported in control arm of phase III PENELOPE-B trial, which 
compared palbociclib + ET vs placebo + ET in women with high-risk HR+/HER2- EBC after NAC4
 Safety profile in this population consistent with prior reports for abemaciclib1
21
1. Martin. ASCO 2021. Abstr 517. 2. Rastogi. SABCS 2020. Abstr GS1-01. 3. Johnston. JCO. 2020;38:3987. 
4. Loibl. JCO. 2021;39:1518.
PENELOPE-B: Palbociclib + ET in HR+/HER2- BC at 
High Risk of Relapse After Neoadjuvant Chemotherapy
 Randomized, double-blind, placebo-controlled phase III trial
Loibl. JCO 2021;10:1200. 
 Primary endpoint: iDFS
 Secondary endpoints include: iDFS excluding second primary invasive non-breast cancers, 
distant DFS, locoregional RFS, OS, safety, compliance, QoL
Adult patients with confirmed 
HR+/HER2- BC with residual 
disease after ≥16 wk of 
neoadjuvant CT*; 
CPS-EG score ≥3 or 
2 with ypN+
(N = 1250)
Stratified by age (≤50 vs >50 yr), nodal status (ypN0-1 vs ypN2-3), Ki-67 
(>15% vs ≤15%), region (Asia vs non-Asia), and CPS-EG score (≤3 vs 2 and ypN+)
Palbociclib 125 mg QD Days 1-21
28-day cycles x 13 
+ ET by local standard
(n = 631)
Placebo QD Days 1-21
28-day cycles x 13 +




*Includes 6 wk of taxanes. 
†Time between locoregional 
therapy and randomization: 
<16 wk from final surgery or 
<10 wk from RT completion.
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PENELOPE-B: iDFS (Primary Endpoint)
Palbociclib + ET
Placebo + ET





 Median f/u: 42.8 mo
 Types of iDFS events
– 74% distant recurrences
– 116 with palbociclib, 
111 with placebo
– 16% invasive 
locoregional recurrences











































Loibl. JCO 2021;10:1200. 
CDK4/6 Inhibition in High-Risk HR+/HER2- EBC:
Summary
 monarchE: In a preplanned interim analysis, adj abemaciclib + ET continued to 
demonstrate improved iDFS vs ET alone for HR+/HER2- EBC at high risk of relapse after 
locoregional tx and/or (neo)adj CT (hazard ratio: 0.75; 95% CI: 0.60-0.93; P = .01)1,2
‒ 2-yr iDFS rates: 92.2% with abemaciclib + ET vs 88.7% with ET
‒ Significant iDFS improvement observed in Ki-67 high (≥20%) tumors
‒ Distant RFS also improved (hazard ratio: 0.72; 95% CI: 0.56-0.92; P = .01), with 2-yr distant 
RFS rates of 93.6% vs 90.3%, respectively
 PENELOPE-B: In the first interim analysis, the addition of 1 yr of adjuvant palbociclib to 
ET in the curative setting failed to demonstrate a benefit in patients with higher-risk 
HR+/HER2- EBC after locoregional tx and neoadjuvant CT3
1. Johnston. JCO. 2020;38:3987. 2. Rastogi. SABCS 2020. Abstr GS1-01. 3. Loibl. SABCS 2020. Abstr GS1-02. 
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Why Different Outcomes Across These Trials 
(or Are There)?
 Different definitions of high risk?
‒ Was there more luminal B (high proliferation) in monarchE than in PALLAS or PENELOPE-B?
 Differences in therapy adherence?
‒ May explain PALLAS results but adherence much higher in PENELOPE-B (though shorter 
duration of therapy with only 1 yr)
 Is abemaciclib a more effective CDK inhibitor?
‒ Possible, although not supported by metastatic first-line trials that have remarkably similar 
hazard ratios (continuous dosing, more potent inhibition of CDK4, monotherapy activity)
 Durations of CDK inhibitor therapy?
‒ Possible PENELOPE-B would have been positive if palbociclib had been given for longer
‒ Await NATALEE results with 3 yr of ribociclib
O’Regan. SABCS 2020. Abstr GS1-03. 
Why Should Neoadjuvant Endocrine Therapy Be Given?
 Down-stage tumor prior to surgery
‒ NET and chemotherapy have similar rates of clinical response, radiographic response, 
and rates of BCS, but lower rates of toxicity
‒ AI superior to tamoxifen in terms of clinical response, radiographic response, and rates 
of BCS
‒ Longer duration of NEC allows for higher rates of BCS and pCR
 Identify HR+ tumors that may not require chemotherapy
 Gain insights into the biology of the tumors
‒ Biomarkers response/resistance to treatment
‒ Predict phase III trial results
Barchiesi. Int J Mol Sci. 2020;21:3528.
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No Significant Improvement in ORR/BCS With 
Neoadjuvant Chemotherapy vs Endocrine Therapy
Reinert. Curr Treat Options Oncol. 2018;19:23.






A: CT (n = 118) 
(dox + paclitaxel) 
B: ET (total n = 121) 















B: Exe (+ goserelin if 
premenopausal)
--







A: CT (n = 22)









A: CT (n = 53)








Spring. JAMA Oncol. 2016;2:1477.
Neoadjuvant ET vs CT: Systematic Review/
Meta-analysis of 20 RCTs Through 2015 (N = 3490)
 AIs showed significantly higher rates of clinical response, radiologic response, and BCS vs tamoxifen; 
radiologic response rate higher with CT + ET vs ET
Clinical Response
Source OR (95% CI)
Alba 2012 2.11 (0.92-4.82)
Palmieri 2014 0.34 (0.6-1.98)
Semiglazov 2007 0.93 (0.55-1.57)
Total 1.08 (0.50-2.35)
Heterogeneity: x22 = 4.47 (P = .11), I
2 = 55%.







Source OR (95% CI)
Alba 2012 2.11 (0.92-4.82)
Palmieri 2014 0.83 (0.25-2.74)
Semiglazov 2007 1.28 (0.77-2.14)
Total 1.38 (0.92-2.07)
Heterogeneity: x22 = 1.77 (P = .41), I
2 = 0%
Test for overall effect: z = 1.54 (P = .12) 0.01 0.1 1.0 10 100
OR (95% CI)
Pathologic CR
Source OR (95% CI)
Alba 2012 3.13 (0.12-78.77)
Palmieri 2014 Not estimated
Semiglazov 2007 1.84 (0.53-6.47)
Total 1.99 (0.62-6.39)
Heterogeneity: x22 = 0.09 (P = .76), I
2 = 0%.







Source OR (95% CI)
Alba 2012 0.68 (0.30-1.54)
Semiglazov 2007 0.63 (0.36-1.11)
Total 0.65 (0.41-1.03)
Heterogeneity: x22 = 0.03 (P = .87), I
2 = 0%
Test for overall effect: z = 1.83 (P = .07) 0.01 0.1 1.0 10 100
OR (95% CI)
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Summary of Endocrine Therapy Alone
 Neoadjuvant endocrine therapy yields similar ORR response to 
chemotherapy 
‒ AI > tamoxifen in terms of ORR and BCS
 Endpoints of trials in ER+ breast cancer challenging
‒ Achievement of pCR rare (<5%)
‒ Use of Ki67 and PEPI may correlate with long-term outcome and may 
allow triage of patients with no drop in Ki67 to chemotherapy
‒ ALTERNATE: fulvestrant = AI = AI + fulvestrant in terms of Ki67 response, 
PEPI; long-term outcomes are awaited
neoMONARCH: Neoadjuvant Abemaciclib, Anastrozole, 
and Abemaciclib + Anastrozole in HR+/HER2- BC
 RNAseq analysis of biopsy samples from multicenter, randomized, open-label 
phase II trial






















2-wk lead-in 14 wk
n = number of biopsy samples.
 Primary endpoint: percent change in Ki67 from baseline to 2 wk of treatment

















neoMONARCH: Antiproliferative Effects of Abemaciclib, 
Anastrozole, and Combination Tx on HR+/HER2- BC












CCCA 68 58 14































































Abemaciclib + ANZ (n = 59)
Abemaciclib (n = 52)










Abemaciclib + ANZ (n = 40)
Abemaciclib (n = 30)
ANZ (n = 8)
PALLET: Palbociclib + Neoadjuvant Letrozole 
in ER+/HER2- EBC









Letrozole* for 14 wk
Group C
Palbociclib for 2 wk →
Letrozole + palbociclib to wk 14
Group B
Letrozole for 2 wk →
Letrozole + palbociclib† to wk 14
Follow-up 30 days after 














*Letrozole 2.5mb/day PO. †Palbociclib 125 mg/day PO (3 wk on, 1 wk off). 
Dose reduction to 100 mg and 75 mg available.
Core cut biopsies taken at:
 Baseline (post randomization)
 2 wk (prior to start of second drug in groups B 
and C)
 14 wk or at discontinuation treatment
(within 48 hr of last dose)
Johnston. JCO. 2019;37:178.
 Coprimary endpoints (for group A vs B + C + 
D): change in Ki67 (protein between 
baseline and 
14 wk and clinical response (ordinal and 
ultrasound) after 14 wk
 Secondary endpoint: pCR
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PALLET: Clinical Response (Coprimary Endpoint)
 No significant difference in ORR 
with letrozole (Group A) vs 
letrozole + palbociclib (Groups B 
+ C + D)
‒ ORR: 49.5% vs 54.4%; P = .20 




































LET 2 wk then 
LET+PAL 12 wk 
(Group B)
PAL 2 wk then 




























 Compared to letrozole, palbociclib + letrozole:
‒ Enhanced Ki67 suppression (P <.001)
‒ Increased CCCA rate (58.5% to 90.4%; P <.001)
‒ Did not improve ORR (49.5% to 54.4%; P = .2)
‒ pCR rate: 1%
Johnston. JCO. 2019;37:178.
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FELINE: Neoadjuvant Ribociclib + Letrozole 
vs Placebo + Letrozole in ER+/HER2- Breast Cancer
 Randomized, open-label phase II trial (patients accrued Feb 2016 to Aug 2018)
 Primary endpoint: Proportion reaching PEPI score 0 at surgery (ie, removing need for adjuvant chemo)
− PEPI 0: tumor ≤5 cm, node negative, Ki-67 ≤2.7%, Allred ER score 3-8
 Secondary endpoints: complete cell-cycle arrest, responses (RECIST), safety
Khan. ASCO 2020. Abstr 505.
Postmenopausal women 
with HER2- breast cancer, 
stage II/III, primary >2 cm; 
ER+ >66%
(N = 120)
Ribociclib 400 mg/day PO, continuously
Letrozole 2.5 mg PO QD
(n = 41)
Ribociclib 600 mg/day PO, 3 wk on/off
Letrozole 2.5 mg PO QD
(n = 41)
Letrozole 2.5 mg PO QD + 
Placebo
(n = 38)
 6 28-day cycles
 Surgery between D8-21 of cycle 6
 Treatment continued until day 
before surgery
 Clinical response measurement: 
ultrasound, MRI
 Tissue samples: baseline, Day 14 
of cycle 1, and at surgery
 If Ki-67 > 10% at Day 14 of cycle 1, 
patient removed from trial
FELINE: Ki67 Change Between 


















15.8 21.4 .9129 16.5 24.7
Day 14 Ki67 













-15.7 -23.3 .047 -20.6 -25.7




































Group A: Change in Ki67 (Baseline to D14C1)
Khan. ASCO 2020. Abstr 505.
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FELINE: Summary 
 Adding ribociclib to letrozole did not 
 Increase number of patients with PEPI = 0
 Improve ORR
 Adding ribociclib to letrozole did
 Improve complete cell cycle arrest at C1D14
 But this was not maintained at surgery (acquired resistance?)
NeoPal: Neoadjuvant Letrozole + Palbociclib vs CT
 Randomized, parallel, non-comparative phase II trial
*FEC100: 5-FU 500 mg/m2, epirubicin 100 mg/m2, 
cyclophosphamide 500 mg/m2.
Patients with ER+/HER2- BC; 
Prosigna-defined luminal B or 
luminal A/N+; stage II-III; not 
candidate for breast conserving 
surgery
(N = 106)
FEC100* x 3 cycles then 
Docetaxel 100 mg/m2 x three 21-day cycles 
(n = 53)
Letrozole 25 mg QD + 
Palbociclib 125 mg QD 3/4 wk x 19 wk
(n = 53) Outcome, n (%)
LET + PAL 
(n = 52) 
CT
(n = 51)
RCB 0-I 4 (7.7) 8 (15.7)
RCB II-III 48 (92.3) 43 (84.3)
pCR 2 (3.8) 3 (5.9)
Final Analysis








 Primary endpoint: rate of RCB 0-I
 Secondary endpoints: clinical response, 
proliferation-based markers, safety
 Sample size: null hypothesis (p0) was RCB 0-I in 
20% of cases; alternative hypothesis was 40%, 
type I error of 0.045, type II error of 0.042 
(power: 95.8%); required sample size n = 60/arm 
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NeoPal Conclusion
 Neoadjuvant LET + PAL or CT was associated with poor pathologic 
response for Prosigna-defined high-risk luminal breast cancer
– RCB 0-1 rate: 7.7% with LET + PAL; 15.7% with CT
– pCR rate: 3.8% with LET + PAL; 5.9%% with CT
 Neoadjuvant LET + PAL or CT led to similar rates of clinical or radiologic 
response and BCS
 PEPI = 0 was numerically higher with LET + PAL (17.6% vs 8.0% with CT)
Cottu. Ann Oncol. 2018;29:2334.
CORALLEEN: Neoadjuvant Letrozole + Ribociclib vs CT
 Multicenter, randomized, open-label phase II trial
Postmenopausal women with 
HR+/HER2- BC; stage I-IIIA; 
tumor size ≥2 cm; PAM50 
luminal B (Prosigna)
(N = 106)
 Surgery performed within 
7 days of last dose of 
ribociclib or within 2 wk of 
last dose of CT
 ET in the ribociclib + 
letrozole group continued 
until day of surgery
*Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2.
PAM50 + RNA/DNA seq and plasma samples collected at 
baseline, Day 15, and post surgery.
Letrozole 2.5 mg/day + 
Ribociclib 600 mg/day for 3/4 wk
(n = 52)
AC* Q3W x 4 
Paclitaxel 80 mg/m2 wkly x 12
(n = 54) 
Stratified by tumor size (T1/2 vs T3),
nodal involvement
Prat. Lancet Oncol. 2020;21:33. 
 At baseline, ~40% of patients had node-positive disease, median Ki67 expression was 30-35, median ROR 








n (%) 95% CI n (%) 95% CI
Low 23 (46.9) 32.5-61.7 24 (46.1) 32.9-61.5
Intermediate 15 (30.6) 18.2-45.4 13 (30.8) 19.1-45.9
High 11 (22.5) 11.8-36.7 11 (21.2) 11.2-35.2
Missing NA NA 1 (1.9) NA
Prat. Lancet Oncol. 2020;21:33. 
Summary: Neoadjuvant CDK4/6 Inhibitors
 Addition of CDK4/6 inhibitors to ET shows biologic activity (potent reduction 
in Ki67 at 2 wk)
 Addition of CDK4/6 inhibitors to ET does not appear to improve ORR or 
pathologic response vs ET alone or CT, with low rates of pCR or RCB 0-1
 Cross-trial comparisons suggest similar level of benefit across the 3 CDK4/6 
inhibitors; however, there was no head-to-head comparison 
 The optimum endpoint is unknown; it has not been firmly established that 
increasing the rate of pCR and RCB 0-1 improves long-term outcomes for 
luminal cancers




 Use of genomic assays in the preoperative setting may help us best 
select patients who may benefit from preoperative endocrine therapy 
vs chemotherapy
 Assessing endpoint to assess response to endocrine therapy + CDK4/6 
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Anti-HER2 therapy (trastuzumab, 
pertuzumab, lapatinib, T-DM1,
T-Dx, tucatinib















Ovariectomy  or  MOS
AI or  fulvestrant or  tamoxifen AI+  CDK4/6i , or fulvestrant + CDK4/6i if <12 














Everolimus + ET(e.g.. eksemestan, tamoksifen), not used Ai (steroidal or nonsteroidal) fulvestrant, megestrol acetat
CHT (monotherapy , not used before)
HR+ HER2- MBC
VISCERAL CRISIS: leptomeningeal 
carcinomatosis; hepatic 
metastases with endangered  liver 
function: increasing bilirubin 
levels with biliary obstruction 
excluded, elevated liver 
transaminases with diffuse 
hepatic infiltration; pulmonary 
lymphangitic carcinomatosis; large 
lung metastases with respiratory 
insufficency present
No prior treatment with 
anti-HER2 therapy
Prior (neo) adjuvant treatment 
with anti-HER2 therapy
Patients unsuitable for CT or 
long free interval and minimal 
disease extent, HR+
Taxanes+ trastuzumab + 
pertuzumab
Taxanse + trastuzumab + pertuzumab  (if 
the free disease interval is > 12 months)  
or  T-DM1 (if the free disease interval is< 
12 months or  ChT1 + trastuzumab
ET+ anti-HER2 therapy 






The optimal duration of maintenance anti-HER2 
therapy is unknown; possible to stop after several 







T-DX Tukatinib + trast.+ 
capecitabin 3
HER2 +MBC
1 noncardiotoxic CT (taxanes, vinorelbine, 
paclitaxel / carboplatin)
2 non-cardiotoxic CT not previously used
3 preferred in CNS metastases




















Other unused ChTs, selection according to previous efficacy, side effects, performance status





1 with anthracyclines can be treated 
up to the maximum total dose
2 taxanes can be reused if the free 
disease interval after (neo) adjuvant 
treatment is> 12 months
Conclusion
Approximately 20% to 30% of woman initially diagnosed with early stage 
disease will develop metastatic breast cancer.
The goals of treatment are: maximizing the quality of life,  prevention 
and palliation of symptoms, and prolongation of survival. Treatment is 
lifelong, characterized by remissions and relapses.
When choosing a treatment, it is necessary to know the tumor
characteristics and identify molecular targets.
Targeted drugs such are anti-HER2 therapies in HER2 positive subtype, 
CDK4/6, mTOR and PIK3CA  inhibitors in HR+/HER2- subtype and  immune 
check point inhibitors in TNBC have significantly improved disease 
control.
New promising drugs are under way, however  we need clinical trials and  
continued basic and translational research to make new breakthroughs.
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The diffuse large B cell 





LBCL are a heterogeneous group of diseases with different clinical and 
biological features – for an adequate treatment, histopathological evaluation 
of an extirpated lymph node is a prerequisite.
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Conclusion
With current treatment, only 50 to 60% of patients will be cured. In relapsed 
disease, salvage chemotherapy results in long term disease free survival in a 
small minority of patients. Additional curative option is offered through high 
dose therapy and autologous SCT. Multiply relapsed lymphomas can be 
treated with CAR T cell therapy and allogeneic SCT, other treatments are 
predominately palliative.
And results…
Oncol Lett. 2018 Mar; 15(3): 3602–3609. 
Published online 2018 Jan 11. doi: 10.3892/ol.2018.7774
PMCID: PMC5796369
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience
with rituximab plus cyclophosphamide, doxorubicin, vincristine and
prednisolone
Matej Horvat,1 Vesna Zadnik,2 Tanja Južnič Šetina,1 Lučka Boltežar,1 Jana 
Pahole Goličnik,1 Srdjan Novaković,3 and Barbara Jezeršek Novaković1
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And results…
Table I. Patient clinical and demographic characteristics at the start of treatment (n=624).
Sex Male 297 (48%) Female 327 (52%)
Median age 67.0 (19-89) <60 years, 208 (33%)
ECOG performance status 0: 299 (48%) 1: 183 (29%)
2: 90 (14%) 3: 33 (5%)
4: 19 (3%)
Disease stage I: 73 (12%) II: 178 (29%)
III: 111 (18%) IV: 245 (39%)
Elevated LDH level 311 (50%)
Extranodal involvement 439 (70%)
Treatment regimen Rituximab + CHOP 575 (92%)
Rituximab + other chemotherapy 32 (5%)
Chemotherapy alone 17 (3%)
IPI score 0: 63 (10%) 1: 122 (20%)
2: 143 (23%) 3: 141 (23%)










Age, <60 years 88 85 84 83 79 NR
Age. ≥60 years 84 80 79 78 70 NR
Age, <60 years, IPI 0 
or 1
93 90 89 87 77 NR
Age, <60, IPI ≥2 83 79 79 79 79 NR
Overall survival
Age, <60 years 93 85 81 81 76 NR
Age, ≥60 years 82 70 64 56 41 80.1
Age, <60 years, IPI 0 
or 1
98 95 91 91 87 NR
Age, <60, IPI ≥2 87 76 71 71 67 NR
And results…
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Marginal zone lymphoma   (MZL)
Summer school 2021
Oncology institute of Ljubljana
Milica Miljkovi ć, medical oncologist
Introduction
 Indolent (slow growing) Non – Hodgkin B cell lymphomas
 5-15% of Non-Hodgkin lymphomas
 Average age at diagnosis is 60 years
 Slightly more common in women 
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WHO classification
 Clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ)
 Nodal marginal zone lymphoma (NMZL)
 Splenic marginal zone lymphoma (SMZL)
 Extranodal marginal zone lymphoma (EMZL) or Mucosa –Associated Lymphoid 
Tissue (MALT) : The stomach is the most common site, followed by ocular 
adnexa, lung and salivary glands.
Treatment of EMZL, NMZL, SMZL
 Treat just symptomatic systemic disease
 It means:
-B simptomps: fewer, night sweats and weight loss
-Bulky disese
-Symptomatic splenomegaly and/ or any progressive cytopaenias
- Hb < 100 g/L
- Platelets < 80x10/L
- Neutrophils < 1 x10/L
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Treatment of EMZL, NMZL, SMZL
 Stage I and II: surgery +/- RT (25,2GY)
 Stage III and IV and with B simptoms:
6-8 x R-LP (rituximab,chlorambucil, prednisolone)
4-6 x R-Bendamustine
6-8 x R-Lenalidomide
4 x Rituksimab + RT for old and unfit patients 
6-8 x R-CHOP for aggressive disease 
(rituximab,ciklofosfamid,doxorubicin,vincristine,prednisolone)
Treatment algorithm for localised gastric MZL 
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Treatment algorithm for advanced gastric MZL
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Sekcija internistične onkologije pri SZD, Onkološki inštitut Ljubljana in Katedra za onkologijo
2nd Summer School in medical oncology –
Precision oncology – Are we there yet
7-10 September 2021
Institute of Oncology Ljubljana, Zaloška 2, Ljubljana
Standards and perspectives in the systemic treatment 
of Lymphomas –
Follicular lymphoma
dr. Tanja Južnič Šetina, dr.med
Institute of Oncology, Ljubljana
Follicular lymphoma
• Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma
• It accounts for 20% of all NHL cases and around 70 % of indolent lymphomas
• The clinical presentation is usually characterized by asymptomatic peripheral lymphadenopathy in 
cervical, axillary, inguinal and femoral regions. Most patients are diagnosed with advanced stage 
disease. Bone marrow involvement is present in more than >80%.
• The course of FL is quite variable. The disease is usually characterized by an indolent clinical 
course and response to initial therapy, but relapses are common.
• The prognosis of FL is good. The median survival of FL is over 15 years but considering it`s 
indolent nature, survival can often be measured in decades.
• Histologic transformation of FL to a DLBCL has been reported in up to 70 percent of patients over 




• Bone marrow involvement
• low risk: B2M normal and bone 
marrow not involved
• intermediate risk: B2M normal 
and bone marrow involved
• high risk: B2M elevated
Risk group score 5 year OS % 10-year OS %
Low 0 to 1 91 71
Intermediate 2 78 51
High > 3 52 36
FLIPI - outcome according to risk group   
1. Solal-Celigny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international
prognostic index. Blood 2004; 104:1258
2. Nooka AK, Nabhan C, Zhou X, et al.. Ann Oncol 2013; 24:441.
FLIPI score applied to patients in the rituximab era (68% 
received R, n=2192)
score 2- yr OS % 2-yr PFS % mPFS (months)
0 to 1 98 84 84
2 94 72 70
> 3 87 65 42
OS by FLIPI risk groups for R-containing regimens²
OS by FLIPI risk groups¹
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Initial treatment of stage I to IV follicular lymphoma
 treatment of FL depends on the stage of disease at presentation
 introduction of anti-CD20 monoclonal antibody rituksimab into first line FL treatment or relapsed 
disease significantly improved the outcome of FL patients
Stage I/II
• 10-20% of FL patients present with limited stage I/II disease
• radiotherapy (24-30 Gy) is generally the treatment of choice for limited stage FL, and results in 10-year OS rates of 
60% to 80%;
• 2 x 2 Gy schedule is less durable but might be used in special situations to minimize side-effects (e.g. lacrimal gland, 
parotid glands)
• In selected cases (e.g. limited life expectancy, large abdominal fields), observation or rituximab monotherapy may be 
considered
Stage III/IV
• Initial observation ("watch and wait" ) is the standard approach in asymptomatic, stable patients with stage II (high 
tumor burden), III, or IV 
• Immunotherapy-based treatment (rituximab, obinutuzumab and chemotherapy)
• Radioimmunotherapy
• lenalidomide-rituximab
• rituximab monotherapy or R in combination with chlorambucil
Indications for treatment
• local symptoms due to progressive or bulky nodal disease
• vital organ compression
• presence of systemic B symptoms ( fevers >38°C, weight loss, night sweats)
• presence of symptomatic extranodal disease, such as effusions
• cytopenias due to extensive bone marrow infiltration, autoimmune 
hemolytic anemia or thrombocytopenia, or hypersplenism




• R – bendamustin, R-CHOP or R-CVP
• Obinutuzumab / bendamustin, CHOP or CVP
• Rituximab+ lenalidomide
• Less preferred
• Rituximab – monotherapy (4 weekly doses)
• Rituximab+chlorambucil
• Radioimmunotherapy
• Rituximab maintenance (every 8 weeks for 2 years) - improves PFS 
and OS
• Obinutuzumab maintenance (every 8 weeks, 12 doses)

































































PFS: R-ChT vs ChT ( HR 0,62, CI 0,55-0,71, p<0,001) 
OS: R-ChT vs ChT, 1480 (1.line+relapses)    











Morschhauser et al. 
2018
R-CHOP/BR
+ R maint., 517
R-lenalidomide









 With the introduction of R,
survival of FL has improved. 
 The improvement was established  
in at least four prospective first-
line trials and a systematic meta-
analysis.
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Maintenance treatment with rituximab
(PRIMA study)
CONCLUSION (PRIMA)
• rituximab maintenance after induction immunochemotherapy provides a 
significant PFS benefit over observation
• no OS benefit
1. Long-Term Results of the PRIMA Study (9y FU)
1. Bachy E, et al. J Clin Oncol. 2019;37(31):2815-2824. Sustained Progression-Free Survival Benefit of Rituximab 
Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
2. Vidal L, Gafter-Gvili A, Salles G, et al. Eur J Cancer. 2017;76:216 
PFS (PRIMA)
OS (PRIMA)
2. Meta-analysis (Vidal et al, 2017); seven trials including PRIMA, 2315 pts
with FL evaluating rituximab maintenance on OS
CONCLUSION: Maintenance rituximab improved PFS (HR 0.57; 95% CI 0.51-
0.64) and OS (HR 0.79; 95% CI 0.66-0.96)
GALLIUM Study
(randomised phase III study in previously untreated FL patients) 
G-chemo (601 pts)
G 1000mg IV on D1, D8, 
D15 of C1 and 
D1 of C2–8 (q3w) or C2–6 
(q4w) plus chop,CVP or
bendamustine
R-chemo (601 pts)
R 375mg/m2 IV on D1 of 




G 1000mg IV q2m for 
2 years or until PD
R
R 375mg/m2 IV q2m for 




















Stage III/IV or stage II 












GALLIUM study results : PFS and OS in patients with FL
(first-line)






3-y PFS,% 73,3                    80,0
(95% CI) (68.8-77.2) (75.9-83.6)
HR (95% CI), =p=0.001
3-y OS                                             92                   94
HR 0.75, P=0,21
Conclusion:
 Obinutuzumab/chemo + maintenance
is superior to similar R-based regimens
with improvement of PFS
 no difference in OS
RELEVANCE: Phase III Trial Design (previously untreated FL patients)
Morschhauser F, Fowler NH, et al. N Engl J Med. 2018;379(10):934
Primary endpoints: CR/CRu at 120 weeks and PFS
R2
R2 = lenalidomide/rituximab; R = rituximab; 























RELEVANCE: Interim PFS (first-line FL patients)
• At median follow-up of 37.9 mo, interim PFS was similar in both arms
• 3-y OS = 94% (R2) vs 94% (R-chemo), HR 1.16












• similar rates of CR (48% in R2 vs 53 % in R chemo)
• similar 3-y PFS (77% vs 78 %, HR 1.10, 95% CI 
0.85-1.43)
• similar OS (94 vs 94 %, HR 1.16, 95% CI 0.72-1.86)
• more rash, diarrhea and tumor flare, less
neutropenia in the R2
Treatment of R/R FL
• 20 to 30 % of patients with FL relapse after first- line therapy
• rule out histologic transformation
• patients who progress within 24 months have significantly worse OS than those who do not
• asymptomatic recurrent FL do not necessarily require immediate treatment
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Treatment regimens for R/R FL
• Preferred regimens
• Bendamustin + rituximab or obinutuzumab
• CHOP or R-CVP + obinutuzumab or rituximab
• Lenalidomide + rituximab or obinutuzumab
• PI3K inhibitors (after 2 prior therapies)
• Less preferred (eldery, frail pts)
• Rituximab alone (4 weekly doses)
• Chlorambucil +/- R
• Cyclophosphamide +/- R
• Radioimmunotherapy
• Rituximab maintenance (every 3 months for 2 years) 
• Obinutuzumab maintenance for R-refractory (every 8 weeks, 12 doses)
• Other
• High dose therapy with ASCT, allogeneic transplant for selected patients
• Novel treatments (CAR-T-cell therapy, tazemetostat – EZH2 mut posit after 2 prior
therapies or EZH2 WT in pts with no other alternative), mosunetuzumab
R, rituximab
Randomised phase III study for R/R FL patients
Obinutuzumab
maintenan. (1000 mg 




median follow-up 31,8 months
Conclusion: the addition of obinutuzumab improves PFS and
OS. Toxicity was similar in both treatments.
OS (HR, 0.67; 95% CI, 0.47 to 0.96; P = .027)
Cheson BD. J Clin Oncol. 2018;36(22):2259.
AUGMENT: R2 versus Rituximab/Placebo for R/R FL or 
Marginal Zone Lymphoma - randomised phase III study
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Conclusions:
• improved PFS with R2 vs R alone (39 mo vs 14 mo)
• 2-year OS was 95% for R2 and 86% for R/placebo
• similar efficacy to chemoimmunotherapy
• oral PI3K inhibitor that has shown therapeutic activity in initial studies of patients with multiple 
relapsed FL
• approved by EMA and FDA as a single agent for the treatment of patients with relapsed FL who 
have received at least two prior systemic therapies
• approval based on a phase 2 study of idelalisib (n=72) in patients with FL who have received at 
least 2 prior lines of therapy1
• ORR was 57 % with a median duration of response of 12.5 months
• The starting dose is 150 mg twice daily
• toxicity: 
• diarrhea – 14% pneumonitis - 4%
• cytopenias – 28% hepatotoxicity – 18%
• infections – 21% hypertriglyceridemia, hyperglycemia
• anti-infectious prophylaxis
Idelalisib
1.Gopal AK, et al. N Engl J Med. 2014
344
Avtologous, allogeneic transplantation
• an appropriate consolidative therapy for patients in second or third remission
• may have the greatest benefit in patients with early treatment failure, refractory FL and 
those with histologic transformation to a more aggressive histology
• there is a plateau in the survival curves between 10 and 15 years after autologous HCT, 
suggesting that this procedure may be curative for one-quarter to one-third of transplanted 
patients1,2
• allogeneic transplantation can be considered in highly selected patients (lower rates of 
relapse vs autoHCT, high TRM up to 20%)
1. Metzner B, et al. Ann Oncol. 2013
2. Casulo C, et al. Biol Blood Marrow Transplant. 2018
Conclusions
• FL is a chronic, incurable disease with a long natural history
• a small subgroup of patients presenting with limited stage disease may be cured with radiation 
• observation is the first approach in asymptomatic patients 
• for those who require therapy : multiple treatment regimens, anti-CD20 +/- chemotherapy and    
chemotherapy-free alternatives, novel agents,…
o antiCD20 +/- chemotherapy 
o lenalidomide +/- rituximab
o PI3K inhibitors
o autologous and allogeneic stem cell transplantation
o novel agents (tazemetostat - EZH2 inhibitor, mosunetuzumab - bispecific antibody ,…)
o CAR-T cell therapy - may dramatically alter the prognosis for heavily pretreated patients
(ZUMA-5 study with high ORR more than 90%, median PFS at 2 years 78%, CR rate 80 %,..)
• disease can still be fatal in patients with histologic transformation
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MANTLE CELL LYMPHOMA
Monika Jagodic, MD, PhDmmd
Histology: the image is of mantle zone cells surrounding normal germinal centre follicles
Biology: the translocation t (11;14) (q13; q32) leading to cyclin-D1 overexpression is typical
Prognosis: Clinical and biological prognosticators (combined mantle cell lymphoma International Prognostic Index, MIPI-c) should be
used routinely to estimate clinical behaviour) including age, ECOG, LDH, WBC count, Ki-67 index.  Other prognosticators: SOX-11 
expression, TP 53 mutations
Initial treatment approach: a short course of watch-wait under close observation is recommended for suspected indolent cases with low
tumour burden and asymptomatic disease at diagnosis.
When starting of treatment is required (symptoms, high tumour burden) initial treatment is conventional chemoterapy (ChT) with rituximab
(Rx) +/-consolidation RT. In younger patients are used aggresive regimens by autologous stem-cell transplantation (SCT)  as 1st line. 
In older patients are  used conventional ChT combinations and less intense immunoChT or low- toxicity single agent targeted therapy
in frail patients.
Maintenance with rituximab significantly improves progression-free survival and overall survival. 
Relapse disease treatment: salvage therapy: in early relapses (<12-24 months) a non-cross resistant scheme after R-CHOP or vice versa
is recommended, with Rx maintenance.
Molecular targeted substances (ibrutinib, lenalidomide) should be considered in refractory disease. Additional options: temsirolimus, 
bortezomid. 
AlloSCT transplantation should be considered in younger patients as potentially curative treatment in early relapse and refractory disease. 




Institute of Oncology Ljubljana
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T-CELL LYMPHOMA – short facts
• 7-10% of all NHL
• Most are clinically aggressive
• Heterogenous in their presentation, features and prognosis
• Lack of efficient treatment
• Most can be healed not cured 
• Outcomes are poor
• Low response rates
• 5-year OS ~32%
• 5-year failure-free survival ~20%




• T-cell prolymphocite 
leukemia 
• Adult T-cell 
leukemia/lymphoma
• T-cell large granular 
lymphocytic leukemia
• NK cell leukemia
• Peripheral T-cell 
lymphoma NOS
• Nodal PTCL with TFH
• Angioimmunoblastic 
lymphoma
• Follicular T-cell 
lymphoma
• Anaplastic largecell 
lymphoma (ALK+/ALK-
/breast implant) 
• Extranodaln NK/T cell
• Hepatosplenic




• Primary cutaneous CD30+
Swerdlow et al Blood 2016
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Standards and perspectives in 




2nd Summer School in medical oncology
Conclusions
• Incidence in EU 2.3/100.000, most often affects young adults
• Multiple signaling pathways/transcription factors deregulated activities in RS cells 
involved in pathogenesis 
• 5-FDG PET-CT scan an important part of diagnostic and treatment modifying 
decisions
• Type of treatment depends on clinical stage and risk factors
• Combined approach of treatment in early stages, chemotherapy-based treatment 
for advance disease
• Overall >80% achieve long remission – are cured
• Standard care of relapse in young fit patient is high-dose ChT + AutoSCT
• In relapse settings  already approved use of some novel drugs as antibody-drug 
conjugates, anti PD-1 antibodies, others as small molecule inhibitors, cellular 
therapies in study settings
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PRINCIPLES OF RADIOTHERAPY 
IN LYMPHOMAS
Assist. Prof. PhD Lorna Zadravec Zaletel, MD
2nd Summer School in medical oncology, 2021
Conclusions
• malignant lymphomas are radiosensitive.
• RT may be a stand-alone treatment for some indolent
NHL and for low stage HL- type lymphocyte
predominance .
• in indolent NHL of higher stages, RT is reserved for
treating the rest of the disease after CT or low-dose
RT of larger infiltrates in order to delay CT.
• in aggressive lymphomas, radiation is always
associated with systemic treatment.
• life-long follow-up of late sequelae of treatment is of
vital importance.
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ZAUSTAVITE NAPREDOVANJE  
BOLEZNI IN PODALJŠAJTE PREŽIVETJE
Pri bolnikih z mHSPC, zdravljenje samo z ADT ni dovolj.
SAMO ZA STROKOVNO JAVNOST
Janssen, farmacevtski del Johnson & Johnson d.o.o., Šmartinska cesta 53, 1000 Ljubljana,  









Zgodnja uporaba zdravila ERLEADA+ADT v primerjavi z ADT pomembno podaljša preživetje bolnikov in zmanjša 
tveganje za napredovanje bolezni, hkrati pa prihrani druge oblike zdravljenja za kasnejše stadije bolezni.1-3
 ZDRAVILO ERLEADA® JE SEDAJ ODOBRENO TUDI ZA  ZDRAVLJENJE BOLNIKOV S 
HORMONSKO OBČUTLJIVIM, METASTATSKIM RAKOM PROSTATE (mHSPC).¹  
(apalutamid) tablete
▼ Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo hitreje na voljo nove informacije o 
njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o katerem koli domnevnem neželenem 
učinku zdravila. Glejte poglavje 4.8 povzetka glavnih značilnosti zdravila, kako poročati o neželenih učinkih.
Ime zdravila: Erleada 60 mg filmsko obložene tablete. Kakovostna in količinska sestava: 60 mg 
apalutamida; pomožne snovi: brezvodni koloidni silicijev dioksid, premreženi natrijev karmelozat, 
hipromeloza acetat sukcinat, magnezijev stearat, mikrokristalna celuloza, mikrokristalna celuloza 
(silicifirana), črni in rumeni železov dioksid, makrogol, polivinilalkohol (delno hidroliziran), smukec, 
titanov dioksid. Indikacije: Zdravljenje odraslih moških z nemetastatskim, na kastracijo odpornim rakom 
prostate (nmCRPC), pri katerih obstaja veliko tveganje za razvoj metastatske bolezni. Za zdravljenje 
odraslih moških s hormonsko občutljivim metastatskim rakom prostate (mHSCP) v kombinaciji z 
zdravljenjem z odtegnitvijo androgenov. Odmerjanje in način uporabe: Priporočeni odmerek je 240 mg 
(štiri 60‑miligramske tablete) v enkratnem peroralnem odmerku na dan. Med zdravljenjem je treba pri 
bolnikih, ki niso bili kirurško kastrirani, nadaljevati medicinsko kastracijo z analogom gonadoliberina. V 
primeru izpuščenega odmerka je treba zdravilo vzeti čimprej še isti dan, naslednji dan pa naj odmerjanje 
nadaljuje po običajnem razporedu. Dodatnih tablet za nadomestitev pozabljenega odmerka se ne sme 
vzeti. Če se pri bolniku pojavijo toksični učinki ≥  3.  stopnje ali nesprejemljivi neželeni učinki, je treba 
uporabo zdravila prekiniti začasno in ne dokončno, dokler se simptomi ne izboljšajo na ≤  1.  stopnjo 
oziroma na začetno stopnjo, nato pa z zdravljenjem nadaljevati z enakim ali manjšim odmerkom (180 mg 
ali 120  mg), če je potrebno. Starejšim bolnikom, bolnikom z blago do zmerno okvaro ledvic ali jeter 
odmerka ni treba prilagajati. Pri bolnikih s hudo okvaro ledvic je potrebna previdnost, pri bolnikih s hudo 
okvaro jeter pa uporaba ni priporočljiva. Tablete je treba pogoltniti cele in se jih lahko jemlje s hrano ali 
brez nje. Apalutamid ni namenjen za uporabo pri pediatrični populaciji. Kontraindikacije: Preobčutljivost 
na učinkovino ali katero koli pomožno snov, nosečnice in ženske, ki bi lahko zanosile. Posebna opozorila 
in previdnostni ukrepi: Uporaba zdravila ni priporočljiva pri bolnikih z anamnezo konvulzij ali drugimi 
predispozicijskimi dejavniki, med drugim tudi pri bolnikih s poškodbo možganov, nedavno kapjo (v 
zadnjem letu), pri bolnikih s primarnimi možganskimi tumorji ali metastazami v možganih. Pri bolnikih, ki 
so prejemali apalutamid je prišlo do padcev in zlomov, zato je treba pred uvedbo zdravljenja pri bolnikih 
oceniti tveganje za zlome in padce, bolnike pa spremljati po ustaljenih smernicah in premisliti o uporabi 
učinkovin, ki delujejo na kosti. Bolnike je treba spremljati tudi glede znakov in simptomov ishemične 
bolezni srca in ishemičnih možganskožilnih bolezni ter optimatizirati obvladovanje dejavnikov tveganja, 
kot so hipertenzija, diabetes ali dislipidemija, skladno s standardno oskrbo. Sočasni uporabi apalutamida z 
zdravili, ki so občutljivi substrati več presnovnih encimov ali prenašalcev, se je načeloma treba izogibati, če 
je terapevtski učinek teh zdravil za bolnika zelo pomemben in njihovega odmerjanja ni mogoče enostavno 
prilagajati na osnovi spremljanja učinkovitosti ali koncentracij v plazmi. Sočasni uporabi z varfarinom 
ali kumarinskimi antikoagulansi se je treba izogibati. Če se predpiše apalutamid, je treba pri bolnikih s 
klinično pomembnimi boleznimi srca in ožilja spremljati dejavnike tveganja kot so hiperholesterolemija, 
hipertrigliceridemija ali druge srčno presnovne bolezni. Zdravljenje z odtegnitvijo androgenov lahko 
podaljša interval QT. Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Apalutamid 
je induktor encimov in prenašalcev in lahko povzroči povečan obseg odstranjevanja številnih pogosto 
uporabljanih zdravil. Pri sočasnem odmerjanju tega zdravila s katerim od močnih zaviralcev CYP2C8 
ali močnih zaviralcev CYP3A4 začetnega odmerka ni treba prilagajati, premisliti pa velja o zmanjšanju 
odmerka zdravila Erleada na osnovi prenašanja zdravila. Ni pričakovati, da bi induktorji CYP3A4 ali CYP2C8 
klinično pomembno vplivali na farmakokinetiko apalutamida in aktivnih frakcij. . Pri sočasni uporabi s 
substrati CYP2B6 je treba spremljati neželene učinke in oceniti izgubo učinka substrata ter za zagotovitev 
optimalnih plazemskih koncentracij morda prilagoditi odmerek substrata. Sočasna uporaba z zdravili, ki 
se primarno presnavljajo s CYP3A4 (kot so darunavir, felodipin, midazolam in simvastatin), s CYP2C19 
(kot sta diazepam in omeprazol) ali s CYP2C9 (kot sta varfarin in fenitoin), lahko povzroči zmanjšanje 
izpostavljenosti tem zdravilom. Pri sočasni uporabi s substrati UDP‑glukuronil transferaze je potrebna 
previdnost. Pri sočasni uporabi s substrati P‑gp, BCRP ali OATP1B1 je potrebna ocena obsega zmanjšanja 
učinka ter za zagotovitev optimalnih plazemskih koncentracij morda prilagoditi odmerek substrata. Ni 
mogoče izključiti možnosti, da apalutamid in njegov N‑desmetil presnovek zavirata prenašalce OCT2,OAT3 
in MATE. Pri preiskovancih z mHSPC, ki so prejemali levprorelinijev acetat (analog GnRH), sočasna uporaba 
apalutamida ni bistveno vplivala na izpostavljenost leuprolidu v stanju dinamičnega ravnovesja. Skrbna 
presoja je potrebna tudi pri sočasni uporabi z zdravili, za katera je ugotovljeno, da podaljšujejo interval QT, 
oziroma z zdravili, ki lahko izzovejo Torsades de pointes. Plodnost, nosečnost in dojenje: Ni znano, ali so 
apalutamid ali njegovi presnovki prisotni v spermi, zato lahko to zdravilo škoduje plodu v razvoju. Bolniki, 
ki imajo spolne odnose z žensko v rodni dobi, morajo med zdravljenjem in še 3  mesece po zadnjem 
odmerku zdravila Erleada uporabljati kondome skupaj s še katero od drugih visoko učinkovitih metod 
kontracepcije. Zdravilo je kontraindicirano pri nosečnicah in ženskah , ki bi lahko zanosile in se ne sme 
uporabljati med dojenjem. Neželeni učinki: Hipotiroidizem, zmanjšan apetit, hiperholesterolemija, 
hipertrigliceridemija, disgevzija, ishemične možganskožilne bolezni, konvulzije, ishemična bolezen srca, 
podaljšanje intervala QT, vročinski oblivi, hipertenzija, driska, kožni izpuščaj, srbenje, alopecija, TEN, zlomi, 
artralgija, mišični krči, utrujenost, zmanjšanje telesne mase, padci. Za popoln seznam neželenih učinkov 
glejte Povzetek glavnih značilnosti zdravila. Imetnik DzP: Janssen‑Cilag International NV, Turnhoutseweg 
30, 2340 Beerse, Belgija Predstavnik imetnika DzP v Sloveniji: Johnson & Johnson d.o.o., Šmartinska 
cesta 53, Ljubljana. 
Režim izdajanja zdravila: Rp/Spec. Datum zadnje revizije besedila: 10. junij 2021
Povzetek glavnih značilnosti zdravila s podrobnejšimi informacijami o zdravilu je dostopen pri 
predstavniku imetnika dovoljenja za promet.
Viri:
1. Povzetek glavnih značilnosti zdravila ERLEADA® (apalutamid).
2. Chi KN, et al. N Engl J Med. 2019;81(1):13–24
3. Chi KN, et al. N Engl J Med. 2019;81(1):13–24. Supplementary information.
Skrajšan povzetek glavnih značilnosti zdravila ERLEADA®
Izkušnje, na katere  
se lahko zanesete
tablete
ENA TABLETA ENKRAT  
NA DAN DOMA
KLL=kronična limfocitna levkemija; MCL=limfom plaščnih celic; WM=Waldenströmova makroglobulinemija.
Janssen, farmacevtski del Johnson & Johnson d.o.o.
Šmartinska 53, 1000 Ljubljana, Slovenia, Tel: 01 401 18 00, e-mail: info@janssen-slovenia.si, www.janssen.com/slovenia CP-214010/020921
SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Ime zdravila: IMBRUVICA 140 mg/280 mg/420 mg/560 mg filmsko obložene tablete
Kakovostna in količinska sestava: 140/280/420 ali 560 mg ibrutiniba, brezvodni koloidni silicijev dioksid, premrežen 
natrijev karmelozat, laktoza monohidrat, magnezijev stearat, mikrokristalna celuloza, natrijev lavrilsulfat (E487), 
povidon; filmska obloga: makrogol, polivinilalkohol, smukec, titanov dioksid (E171), črni železov oksid (E172), rumeni 
železov oksid (E172 – 140, 420 in 560 mg), rdeči železov oksid (E172 – 280 in 560 mg) Indikacije: Kot samostojno 
zdravilo: zdravljenje odraslih bolnikov s ponovitvijo limfoma plaščnih celic (MCL) ali z na zdravljenje neodzivno obliko 
te bolezni, zdravljenje odraslih bolnikov z Waldenstromovo makroglobulinemijo (WM - Waldenström’s 
macroglobulinaemia), ki so predhodno prejeli vsaj eno vrsto zdravljenja oziroma v prvi liniji pri bolnikih, ki niso 
primerni za kemoimunoterapijo. Kot samostojno zdravilo ali v kombinaciji z obinutuzumabom za zdravljenje odraslih 
bolnikov s predhodno neozdravljivo kronično limfocitno levkemijo (KLL)/z bendamustinom in rituksimabom za 
zdravljenje odraslih bolnikov s KLL, ki so predhodno prejeli vsaj eno vrsto zdravljenja; samostojno zdravilo indicirano. 
V kombinaciji z rituksimabom za zdravljenje odraslih bolnikov z WM. Odmerjanje: Zdravilo je treba jemati peroralno 
enkrat na dan s kozarcem vode, in sicer vsak dan ob približno istem času. Tablete je treba pogoltniti cele z vodo. Tablet 
se ne sme drobiti ali žvečiti. Zdravljenje mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo onkoloških 
zdravil. MCL: priporočeni odmerek je 560 mg enkrat na dan. KLL (samostojno ali v kombinaciji) in WM: priporočeni 
odmerek je 420 mg enkrat na dan. Z zdravljenjem je treba nadaljevati do napredovanja bolezni oz. dokler bolnik 
zdravilo prenaša. Pri odmerjanju tega zdravila v kombinaciji z zdravilom, ki je usmerjeno proti CD20, je priporočljivo 
vzeti ibrutinib pred zdravilom, ki je usmerjeno proti CD20, kadar ju je treba vzeti na isti dan. Podrobna navodila za 
odmerjanje pri posebnih skupinah bolnikov in za prilagajanje odmerkov v primeru sočasne uporabe z zmernimi in 
močnimi zaviralci CYP3A4 in ob pojavu hematološke toksičnosti so navedena v Povzetku glavnih značilnosti zdravila. Če 
bolnik izpusti odmerek, ga lahko vzame čimprej istega dne, naslednjega dne pa spet začne z odmerjanjem po običajnem 
razporedu. Bolnik naj ne jemlje dodatnih tablet, da bi nadomestil pozabljeni odmerek. Kontraindikacije: 
Preobčutljivost na učinkovino ali katero koli pomožno snov, sočasna uporaba pripravkov rastlinskega izvora s šentanževko 
(Hypericum perforatum). Posebna opozorila in previdnostni ukrepi: Poročali so o krvavitvah s trombocitopenijo ali 
brez nje (vključno z manjšimi hemoragičnimi dogodki (podplutbe, krvavitev iz nosu, petehije) ter večjimi krvavitvami 
(gastrointestinalna in intrakranialna krvavitev, hematurija)). Sočasno se ne sme jemati varfarina in drugih antagonistov 
vitamina K. Izogibati se je treba prehranskim dopolnilom (npr. pripravki ribjega olja ali vitamina E). Pri sočasnem 
zdravljenju z antikoagulanti je potrebna posebna previdnost. Zdravila se ne sme jemati najmanj 3 do 7 dni (odvisno od 
vrste kirurškega posega in tveganja za krvavitev) pred kirurškim posegom in po njem. Poročali so o primerih levkostaze. 
Po prekinitvi zdravljenja z ibrutinibom so poročali o primerih rupture vranice. Veliko število cirkulirajočih limfocitov 
(> 400.000/mikroliter) lahko pomeni povečano tveganje; treba je razmisliti o začasni prekinitvi jemanja zdravila, 
bolnika skrbno spremljati in po potrebi uvesti podporne ukrepe vključno s hidracijo in/ali citoredukcijo. Opažali so 
okužbe; bolnike je treba spremljati glede morebitnega pojava zvišane telesne temperature, nenormalnih izvidov 
preiskav delovanja jeter, nevtropenije in okužbe ter po potrebi uvesti ustrezno antimikrobno zdravljenje. Pri bolnikih s 
povečanim tveganjem za oportunistične okužbe razmislite o standardnih ukrepih za njihovo preprečevanje. Po uporabi 
ibrutiniba so poročali so o primerih invazivnih glivičnih okužb, vključno s primeri aspergiloze, kriptokokoze in okužbe s 
Pneumocystis jiroveci. Pri uporabi ibrutiniba ob predhodni ali sočasni uporabi imunosupresivnega zdravljenja so poročali 
o PML, vključno s smrtnimi primeri. PML je treba upoštevati v diferencialni diagnozi pri bolnikih z novimi ali s 
poslabšanjem obstoječih nevroloških, kognitivnih ali vedenjskih znakov ali simptomov. Če obstaja sum za PML, je treba 
opraviti diagnostične preiskave in zdravljenje prekiniti dokler ni izključena. Pri bolnikih, zdravljenih z ibrutinibom so se 
pojavili primeri hepatotoksičnosti, reaktivacije virusa hepatitisa B in primeri hepatitisa E, ki so lahko kronične narave, 
prišlo je tudi do odpovedi jeter, vključno s smrtnimi izidi. Pred uvedbo zdravila je treba preveriti delovanje jeter in 
prisotnost virusa hepatitisa. Poročali so tudi o citopenijah, zato je treba enkrat mesečno določati celotno krvno sliko. 
Pri bolnikih, ki so jemali ibrutinib so poročali tudi o primerih atrijske fibrilacije, atrijske undulacije, ventrikularne 
tahiaritmije in srčnega popuščanja. Zaradi možnosti pojava srčnih bolezni, vključno s srčnimi aritmijami in srčnim 
popuščanjem je treba vse bolnike občasno klinično pregledati. Pri bolnikih, pri katerih so se pojavili simptomi in/ali 
znaki ventrikularne tahiaritmije je treba zdravljenje s tem zdravilom začasno prekiniti, pred ponovno uvedbo je treba 
temeljito oceniti klinično razmerje med koristjo in tveganjem. Bolnike, pri katerih se pojavijo simptomi aritmije ali se 
na novo pojavi zadihanost, omotica ali omedlevica, je treba klinično pregledati in jim po potrebi posneti EKG. Pri 
bolnikih z obstoječo atrijsko fibrilacijo, ki potrebujejo zdravljenje z antikoagulanti, je treba razmisliti o drugih 
možnostih zdravljenja. Če se atrijska fibrilacija pojavi med zdravljenjem, je treba temeljito oceniti tveganje za 
trombembolične bolezni. Pri bolnikih z velikim tveganjem in kadar druge možnosti zdravljenja niso primerne, je treba 
razmisliti o skrbno nadzorovanem zdravljenju z antikoagulanti Bolnike je treba med zdravljenjem skrbno spremljati 
glede znakov in simptomov srčnega popuščanja. Pri bolnikih, ki so jemali to zdravilo so poročali o primerih ILD. Bolnike 
spremljajte glede pljučnih simptomov ILD. Če se simptomi pojavijo, je treba zdravljenje prekiniti in ILD ustrezno 
zdraviti. Če simptomi vztrajajo je treba oceniti tveganje in korist zdravljenja in upoštevati smernice za prilagoditev 
odmerjanja. Pri bolnikih, ki so prejemali ibrutinib so poročali o primerih cerebrovaskularnega insulta, prehodnega 
ishemičnega napada in ishemične možganske kapi s sočasno atrijsko fibrilacijo in/ali hipertenzijo ali brez njiju. Med 
primeri, ki so bili poročani z zakasnitvijo, je od začetka zdravljenja do pojava ishemičnih žilnih bolezni osrednjega 
živčevja večinoma minilo nekaj mesecev. Bolnike z večjo maso tumorja pred začetkom zdravljenja je treba skrbno 
spremljati zaradi večjega tveganja za pojav sindroma razpada tumorja. Med zdravljenjem je treba bolnike spremljati 
glede morebitnega pojava nemelanomskega kožnega raka. Bolnikom, ki prejemajo ibrutinib, je treba med celotnim 
potekom zdravljenja redno meriti krvni tlak in jim po potrebi uvesti ali prilagoditi odmerjanje antihipertenzivnih 
zdravil. Poročali so tudi o primerih hemofagocitne limfohistiocitoze, vključno s smrtnimi primeri. Pri sočasni uporabi z 
zmernimi/močnimi zaviralci CYP3A4 lahko pride do povečane izpostavljenosti ibrutinibu in večjega tveganja za pojav 
toksičnosti, pri sočasni uporabi z indukdorji CYP3A4 pa do zmanjšane izpostavljenosti in tveganja za pomanjkanje 
učinkovitosti. Zato se je treba sočasni uporabi z močnimi zaviralci CYP3A4 in močnimi ali zmernimi induktorji CYP3A4 
izogibati. O sočasni uporabi lahko razmislite samo, kadar pričakovane koristi nedvoumno presegajo morebitno tveganje. 
Pri bolnikih, ki morajo jemati zaviralce CYP3A4, je treba skrbno spremljati morebitne znake toksičnega delovanja 
zdravila; pri tistih, ki jemljejo induktorje CYP3A4 pa znake pomanjkanja učinkovitosti. Bolniki z redko dedno 
intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega 
zdravila. Ena filmsko obložena tableta vsebuje manj kot 1 mmol natrija (23 mg) kar v bistvu pomeni ‘brez natrija’. 
Interakcije: Sočasna uporaba z zdravili, ki močno/zmerno zavirajo CYP3A4, lahko poveča izpostavljenost ibrutinibu, 
zato se je treba uporabi močnih zaviralcev CYP3A4 izogibati. Če mora bolnik jemati katerega od močnih/zmernih 
zaviralcev CYP3A4, je treba odmerek zdravila Imbruvica prilagoditi (glejte Povzetek glavnih značilnosti zdravila), 
bolnike pa skrbno spremljati. V kombinaciji s šibkimi zaviralci prilagajanje odmerjanja ni potrebno. Bolnike je treba 
skrbno spremljati in po potrebi upoštevati smernice za prilagajanje odmerka. Med zdravljenjem se je treba izogibati 
uživanju grenivk in seviljskih pomaranč, ker vsebujejo zmerne zaviralce CYP3A4. Sočasna uporaba zdravila Imbruvica z 
induktorji CYP3A4 lahko zmanjša koncentracijo ibrutiniba v plazmi. Razmisliti velja o uporabi drugih učinkovin, ki v 
manjši meri inducirajo CYP3A4. Če je potrebna uporaba močnega ali zmernega induktorja CYP3A4 in pričakovana korist 
presega morebitno tveganje, je treba bolnika skrbno spremljati glede znakov pomanjkanja učinkovitosti. Zdravilo se 
lahko sočasno uporablja z blagimi induktorji, vendar je treba bolnike skrbno spremljati glede znakov pomanjkanja 
učinkovitosti. Topnost ibrutiniba je odvisna od pH, zato lahko zdravila, ki zvečajo pH v želodcu (npr. zaviralci protonske 
črpalke), zmanjšajo izpostavljenost ibrutinibu. In vitro ibrutinib zavira P-glikoprotein in BCRP, zato je treba substrate 
P-glikoproteina in BCRP, ki imajo ozko peroralno terapevtsko okno (npr. digoksin, metotreksat) jemati najmanj 6 ur pred 
oz. najmanj 6 ur po odmerjanju zdravila Imbruvica. Ibrutinib lahko zavira tudi BCRP v jetrih in zveča izpostavljenost 
zdravilom, katerih izločanje skozi jetra je povezano z BCRP (rosuvastatin). V študiji medsebojnega delovanja z drugimi 
zdravili pri bolnikih z malignomi celic B, ibrutinib v enkratnem, 560 mg odmerku ni klinično pomembno vplival na 
izpostavljenost substratu CYP3A4 midazolamu. V isti študiji, 2 tedensko zdravljenje z ibrutinibom v odmerku 560 mg na 
dan, ni klinično pomembno vplivalo na farmakokinetiko oralnih kontraceptivov (etiniletradiol in levonorgestrel), 
substrata CYP3A4 midazolama ali substrata CYP2B6 bupropiona. Nosečnost, dojenje in plodnost: Ženske v rodni dobi 
morajo med zdravljenjem in še tri mesece po zaključku zdravljenja uporabljati zelo učinkovito metodo kontracepcije. 
Zdravila ne smete uporabljati pri nosečnicah. Med zdravljenjem je treba prenehati z dojenjem. Podatkov o vplivu 
ibrutiniba na plodnost pri ljudeh ni na voljo. Vpliv na sposobnost vožnje in upravljanja strojev: Zdravilo ima blag vpliv 
na sposobnost vožnje in upravljanja strojev. Pri nekaterih bolnikih so poročali o utrujenosti, omotičnosti in asteniji, kar 
je treba upoštevati pri presoji bolnikove sposobnosti za vožnjo in upravljanje strojev. Neželeni učinki: pljučnica, 
okužba zgornjih dihal, sinusitis, sepsa, kriptokokna/pnevmocistična okužba, okužba z aspergilusom, reaktivacija 
hepatitisa B, nemelanomski kožni raki, okužba sečil, okužba kože, nevtropenija, trombocitopenija, limfocitoza, 
anemija, febrilna nevtropenija, levkocitoza, sindrom levkostaze, ILD, dehidracija, hiperurikemija, sindrom razpada 
tumorja, omotičnost, glavobol, periferna nevropatija, cerebrovaskularni insult, prehodni ishemični napad, ishemična 
možganska kap, zamegljen vid, očesna krvavitev, srčno popuščanje, atrijska fibrilacija, ventrikularna tahiaritmija, 
krvavitev, podplutba,petehije, subduralni hematom, krvavitev iz nosu, diareja, bruhanje, stomatitis, navzea, 
obstipacija, suha usta, odpoved jeter, izpuščaj, angioedem, panikulitis, nevtrofilne dermatoze, urtikarija, eritem, 
lomljenje nohtov, Stevens-Johnsonov sindrom, artralgija, mišičnoskeletne bolečine, zvišana telesna temperatura, 
periferni edem, zvišanje kreatinina v krvi (vsi NU so opisani v povzetku glavnih značilnosti zdravila) Način in režim 
izdajanja zdravila: Rp/Spec. Imetnik DzP: Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgija 
Predstavnik Imetnika DzP v Sloveniji: Johnson & Johnson d.o.o., Šmartinska cesta 53, 1000 Ljubljana 
Datum zadnje revizije besedila: 20. 08. 2021
Povzetek glavnih značilnosti zdravila s podrobnejšimi informacijami o zdravilu je dostopen pri predstavniku imetnika 
dovoljenja za promet.
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Prevzemite nadzor nad  
KLL, MCL in WM z zdravilom IMBRUVICA®1-6
Dolgotrajno izboljšanje preživetja po 8 letih spremljanja.2-3
Poznan in obvladljiv varnostni profil.2-6
 Enostavno, enkrat dnevno jemanje zdravila na domu.1
SAMO ZA STROKOVNO JAVNOST
Referenca: 1. Keytruda EU SmPC
SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA 
Pred predpisovanjem, prosimo, preberite celoten Povzetek glavnih značilnosti 
zdravila! 
Ime zdravila: KEYTRUDA 25 mg/ml koncentrat za raztopino za infundiranje vsebuje 
pembrolizumab. Terapevtske indikacije: Zdravilo KEYTRUDA je kot samostojno 
zdravljenje indicirano za zdravljenje: napredovalega (neoperabilnega ali metastatskega) 
melanoma pri odraslih; za adjuvantno zdravljenje odraslih z melanomom v stadiju III, ki se 
je razširil na bezgavke, po popolni kirurški odstranitvi; metastatskega nedrobnoceličnega 
pljučnega raka (NSCLC) v prvi liniji zdravljenja pri odraslih, ki imajo tumorje z ≥ 50 % 
izraženostjo PD-L1 (TPS) in brez pozitivnih tumorskih mutacij EGFR ali ALK; lokalno 
napredovalega ali metastatskega NSCLC pri odraslih, ki imajo tumorje z ≥ 1 % izraženostjo 
PD-L1 (TPS) in so bili predhodno zdravljeni z vsaj eno shemo kemoterapije, bolniki s 
pozitivnimi tumorskimi mutacijami EGFR ali ALK so pred prejemom zdravila KEYTRUDA 
morali prejeti tudi tarčno zdravljenje; odraslih in pediatričnih bolnikov, starih 3 leta ali več, 
s ponovljenim ali neodzivnim klasičnim Hodgkinovim limfomom (cHL), pri katerih 
avtologna presaditev matičnih celic (ASCT) ni bila uspešna, ali po najmanj dveh 
predhodnih zdravljenjih kadar ASCT ne pride v poštev kot možnost zdravljenja; lokalno 
napredovalega ali metastatskega urotelijskega raka pri odraslih, predhodno zdravljenih s 
kemoterapijo, ki je vključevala platino; lokalno napredovalega ali metastatskega 
urotelijskega raka pri odraslih, ki niso primerni za zdravljenje s kemoterapijo, ki vsebuje 
cisplatin in imajo tumorje z izraženostjo PD-L1 ≥ 10, ocenjeno s kombinirano pozitivno 
oceno (CPS); ponovljenega ali metastatskega ploščatoceličnega raka glave in vratu 
(HNSCC) pri odraslih, ki imajo tumorje z ≥ 50 % izraženostjo PD-L1 (TPS), in pri katerih je 
bolezen napredovala med zdravljenjem ali po zdravljenju s kemoterapijo, ki je vključevala 
platino in za prvo linijo zdravljenja metastatskega kolorektalnega raka z visoko 
mikrosatelitsko nestabilnostjo (MSI-H – microsatellite instability-high) ali s pomanjkljivim 
popravljanjem neujemanja pri podvojevanju DNA (dMMR - mismatch repair deficient) pri 
odraslih. Zdravilo KEYTRUDA je kot samostojno zdravljenje ali v kombinaciji s 
kemoterapijo s platino in 5-fluorouracilom (5-FU) indicirano za prvo linijo zdravljenja 
metastatskega ali neoperabilnega ponovljenega ploščatoceličnega raka glave in vratu pri 
odraslih, ki imajo tumorje z izraženostjo PD-L1 s CPS ≥ 1. Zdravilo KEYTRUDA je v 
kombinaciji s pemetreksedom in kemoterapijo na osnovi platine indicirano za prvo linijo 
zdravljenja metastatskega neploščatoceličnega NSCLC pri odraslih, pri katerih tumorji 
nimajo pozitivnih mutacij EGFR ali ALK; v kombinaciji s karboplatinom in bodisi 
paklitakselom bodisi nab-paklitakselom je indicirano za prvo linijo zdravljenja 
metastatskega ploščatoceličnega NSCLC pri odraslih; v kombinaciji z aksitinibom je 
indicirano za prvo linijo zdravljenja napredovalega raka ledvičnih celic (RCC) pri odraslih; 
v kombinaciji s kemoterapijo s platino in fluoropirimidinom indicirano za prvo linijo 
zdravljenja lokalno napredovalega neoperabilnega ali metastatskega raka požiralnika ali 
HER-2 negativnega adenokarcinoma gastroezofagealnega prehoda pri odraslih, ki imajo 
tumorje z izraženostjo PD-L1 s CPS ≥ 10. Odmerjanje in način uporabe: Testiranje PD-L1: 
Če je navedeno v indikaciji, je treba izbiro bolnika za zdravljenje z zdravilom KEYTRUDA 
na podlagi izraženosti PD-L1 tumorja potrditi z validirano preiskavo. Testiranje MSI-H/
dMMR pri bolnikih s CRC: Za samostojno zdravljenje z zdravilom KEYTRUDA je 
priporočljivo opraviti testiranje MSI-H/dMMR statusa tumorja z validirano preiskavo, da se 
izbere bolnike s CRC. Odmerjanje: Priporočeni odmerek zdravila KEYTRUDA pri odraslih je 
bodisi 200 mg na 3 tedne ali 400 mg na 6 tednov, apliciran z intravensko infuzijo v 30 
minutah. Priporočeni odmerek zdravila KEYTRUDA za samostojno zdravljenje pri 
pediatričnih bolnikih s cHL, starih 3 leta ali več, je 2 mg/kg telesne mase (do največ 200 
mg) na 3 tedne, apliciran z intravensko infuzijo v 30 minutah. Za uporabo v kombinaciji 
glejte povzetke glavnih značilnosti sočasno uporabljenih zdravil. Če se uporablja kot del 
kombiniranega zdravljenja skupaj z intravensko kemoterapijo, je treba zdravilo 
KEYTRUDA aplicirati prvo. Bolnike je treba zdraviti do napredovanja bolezni ali 
nesprejemljivih toksičnih učinkov. Pri adjuvantnem zdravljenju melanoma je treba 
zdravilo uporabljati do ponovitve bolezni, pojava nesprejemljivih toksičnih učinkov 
oziroma mora zdravljenje trajati do enega leta. Če je aksitinib uporabljen v kombinaciji s 
pembrolizumabom, se lahko razmisli o povečanju odmerka aksitiniba nad začetnih 5 mg 
v presledkih šest tednov ali več. Pri bolnikih starih ≥ 65 let, bolnikih z blago do zmerno 
okvaro ledvic, bolnikih z blago okvaro jeter prilagoditev odmerka ni potrebna. Odložitev 
odmerka ali ukinitev zdravljenja: Zmanjšanje odmerka zdravila KEYTRUDA ni priporočljivo. 
Za obvladovanje neželenih učinkov je treba uporabo zdravila KEYTRUDA zadržati ali 
ukiniti, prosimo, glejte celoten Povzetek glavnih značilnosti zdravila. Kontraindikacije: 
Preobčutljivost na učinkovino ali katero koli pomožno snov. Povzetek posebnih 
opozoril, previdnostnih ukrepov, interakcij in neželenih učinkov: Imunsko pogojeni 
neželeni učinki (pnevmonitis, kolitis, hepatitis, nefritis, endokrinopatije, neželeni učinki 
na kožo in drugi): Pri bolnikih, ki so prejemali pembrolizumab, so se pojavili imunsko 
pogojeni neželeni učinki, vključno s hudimi in smrtnimi primeri. Večina imunsko 
pogojenih neželenih učinkov, ki so se pojavili med zdravljenjem s pembrolizumabom, je 
bila reverzibilnih in so jih obvladali s prekinitvami uporabe pembrolizumaba, uporabo 
kortikosteroidov in/ali podporno oskrbo. Pojavijo se lahko tudi po zadnjem odmerku 
pembrolizumaba in hkrati prizadanejo več organskih sistemov. V primeru suma na 
imunsko pogojene neželene učinke je treba poskrbeti za ustrezno oceno za potrditev 
etiologije oziroma izključitev drugih vzrokov. Glede na izrazitost neželenega učinka je 
treba zadržati uporabo pembrolizumaba in uporabiti kortikosteroide – za natančna 
navodila, prosimo, glejte Povzetek glavnih značilnosti zdravila Keytruda. Zdravljenje s 
pembrolizumabom lahko poveča tveganje za zavrnitev pri prejemnikih presadkov čvrstih 
organov. Pri bolnikih, ki so prejemali pembrolizumab, so poročali o hudih z infuzijo 
povezanih reakcijah, vključno s preobčutljivostjo in anafilaksijo. Pembrolizumab se iz 
obtoka odstrani s katabolizmom, zato presnovnih medsebojnih delovanj zdravil ni 
pričakovati. Uporabi sistemskih kortikosteroidov ali imunosupresivov pred uvedbo 
pembrolizumaba se je treba izogibati, ker lahko vplivajo na farmakodinamično aktivnost 
in učinkovitost pembrolizumaba. Vendar pa je kortikosteroide ali druge imunosupresive 
mogoče uporabiti za zdravljenje imunsko pogojenih neželenih učinkov. Kortikosteroide 
je mogoče uporabiti tudi kot premedikacijo, če je pembrolizumab uporabljen v 
kombinaciji s kemoterapijo, kot antiemetično profilakso in/ali za ublažitev neželenih 
učinkov, povezanih s kemoterapijo. Ženske v rodni dobi morajo med zdravljenjem s 
pembrolizumabom in vsaj še 4 mesece po zadnjem odmerku pembrolizumaba 
uporabljati učinkovito kontracepcijo, med nosečnostjo in dojenjem se ga ne sme 
uporabljati. Varnost pembrolizumaba pri samostojnem zdravljenju so v kliničnih študijah 
ocenili pri 6.185 bolnikih z napredovalim melanomom, kirurško odstranjenim 
melanomom v stadiju III (adjuvantno zdravljenje), NSCLC, cHL, urotelijskim rakom, HNSCC 
ali CRC s štirimi odmerki (2 mg/kg telesne mase na 3 tedne, 200 mg na 3 tedne in 10 mg/
kg telesne mase na 2 ali 3 tedne). V tej populaciji bolnikov je mediani čas opazovanja 
znašal 7,6 mesece (v razponu od 1 dneva do 47 mesecev), najpogostejši neželeni učinki 
zdravljenja s pembrolizumabom so bili utrujenost (32 %), navzea (21 %) in diareja (21 %). 
Večina poročanih neželenih učinkov pri samostojnem zdravljenju je bila po izrazitosti 1. 
ali 2. stopnje. Najresnejši neželeni učinki so bili imunsko pogojeni neželeni učinki in hude 
z infuzijo povezane reakcije. Varnost pembrolizumaba pri kombiniranem zdravljenju s 
kemoterapijo so ocenili pri 1.437 bolnikih NSCLC, HNSCC ali rakom požiralnika, ki so v 
kliničnih študijah prejemali pembrolizumab v odmerkih 200 mg, 2 mg/kg telesne mase ali 
10 mg/kg telesne mase na vsake 3 tedne. V tej populaciji bolnikov so bili najpogostejši 
neželeni učinki naslednji: navzea (55 %), anemija (51 %), utrujenost (39 %), zaprtost (37 
%), zmanjšanje apetita (34 %), diareja (33 %), nevtropenija (29 %) in bruhanje (28 %). 
Pojavnost neželenih učinkov 3. do 5. stopnje je pri bolnikih z NSCLC pri kombiniranem 
zdravljenju s pembrolizumabom znašala 67 % in pri zdravljenju samo s kemoterapijo 66 
%, pri bolnikih s HNSCC pri kombiniranem zdravljenju s pembrolizumabom 85 % in pri 
zdravljenju s kemoterapijo v kombinaciji s cetuksimabom 84 %, ter pri bolnikih z rakom 
požiralnika pri kombiniranem zdravljenju s pembrolizumabom 86 % in pri zdravljenju 
samo s kemoterapijo 83 %. Varnost pembrolizumaba v kombinaciji z aksitinibom so 
ocenili v klinični študiji pri 429 bolnikih z napredovalim rakom ledvičnih celic, ki so 
prejemali 200 mg pembrolizumaba na 3 tedne in 5 mg aksitiniba dvakrat na dan. V tej 
populaciji bolnikov so bili najpogostejši neželeni učinki diareja (54 %), hipertenzija (45 %), 
utrujenost (38 %), hipotiroidizem (35 %), zmanjšan apetit (30 %), sindrom palmarno-
plantarne eritrodisestezije (28 %), navzea (28 %), zvišanje vrednosti ALT (27 %), zvišanje 
vrednosti AST (26 %), disfonija (25 %), kašelj (21 %) in zaprtost (21 %). Pojavnost neželenih 
učinkov 3. do 5. stopnje je bila med kombiniranim zdravljenjem s pembrolizumabom 76 
% in pri zdravljenju s sunitinibom samim 71 %. Za celoten seznam neželenih učinkov, 
prosimo, glejte celoten Povzetek glavnih značilnosti zdravila. Način in režim izdaje 
zdravila: H – Predpisovanje in izdaja zdravila je le na recept, zdravilo se uporablja samo v 
bolnišnicah. Imetnik dovoljenja za promet z zdravilom: Merck Sharp & Dohme B.V. , 
Waarderweg 39, 2031 BN Haarlem, Nizozemska.
 Merck Sharp & Dohme inovativna zdravila d.o.o.,  Ameriška ulica 2, 1000 Ljubljana,  
tel: +386 1/ 520 42 01, fax: +386 1/ 520 43 50;  
Pripravljeno v Sloveniji, julij 2021; SI-KEY-00304 EXP: 07/2023
Samo za strokovno javnost.
H - Predpisovanje in izdaja zdravila je le na recept, zdravilo pa se uporablja samo 
v bolnišnicah. Pred predpisovanjem, prosimo, preberite celoten Povzetek glavnih 


















Q3W = vsake 3 tedne; Q6W = vsakih 6 tednov. Referenca: 1. Keytruda EU SmPC
SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA 
Pred predpisovanjem, prosimo, preberite celoten Povzetek glavnih značilnosti 
zdravila! 
Ime zdravila: KEYTRUDA 25 mg/ml koncentrat za raztopino za infundiranje vsebuje 
pembrolizumab. Terapevtske indikacije: Zdravilo KEYTRUDA je kot samostojno 
zdravljenje indicirano za zdravljenje: napredovalega (neoperabilnega ali metastatskega) 
melanoma pri odraslih; za adjuvantno zdravljenje odraslih z melanomom v stadiju III, ki se 
je razširil na bezgavke, po popolni kirurški odstranitvi; metastatskega nedrobnoceličnega 
pljučnega raka (NSCLC) v prvi liniji zdravljenja pri odraslih, ki imajo tumorje z ≥ 50 % 
izraženostjo PD-L1 (TPS) in brez pozitivnih tumorskih mutacij EGFR ali ALK; lokalno 
napredovalega ali metastatskega NSCLC pri odraslih, ki imajo tumorje z ≥ 1 % izraženostjo 
PD-L1 (TPS) in so bili predhodno zdravljeni z vsaj eno shemo kemoterapije, bolniki s 
pozitivnimi tumorskimi mutacijami EGFR ali ALK so pred prejemom zdravila KEYTRUDA 
morali prejeti tudi tarčno zdravljenje; odraslih in pediatričnih bolnikov, starih 3 leta ali več, 
s ponovljenim ali neodzivnim klasičnim Hodgkinovim limfomom (cHL), pri katerih 
avtologna presaditev matičnih celic (ASCT) ni bila uspešna, ali po najmanj dveh 
predhodnih zdravljenjih kadar ASCT ne pride v poštev kot možnost zdravljenja; lokalno 
napredovalega ali metastatskega urotelijskega raka pri odraslih, predhodno zdravljenih s 
kemoterapijo, ki je vključevala platino; lokalno napredovalega ali metastatskega 
urotelijskega raka pri odraslih, ki niso primerni za zdravljenje s kemoterapijo, ki vsebuje 
cisplatin in imajo tumorje z izraženostjo PD-L1 ≥ 10, ocenjeno s kombinirano pozitivno 
oceno (CPS); ponovljenega ali metastatskega ploščatoceličnega raka glave in vratu 
(HNSCC) pri odraslih, ki imajo tumorje z ≥ 50 % izraženostjo PD-L1 (TPS), in pri katerih je 
bolezen napredovala med zdravljenjem ali po zdravljenju s kemoterapijo, ki je vključevala 
platino in za prvo linijo zdravljenja metastatskega kolorektalnega raka z visoko 
mikrosatelitsko nestabilnostjo (MSI-H – microsatellite instability-high) ali s pomanjkljivim 
popravljanjem neujemanja pri podvojevanju DNA (dMMR - mismatch repair deficient) pri 
odraslih. Zdravilo KEYTRUDA je kot samostojno zdravljenje ali v kombinaciji s 
kemoterapijo s platino in 5-fluorouracilom (5-FU) indicirano za prvo linijo zdravljenja 
metastatskega ali neoperabilnega ponovljenega ploščatoceličnega raka glave in vratu pri 
odraslih, ki imajo tumorje z izraženostjo PD-L1 s CPS ≥ 1. Zdravilo KEYTRUDA je v 
kombinaciji s pemetreksedom in kemoterapijo na osnovi platine indicirano za prvo linijo 
zdravljenja metastatskega neploščatoceličnega NSCLC pri odraslih, pri katerih tumorji 
nimajo pozitivnih mutacij EGFR ali ALK; v kombinaciji s karboplatinom in bodisi 
paklitakselom bodisi nab-paklitakselom je indicirano za prvo linijo zdravljenja 
metastatskega ploščatoceličnega NSCLC pri odraslih; v kombinaciji z aksitinibom je 
indicirano za prvo linijo zdravljenja napredovalega raka ledvičnih celic (RCC) pri odraslih; 
v kombinaciji s kemoterapijo s platino in fluoropirimidinom indicirano za prvo linijo 
zdravljenja lokalno napredovalega neoperabilnega ali metastatskega raka požiralnika ali 
HER-2 negativnega adenokarcinoma gastroezofagealnega prehoda pri odraslih, ki imajo 
tumorje z izraženostjo PD-L1 s CPS ≥ 10. Odmerjanje in način uporabe: Testiranje PD-L1: 
Če je navedeno v indikaciji, je treba izbiro bolnika za zdravljenje z zdravilom KEYTRUDA 
na podlagi izraženosti PD-L1 tumorja potrditi z validirano preiskavo. Testiranje MSI-H/
dMMR pri bolnikih s CRC: Za samostojno zdravljenje z zdravilom KEYTRUDA je 
priporočljivo opraviti testiranje MSI-H/dMMR statusa tumorja z validirano preiskavo, da se 
izbere bolnike s CRC. Odmerjanje: Priporočeni odmerek zdravila KEYTRUDA pri odraslih je 
bodisi 200 mg na 3 tedne ali 400 mg na 6 tednov, apliciran z intravensko infuzijo v 30 
minutah. Priporočeni odmerek zdravila KEYTRUDA za samostojno zdravljenje pri 
pediatričnih bolnikih s cHL, starih 3 leta ali več, je 2 mg/kg telesne mase (do največ 200 
mg) na 3 tedne, apliciran z intravensko infuzijo v 30 minutah. Za uporabo v kombinaciji 
glejte povzetke glavnih značilnosti sočasno uporabljenih zdravil. Če se uporablja kot del 
kombiniranega zdravljenja skupaj z intravensko kemoterapijo, je treba zdravilo 
KEYTRUDA aplicirati prvo. Bolnike je treba zdraviti do napredovanja bolezni ali 
nesprejemljivih toksičnih učinkov. Pri adjuvantnem zdravljenju melanoma je treba 
zdravilo uporabljati do ponovitve bolezni, pojava nesprejemljivih toksičnih učinkov 
oziroma mora zdravljenje trajati do enega leta. Če je aksitinib uporabljen v kombinaciji s 
pembrolizumabom, se lahko razmisli o povečanju odmerka aksitiniba nad začetnih 5 mg 
v presledkih šest tednov ali več. Pri bolnikih starih ≥ 65 let, bolnikih z blago do zmerno 
okvaro ledvic, bolnikih z blago okvaro jeter prilagoditev odmerka ni potrebna. Odložitev 
odmerka ali ukinitev zdravljenja: Zmanjšanje odmerka zdravila KEYTRUDA ni priporočljivo. 
Za obvladovanje neželenih učinkov je treba uporabo zdravila KEYTRUDA zadržati ali 
ukiniti, prosimo, glejte celoten Povzetek glavnih značilnosti zdravila. Kontraindikacije: 
Preobčutljivost na učinkovino ali katero koli pomožno snov. Povzetek posebnih 
opozoril, previdnostnih ukrepov, interakcij in neželenih učinkov: Imunsko pogojeni 
neželeni učinki (pnevmonitis, kolitis, hepatitis, nefritis, endokrinopatije, neželeni učinki 
na kožo in drugi): Pri bolnikih, ki so prejemali pembrolizumab, so se pojavili imunsko 
pogojeni neželeni učinki, vključno s hudimi in smrtnimi primeri. Večina imunsko 
pogojenih neželenih učinkov, ki so se pojavili med zdravljenjem s pembrolizumabom, je 
bila reverzibilnih in so jih obvladali s prekinitvami uporabe pembrolizumaba, uporabo 
kortikosteroidov in/ali podporno oskrbo. Pojavijo se lahko tudi po zadnjem odmerku 
pembrolizumaba in hkrati prizadanejo več organskih sistemov. V primeru suma na 
imunsko pogojene neželene učinke je treba poskrbeti za ustrezno oceno za potrditev 
etiologije oziroma izključitev drugih vzrokov. Glede na izrazitost neželenega učinka je 
treba zadržati uporabo pembrolizumaba in uporabiti kortikosteroide – za natančna 
navodila, prosimo, glejte Povzetek glavnih značilnosti zdravila Keytruda. Zdravljenje s 
pembrolizumabom lahko poveča tveganje za zavrnitev pri prejemnikih presadkov čvrstih 
organov. Pri bolnikih, ki so prejemali pembrolizumab, so poročali o hudih z infuzijo 
povezanih reakcijah, vključno s preobčutljivostjo in anafilaksijo. Pembrolizumab se iz 
obtoka odstrani s katabolizmom, zato presnovnih medsebojnih delovanj zdravil ni 
pričakovati. Uporabi sistemskih kortikosteroidov ali imunosupresivov pred uvedbo 
pembrolizumaba se je treba izogibati, ker lahko vplivajo na farmakodinamično aktivnost 
in učinkovitost pembrolizumaba. Vendar pa je kortikosteroide ali druge imunosupresive 
mogoče uporabiti za zdravljenje imunsko pogojenih neželenih učinkov. Kortikosteroide 
je mogoče uporabiti tudi kot premedikacijo, če je pembrolizumab uporabljen v 
kombinaciji s kemoterapijo, kot antiemetično profilakso in/ali za ublažitev neželenih 
učinkov, povezanih s kemoterapijo. Ženske v rodni dobi morajo med zdravljenjem s 
pembrolizumabom in vsaj še 4 mesece po zadnjem odmerku pembrolizumaba 
uporabljati učinkovito kontracepcijo, med nosečnostjo in dojenjem se ga ne sme 
uporabljati. Varnost pembrolizumaba pri samostojnem zdravljenju so v kliničnih študijah 
ocenili pri 6.185 bolnikih z napredovalim melanomom, kirurško odstranjenim 
melanomom v stadiju III (adjuvantno zdravljenje), NSCLC, cHL, urotelijskim rakom, HNSCC 
ali CRC s štirimi odmerki (2 mg/kg telesne mase na 3 tedne, 200 mg na 3 tedne in 10 mg/
kg telesne mase na 2 ali 3 tedne). V tej populaciji bolnikov je mediani čas opazovanja 
znašal 7,6 mesece (v razponu od 1 dneva do 47 mesecev), najpogostejši neželeni učinki 
zdravljenja s pembrolizumabom so bili utrujenost (32 %), navzea (21 %) in diareja (21 %). 
Večina poročanih neželenih učinkov pri samostojnem zdravljenju je bila po izrazitosti 1. 
ali 2. stopnje. Najresnejši neželeni učinki so bili imunsko pogojeni neželeni učinki in hude 
z infuzijo povezane reakcije. Varnost pembrolizumaba pri kombiniranem zdravljenju s 
kemoterapijo so ocenili pri 1.437 bolnikih NSCLC, HNSCC ali rakom požiralnika, ki so v 
kliničnih študijah prejemali pembrolizumab v odmerkih 200 mg, 2 mg/kg telesne mase ali 
10 mg/kg telesne mase na vsake 3 tedne. V tej populaciji bolnikov so bili najpogostejši 
neželeni učinki naslednji: navzea (55 %), anemija (51 %), utrujenost (39 %), zaprtost (37 
%), zmanjšanje apetita (34 %), diareja (33 %), nevtropenija (29 %) in bruhanje (28 %). 
Pojavnost neželenih učinkov 3. do 5. stopnje je pri bolnikih z NSCLC pri kombiniranem 
zdravljenju s pembrolizumabom znašala 67 % in pri zdravljenju samo s kemoterapijo 66 
%, pri bolnikih s HNSCC pri kombiniranem zdravljenju s pembrolizumabom 85 % in pri 
zdravljenju s kemoterapijo v kombinaciji s cetuksimabom 84 %, ter pri bolnikih z rakom 
požiralnika pri kombiniranem zdravljenju s pembrolizumabom 86 % in pri zdravljenju 
samo s kemoterapijo 83 %. Varnost pembrolizumaba v kombinaciji z aksitinibom so 
ocenili v klinični študiji pri 429 bolnikih z napredovalim rakom ledvičnih celic, ki so 
prejemali 200 mg pembrolizumaba na 3 tedne in 5 mg aksitiniba dvakrat na dan. V tej 
populaciji bolnikov so bili najpogostejši neželeni učinki diareja (54 %), hipertenzija (45 %), 
utrujenost (38 %), hipotiroidizem (35 %), zmanjšan apetit (30 %), sindrom palmarno-
plantarne eritrodisestezije (28 %), navzea (28 %), zvišanje vrednosti ALT (27 %), zvišanje 
vrednosti AST (26 %), disfonija (25 %), kašelj (21 %) in zaprtost (21 %). Pojavnost neželenih 
učinkov 3. do 5. stopnje je bila med kombiniranim zdravljenjem s pembrolizumabom 76 
% in pri zdravljenju s sunitinibom samim 71 %. Za celoten seznam neželenih učinkov, 
prosimo, glejte celoten Povzetek glavnih značilnosti zdravila. Način in režim izdaje 
zdravila: H – Predpisovanje in izdaja zdravila je le na recept, zdravilo se uporablja samo v 
bolnišnicah. Imetnik dovoljenja za promet z zdravilom: Merck Sharp & Dohme B.V. , 
Waarderweg 39, 2031 BN Haarlem, Nizozemska.
 Merck Sharp & Dohme inovativna zdravila d.o.o.,  Ameriška ulica 2, 1000 Ljubljana,  tel: +386 1/ 520 42 01, fax: +386 1/ 520 43 50;  Pripravljeno v Sloveniji, julij 2021; SI-KEY-00305 EXP: 07/2023
Samo za strokovno javnost.
H - Predpisovanje in izdaja zdravila je le na recept, zdravilo pa se uporablja samo 
v bolnišnicah. Pred predpisovanjem, prosimo, preberite celoten Povzetek glavnih 
značilnosti zdravila Keytruda, ki je na voljo  pri naših strokovnih sodelavcih ali na 
lokalnem sedežu družbe.
Zdravilo KEYTRUDA®  
OMOGOČA VEČ ČASA
Q6W - samo 9 infuzij letno*
ODMERJANJE NA 6 TEDNOV:  
MANJ INFUZIJ ZA VAŠE BOLNIKE, VEČ ČASA ZA VAS!
* Priporočeni odmerek zdravila KEYTRUDA pri odraslih je bodisi 200 mg na 3 tedne ali 400 mg na 6 tednov,  
apliciran z intravensko infuzijo v 30 minutah.
(pembrolizumab, MSD)






NAJDALJŠE CELOKUPNO PREŽIVETJE1,2* in 
IZBOLJŠANA ALI OHRANJENA KVALITETA ŽIVLJENJA3,4
KISQALI + fulvestrant, 1. in 2. red zdravljenja: mOS = 53,7 meseca#KISQALI + zaviralec aromataze + goserelin, 1. red zdravljenja: mOS = 58,7 meseca*
KISQALI je edini zaviralec CDK4/6, ki dokazano podaljša življenje v različnih kombinacijah  
(zaviralec aromataze ali fulvestrant) in redih zdravljenja ter hkrati izboljša ali ohranja kvaliteto življenja1-6
HR+ hormonsko odvisen rak dojk, HER2- rak dojk, negativen na receptorje humanega epidermalnega rastnega faktorja 2, Overall Survival, OS Celokupno preživetje, mediani OS, mOS mediana celokupnega preživetja. ESMO-MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale: ESMO lestvica obsega klinične koristi.† Zdravilo KISQALI je po ESMO-MCBS lestvici za študijo MONALEESA-7 prejelo največje možno število točk (5 točk)5. 
* MONALEESA-7 je bila randomizirana, dvojno slepa, s placebom nadzorovana multicentrična klinična študija faze III zdravljenja premenopavznih in perimenopavznih žensk z napredovalim HR+ HER2- rakom dojk, ki so poleg endokrinega zdravljenja prejemale še zdravilo Kisqali ali placebo. V raziskavo je bilo vključenih 672 bolnic, zdravilo Kisqali. je prejemalo 335 bolnic. V študiji je bil dosežen sekundarni cilj, dokazana je bila statistično značilna razlika med obema skupinama v dolžini preživetja bolnic1,6,7. Relativno znižanje tveganja za smrt je bilo 24% (razmerje ogroženosti = 0,76: 95% 
IZ [0,608; 0,956])1. V skupini bolnic, ki so prejemale kombinacijo zdravila KISQALI + zaviralec aromataze je bilo doseženo najdaljše mediano celokupno preživetje med vsemi raziskavami faze III v katere so bile vključene bolnice s HR+ HER2- napredovalim rakom dojk: 58,7 meseca1. 
# MONALEESA- 3 je bila randomizirana, dvojno slepa, s placebom nadzorovana multicentrična klinična študija faze III zdravljenja pomenopavznih žensk z napredovalim HR+ HER2- rakom dojk, ki so poleg fulvestranta prejemale še zdravilo Kisqali ali placebo v prvi ali drugi liniji zdravljenja. V študijo je bilo vključenih 726 bolnic, zdravilo Kisqali je prejemalo 484 bolnic. V študiji je bil dosežen sekundarni cilj, dokazana je bila statistično značilna razlika med obema skupinama v dolžini preživetja bolnic2,6,8. Relativno znižanje tveganja za smrt je bilo 28% (razmerje ogroženosti = 0,72: 95% IZ 
[0,568; 0,924])8. Podatki do presečnega datuma 30. oktober 2020 za skupino bolnic, ki so prejemale kombinacijo zdravila Kisqali in fulvestranta kažejo mediano celokupno preživetje, 53,7 meseca (razmerje ogroženosti 0,73: 95% IZ [0,59; 0,90]).2 
Reference: 1. Tripathy D, Im S-A, Colleoni M, in sod. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2–) advanced breast cancer (ABC) treated with endocrine therapy (ET) +/- ribociclib. Predstavljeno na: San Antonio Breast Cancer Symposium; 8-12. december 2020, 2020; San Antonio, Texas. Poster PD2-04. 2. Slamon D, Neven P, Chia S, in sod. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of post-
menopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant ± placebo. Predstavljeno na kongresu American Society of Clinical Oncology (ASCO) 2021, 4-8. junij 2021, virtualni kongres. 3. Harbeck N, Vazquez RV, Franke F, in sod. Ribociclib+ tamoxifen or a non-steroidal aromatase inhibitor in premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 patient-reported outcomes. Predstavljeno na: European Society for Medical Oncology Congress; 19- 23 oktober 2018; Munchen, Nemčija. 4. 
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SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA KISQALI®
 Za to zdravilo se izvaja dodatno spremljanje varnosti. Zdravstvene delavce naprošamo, da poročajo o katerem koli domnevnem neželenem učinku zdravila. Glejte poglavje 4.8 povzetka glavnih značilnosti zdravila, kako poročati o neželenih učinkih.
Ime zdravila: Kisqali 200 mg filmsko obložene tablete. Sestava: Ena tableta vsebuje ribociklibijev sukcinat v količini, ki ustreza 200 mg ribocikliba. Indikacija: Zdravilo Kisqali je v kombinaciji z zaviralcem aromataze ali fulvestrantom indicirano za zdravljenje žensk z lokalno napredovalim ali metastatskim rakom dojk, ki je hormonsko odvisen (HR pozitiven) in negativen na receptorje humanega epidermalnega rastnega faktorja 2 (HER2 negativen), in sicer kot začetno hormonsko zdravljenje ali pri ženskah, ki so predhodno že prejemale 
hormonsko zdravljenje. Pri ženskah pred menopavzo ali v perimenopavzi je treba hormonsko zdravljenje uporabljati skupaj z agonistom gonadoliberina (LHRH-luteinizing hormone releasing hormone). Odmerjanje in način uporabe: Zdravljenje mora uvesti zdravnik, ki ima izkušnje z uporabo zdravil proti raku. Priporočeni odmerek je 600 mg (tri 200-miligramske tablete) ribocikliba 1x/dan 21 dni zaporedoma, čemur sledi 7 dni brez zdravljenja, tako da celotni ciklus traja 28 dni. Zdravljenje je treba nadaljevati, dokler ima bolnik od zdravljenja 
klinično korist oz. do pojava nesprejemljivih toksičnih učinkov. Kisqali je treba uporabljati skupaj z 2,5 mg letrozola ali drugim zaviralcem aromataze ali s 500 mg fulvestranta. Zaviralec aromataze je treba jemati peroralno 1x/dan neprekinjeno vseh 28 dni ciklusa. Fulvestrant je treba odmerjati intramuskularno 1., 15. in 29. dan ciklusa, nato pa 1x/mesec. Za več podatkov glejte povzetek glavnih značilnosti zdravila za zaviralec aromataze oz. fulvestrant. Ženske pred menopavzo ali v perimenopavzi morajo prejemati tudi katerega od agonistov 
gonadoliberina v skladu z lokalno klinično prakso. Kisqali je treba jemati peroralno 1x/dan skupaj s hrano ali brez nje. Bolniki naj vzamejo odmerek zdravila vsak dan ob približno istem času, najbolje zjutraj. Tablete je treba pogoltniti cele in se jih pred zaužitjem ne sme gristi, drobiti ali lomiti. Tablet, ki so razlomljene, zdrobljene ali kako drugače poškodovane, se ne sme zaužiti. Če bolnik po zaužitju odmerka bruha ali pozabi vzeti odmerek, na ta dan ne sme vzeti dodatnega odmerka. Naslednji predpisani odmerek mora vzeti ob običajnem času. 
Prilagajanje odmerkov: Obvladovanje hudih ali nesprejemljivih neželenih dogodkov zdravila lahko vključuje prekinitev jemanja zdravila, znižanje odmerka ali ukinitev zdravila Kisqali. Ob prvem zmanjšanju odmerek zmanjšamo na 400 mg/dan (dve 200-miligramski tableti), ob drugem zmanjšanju pa na 200 mg/dan (ena 200-miligramska tableta). Če bi bilo treba odmerek zmanjšati na manj kot 200 mg/dan, je treba zdravljenje ukiniti. Za priporočila glede prekinitve jemanja zdravila, zmanjšanje odmerka ali ukinitev zdravljenja v primerih, ko je 
to potrebno za obvladovanje določenih neželenih dogodkov zdravila, prosimo glejte povzetek glavnih značilnosti zdravila. Za prilagajanje odmerkov in druge pomembne podatke v primeru toksičnega delovanja glejte povzetek glavnih značilnosti zdravila za sočasno uporabljeni zaviralec aromataze, fulvestrant oz. agonist gonadoliberina. Okvara ledvic: Pri bolnikih z blago ali zmerno okvaro ledvic prilagajanje odmerka ni potrebno. Pri bolnikih s hudo okvaro ledvic (aGFR 15 do < 30 ml/min) je priporočen začetni odmerek 200 mg. Okvara jeter: 
Bolnikom z blago okvaro jeter (Child-Pugh razreda A) odmerka ni potrebno prilagajati. Pri bolnikih z zmerno (Child-Pugh razreda B) ali hudo okvaro jeter (Child-Pugh razreda C) je priporočeni začetni odmerek zdravila Kisqali 400 mg 1x/dan. Pediatrična populacija: Varnost in učinkovitost zdravila pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani. Starostniki: Pri bolnikih, ki so stari več kot 65 let, prilagajanje odmerka ni potrebno. Kontraindikacije: Preobčutljivost na učinkovino, arašide, sojo ali katero koli pomožno snov. 
Posebna opozorila in previdnostni ukrepi: Kritična visceralna bolezen: Učinkovitosti in varnosti ribocikliba pri bolnikih s kritično visceralno boleznijo niso proučevali. Nevtropenija in hepatobiliarna toksičnost: Pregled celotne krvne slike in vrednosti jetrnih testov je treba opraviti pred začetkom zdravljenja, nato v prvih 2 ciklusih vsaka 2 tedna, v naslednjih 4 ciklusih na začetku vsakega ciklusa, nato pa kot je klinično indicirano. Če pride do nenormalnih vrednosti jetrnih testov stopnje ≥ 2, so priporočene pogostejše meritve jetrnih testov. Za 
bolnike z zvišanjem vrednosti AST/ALT stopnje ≥3 ob izhodišču priporočila za odmerjanje niso dognana. Glede na to, kako močno je izražena nevtropenija ali zvišane vrednosti aminotransferaz, je morda treba odmerjanje zdravila Kisqali prekiniti, zmanjšati odmerek ali zdravljenje ukiniti. Podaljšanje intervala QT: Pred začetkom zdravljenja je treba posneti EKG. Zdravljenje je mogoče začeti samo pri bolnikih s trajanjem intervala QTcF manj kot 450 ms. EKG je treba ponovno posneti približno 14. dan prvega ciklusa in na začetku drugega ciklusa, 
nato pa kot je klinično indicirano. V primeru, da v času zdravljenja pride do podaljšanja intervala QTcF, je priporočeno pogostejše snemanje EKG. Ustrezno spremljanje koncentracij elektrolitov v serumu (vključno s koncentracijami kalija, kalcija, fosforja in magnezija) je treba izvajati pred začetkom zdravljenja, nato na začetku prvih 6 ciklusov in kasneje kot je klinično indicirano. Kakršnekoli nepravilnosti je treba odpraviti pred začetkom oz. med potekom zdravljenja z zdravilom Kisqali. Uporabi zdravila Kisqali se je treba izogibati pri bolnikih s 
prisotnim podaljšanjem intervala QTc ali s povečanim tveganjem za podaljšanje intervala QTc. To vključuje bolnike s sindromom podaljšanega intervala QT, z neurejenim ali pomembnim srčnim obolenjem, kar vključuje nedaven miokardni infarkt, kongestivno popuščanje srca, nestabilno angino pektoris in bradiaritmije ter bolnike z elektrolitskimi nepravilnostmi. Izogibati se je treba sočasni uporabi zdravila Kisqali z zdravili, za katera je znano, da lahko podaljšajo interval QT, kot so antiaritmiki (med drugim amiodaron, dizopiramid, prokainamid, 
kinidin in sotalol) ter druga zdravila, za katera je znano, da podaljšujejo interval QT (med drugim klorokin, halofantrin, klaritromicin, ciprofloksacin, levofloksacin, azitromicin, haloperidol, metadon, moksifloksacin, bepridil, pimozid in intravenski ondansetron). Zdravila Kisqali prav tako ni priporočeno uporabljati v kombinaciji s tamoksifenom. Če se zdravljenju z močnim zaviralcem CYP3A4 ni mogoče izogniti, je treba odmerek zdravila Kisqali zmanjšati na 400 mg 1x/dan. Glede na izmerjeno podaljšanje intervala QT v času zdravljenja je morda 
treba odmerjanje zdravila Kisqali prekiniti, zmanjšati odmerek ali zdravljenje ukiniti. Hude kožne reakcije: Poročali so o pojavu toksične epidermalne nekrolize (TEN). Če se pojavijo znaki in simptomi, ki lahko pomenijo, da gre za hudo kožno reakcijo (na primer progresiven generaliziran kožni izpuščaj, pogosto z mehurji, ali lezijami sluznice), je treba zdravljenje takoj prekiniti. Intersticijska pljučna bolezen/pnevmonitis: Glede na izraženost intersticijske pljučne bolezni/pnevmonitisa, ki se lahko končata tudi s smrtjo bolnika, bo v skladu s 
priporočilom v povzetku glavnih značilnosti zdravila morda potrebno odmerjanje zdravila Kisqali prekiniti, zmanjšati odmerek ali zdravljenje ukiniti. Bolnike je treba spremljati glede pljučnih simptomov, ki bi lahko nakazovali na intersticijsko pljučno bolezen/pnevmonitis, in lahko vključujejo hipoksijo, kašelj in dispnejo. Zvišanje kreatinina: Če v času zdravljenja pride do zvišanja vrednosti kreatinina v krvi, je priporočeno izvesti dodatno oceno ledvične funkcije za izključitev okvare ledvic. Okvara ledvic: Pri začetnem odmerku 200 mg pri bolnikih 
s hudo okvaro ledvic so ocenili, da je izpostavljenost za približno 45 % nižja kot pri standardnem začetnem odmerku pri bolnikih z normalnim delovanjem ledvic. Učinkovitosti pri tem začetnem odmerku niso preučevali. Pri bolnikih s hudo okvaro ledvic je potrebna previdnost s skrbnim spremljanjem glede znakov toksičnega delovanja. Sojin lecitin: Zdravilo vsebuje sojin lecitin. Bolniki s preobčutljivostjo na arašide ali sojo ne smejo jemati zdravila Kisqali. Plodnost, nosečnost in dojenje: Pred začetkom zdravljenja je treba preveriti status 
nosečnosti. Ženskam v rodni dobi je treba svetovati, naj v času zdravljenja z zdravilom Kisqali in še najmanj 21 dni po prejemu zadnjega odmerka uporabljajo učinkovito kontracepcijsko metodo. Bolnice, ki jemljejo zdravilo Kisqali, ne smejo dojiti še najmanj 21 dni po prejemu zadnjega odmerka. Glede na ugotovitve študij pri živalih lahko zdravilo Kisqali zmanjša plodnost pri reproduktivno sposobnih moških. Vpliv na sposobnost vožnje in upravljanja strojev: Zdravilo ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev. Bolnike 
je treba opozoriti, naj bodo pri vožnji in upravljanju strojev previdni, če imajo v času zdravljenja težave z utrujenostjo, omotičnostjo ali vrtoglavico. Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Snovi, ki lahko zvišajo koncentracijo ribocikliba v plazmi: Izogibati se je treba sočasni uporabi močnih zaviralcev CYP3A4, med drugim klaritromicinu, indinavirju, itrakonazolu, ketokonazolu, lopinavirju, ritonavirju, nefazodonu, nelfinavirju, posakonazolu, sakvinavirju, telaprevirju, telitromicinu, verapamilu in vorikonazolu. Za 
sočasno uporabo je treba razmisliti o izbiri drugih zdravil z manjšim potencialom za zaviranje CYP3A4, bolnike pa je treba spremljati glede neželenih dogodkov v povezavi z ribociklibom. Če mora bolnik sočasno z ribociklibom prejemati močan zaviralec CYP3A4, je treba odmerek zdravila Kisqali zmanjšati na 400 mg 1x/dan. Pri bolnikih, pri katerih je odmerek že zmanjšan na 400 mg/dan, je treba odmerek zmanjšati na 200 mg, pri bolnikih, pri katerih je odmerek ribocikliba že zmanjšan na 200 mg dnevno, pa je treba zdravljenje z zdravilom 
Kisqali prekiniti. Zaradi interindividualne variabilnosti priporočeno prilagajanje odmerjanja morda ni najboljše za vse bolnike, zato je priporočeno skrbno spremljanje bolnikov glede znakov toksičnega delovanja. Če bolnik preneha jemati zdravilo, ki je močan zaviralec, je treba odmerek zdravila Kisqali prilagoditi in po najmanj 5 razpolovnih dobah močnega zaviralca CYP3A4 spet začeti z odmerkom zdravila Kisqali, ki ga je bolnik prejemal pred začetkom uporabe močnega zaviralca CYP3A4. Po začetku sočasne uporabe šibkih ali zmernih 
zaviralcev CYP3A4 odmerka ribocikliba ni treba prilagajati, priporočeno pa je spremljanje bolnikov glede neželenih dogodkov v povezavi z ribociklibom. Bolnikom je treba naročiti, naj se izogibajo uživanju grenivk in njihovega soka, ker lahko povečajo izpostavljenost ribociklibu. Snovi, ki lahko znižajo koncentracijo ribocikliba v plazmi: Sočasna uporaba močnih induktorjev CYP3A4 lahko zmanjša izpostavljenost zdravilu, to pa lahko predstavlja tveganje za manjšo učinkovitost zdravila. Izogibati se je treba sočasni uporabi močnih induktorjev 
CYP3A4, med drugim fenitoina, rifampicina, karbamazepina in šentjanževke (Hypericum perforatum). Za sočasno uporabo je treba razmisliti o izbiri drugega zdravila, ki ne inducira oziroma ima manjši potencial za indukcijo CYP3A4. Učinka zmernega induktorja CYP3A4 na izpostavljenost ribociklibu niso proučevali. Sočasna uporaba zmernega induktorja CYP3A4 lahko privede do zmanjšane izpostavljenosti ribociklibu, to pa lahko predstavlja tveganje za manjšo učinkovitost, še posebej pri bolnikih, ki se zdravijo z ribociklibom v odmerku 400 mg 
ali 200 mg 1x/dan. Snovi, na katerih koncentracijo v plazmi lahko vpliva zdravilo Kisqali: Ribociklib je zmeren do močan zaviralec CYP3A4, zato lahko pride do interakcij z zdravili, ki so substrati oz. jih presnavlja CYP3A4, kar lahko povzroči zvišanje koncentracij sočasno uporabljenih zdravil v serumu. Pri sočasnem odmerjanju ribocikliba z drugimi zdravili je praviloma treba pregledati povzetek glavnih značilnosti drugega zdravila in poiskati priporočila za sočasno odmerjanje z zaviralci CYP3A4. Pri sočasni uporabi z občutljivimi substrati CYP3A4, 
ki imajo nizek terapevtski indeks, je priporočena previdnost. Pri teh substratih, med drugim pri alfentanilu, ciklosporinu, everolimusu, fentanilu, sirolimusu in takrolimusu, je v nekaterih primerih treba zmanjšati njihov odmerek, saj ribociklib lahko poveča izpostavljenost tem snovem. Izogibati se je treba sočasni uporabi ribocikliba v odmerku 600 mg skupaj z naslednjimi substrati CYP3A4: alfuzosin, amiodaron, cisaprid, pimozid, kinidin, ergotamin, dihidroergotamin, kvetiapin, lovastatin, simvastatin, sildenafil, midazolam in triazolam. Pri uporabi 
klinično ustreznega odmerka 600 mg je mogoče pričakovati le šibak zaviralni učinek ribocikliba na substrate CYP1A2 (< 2-kratno povečanje AUC). Snovi, ki so substrati prenašalcev: Vrednotenje podatkov in vitro raziskav kaže, da ima ribociklib potencial za zaviranje aktivnosti prenašalcev P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 in BSEP. Pri sočasnem zdravljenju s snovmi, ki so občutljivi substrati teh prenašalcev in imajo nizek terapevtski indeks, med drugim z digoksinom, pitavastatinom, pravastatinom, rosuvastatinom in metforminom, 
je priporočena previdnost in spremljanje bolnikov glede toksičnega delovanja. Zdravila, ki zvišujejo pH v želodcu: Pri populacijski farmakokinetični analizi in nekompartmentalni farmakokinetični analizi pri sočasni uporabi niso opažali sprememb v absorpciji ribocikliba. Medsebojno delovanje med ribociklibom in letrozolom oz. anastrozolom oz. fulvestrantom oz. tamoksifenom: Med ribociklibom in letrozolom oz. med ribociklibom in anastrozolom ne prihaja do medsebojnega delovanja pri sočasnem odmerjanju obeh zdravil. Po podatkih iz 
klinične študije fulvestrant nima klinično pomembnega vpliva na izpostavljenost ribociklibu pri sočasnem odmerjanju, po sočasnem odmerjanju ribocikliba in tamoksifena pa se je izpostavljenost tamoksifenu povečala na približno 2-kratno vrednost. Neželeni učinki: Zelo pogosti (≥ 1/10): okužbe, nevtropenija, levkopenija, anemija, limfopenija, zmanjšan apetit, glavobol, omotičnost, dispneja, kašelj, navzea, diareja, bruhanje, obstipacija, stomatitis, bolečine v trebuhu, dispepsija, alopecija, izpuščaj, pruritus, bolečine v hrbtu, utrujenost, periferni 
edemi, astenija, zvišana telesna temperatura, nenormalne vrednosti jetrnih testov. Pogosti (≥ 1/100 do < 1/10): trombocitopenija, febrilna nevtropenija, hipokalciemija, hipokaliemija, hipofosfatemija, vrtoglavica, močnejše solzenje, suhe oči, sinkopa, motnje okušanja, hepatotoksičnost, eritem, suha koža, vitiligo, suha usta, orofaringealna bolečina, zvišana vrednost kreatinina v krvi, podaljšan interval QT v elektrokardiogramu. Neznana pogostnost: toksična epidermalna nekroliza (TEN). Imetnik dovoljenja za promet z zdravilom: Novartis 
Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Irska. Dodatne informacije in literatura: Novartis Pharma Services Inc., Podružnica v Sloveniji, Verovškova ulica 57, 1000 Ljubljana. Način/režim izdajanja zdravila: Rp/Spec. Pred predpisovanjem natančno preberite zadnji odobreni povzetek glavnih značilnosti zdravila. Datum zadnje revizije skrajšanega povzetka glavnih značilnosti zdravila: november 2020.
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Prva terapija  
za zdravljenje  odraslih bolnikov 
z metastatskim ali lokalno 
napredovalim ploščatoceličnim 
 karcinomom kože (PCKK), ki 
niso kandidati za  kurativni 
kirurški poseg ali kurativno 
obsevanje. 1,2
Zaviralec PD-1:  
spodbuja bolnikov imunski  protitumorski 
odziv za izboljšanje rezultatov zdravljenja 3
PD-1, receptor programirane celične smrti 1
SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA 
▼Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo hitreje na voljo nove informacije o njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o katerem koli domnevnem neželenem učinku zdravila. 
Ime zdravila: LIBTAYO 350 mg koncentrat za raztopino za infundiranje. Sestava: En mililiter koncentrata vsebuje 50 mg cemiplimaba. Ena viala vsebuje 350 mg cemiplimaba v 7 ml raztopine. Terapevtske indikacije: Ploščatocelični karcinom kože: Zdravilo 
LIBTAYO je kot samostojno zdravljenje (monoterapija) indicirano za zdravljenje odraslih bolnikov z metastatskim ali lokalno napredovalim ploščatoceličnim karcinomom kože (mPCKK ali lnPCKK), ki niso kandidati za kurativni kirurški poseg ali kurativno 
obsevanje. Bazalnocelični karcinom: Zdravilo LIBTAYO je kot samostojno zdravljenje (monoterapija) indicirano za zdravljenje odraslih bolnikov z lokalno napredovalim ali metastatskim bazalnoceličnim karcinomom (1aBCK ali mBCK), pri katerih je bolezen 
napredovala kljub uporabi zaviralca signalne poti Hedgehog (HHI) ali ga ne prenašajo. Nedrobnocelični pljučni rak: Zdravilo LIBTAYO je kot samostojno zdravljenje (monoterapija) indicirano za prvo linijo zdravljenja odraslih bolnikov z nedrobnoceličnim pljučnim 
rakom (NSCLC – Non-Small Cell Lung Cancer), katerih tumorji izražajo PD-L1 (v ≥ 50 % tumorskih celic) brez aberacij EGFR, ALK ali ROSI z: lokalno napredovalim NSCLC, ki niso primerni za definitivno kemoradiacijo, ali metastatskim NSCLC. Odmerjanje in 
način uporabe: Zdravljenje mora uvesti in nadzorovati zdravnik, izkušen na področju zdravljenja raka. Testiranje PD-L1 pri bolnikih z NSCLC: Za zdravljenje s cemiplimabom kot monoterapijo je treba bolnike izbrati na podlagi validiranega testa izražanja PD-L1 
v tumorju. Priporočeni odmerek: Priporočeni odmerek cemiplimaba je 350 mg na 3 tedne v 30 minutni intravenski infuziji. Zdravljenje se sme nadaljevati do napredovanja bolezni ali nesprejemljivih toksičnih učinkov. Prilagoditve odmerka: Zmanjšanja odmerka 
niso priporočena. Glede na varnost in prenašanje pri posameznem bolniku je lahko potrebna odložitev odmerka ali prenehanje uporabe. Za priporočene prilagoditve za obvladovanje neželenih učinkov glejte celoten Povzetek glavnih značilnosti zdravila. Posebne 
populacije: Pediatrična populacija: Varnost in učinkovitost zdravila LIBTAYO pri otrocih in mladostnikih, mlajših od 18 let, nista ugotovljeni. Starejše osebe, okvara ledvic, okvara jeter: odmerka ni treba prilagoditi. Način uporabe: Zdravilo LIBTAYO je namenjeno 
intravenski uporabi. Daje se v intravenski infuziji v obdobju 30 minut po intravenski liniji, ki vsebuje sterilen, nepirogen filter (v sami liniji ali kot dodatek), ki malo veže beljakovine (velikost por od 0,2 do 5 mikronov). Po isti infuzijski liniji se ne sme istočasno 
dajati drugih zdravil. Kontraindikacije: Preobčutljivost na učinkovino ali katero koli pomožno snov. Posebna opozorila in previdnostni ukrepi: Sledljivost: Z namenom izboljšanja sledljivosti bioloških zdravil je treba jasno zabeležiti ime in številko serije 
uporabljenega zdravila. Imunsko pogojeni neželeni učinki: Med uporabo cemiplimaba so opažali hude imunsko pogojene neželene učinke, tudi s smrtnim izidom. Pri bolnikih, zdravljenih s cemiplimabom ali drugimi zaviralci PD-1/PD-L1, se lahko sočasno pojavijo 
imunski neželeni učinki, ki vplivajo na več telesnih sistemov, na primer miozitis in miokarditis ali miastenija gravis. Za obvladanje imunsko pogojenih neželenih učinkov je treba prilagoditi odmerek cemiplimaba, nadomestno hormonsko zdravljenje (če je klinično 
indicirano) in kortkosteroide. Odvisno od izrazitosti neželenega učinka je treba uporabo cemiplimaba začasno prekiniti ali za stalno prenehati. Imunsko pogojeni pnevmonitis: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni pnevmonitis, 
opredeljen s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije, vključno s primeri s smrtnim izidom. Imunsko pogojeni kolitis: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeno drisko ali kolitis, opredeljena s potrebo 
po uporabi kortikosteroidov in brez jasne alternativne etiologije. Imunsko pogojeni hepatitis: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni hepatitis, opredeljen s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije, 
vključno s primeri s smrtnim izidom. Imunsko pogojene endokrinopatije: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojene endokrinopatije, opredeljene kot med zdravljenjem nastale endokrinopatije brez jasne alternativne etiologije. Motnje v 
delovanju ščitnice (hipotiroidizem/hipertiroidizem/tiroiditis): Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojene motnje v delovanju ščitnice. Tiroiditis se lahko pojavi s spremembo testov delovanja ščitnice ali brez nje. Hipertiroidizmu lahko sledi 
hipotiroidizem. Hipofizitis: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni hipofizitis. Nadledvična insuficienca: Pri bolnikih, ki so prejemali cemiplimab, so opažali nadledvično insuficienco. Sladkorna bolezen tipa 1: Pri bolnikih, ki so prejemali 
cemiplimab, so opažali imunsko pogojeno sladkorno bolezen tipa 1, vključno z diabetično ketoacidozo. Imunsko pogojeni neželeni učinki na kožo: Med zdravljenjem s cemiplimabom so poročali o imunsko pogojenih neželenih učinkih na kožo, opredeljenih s potrebo 
po uporabi sistemskih kortikosteroidov in brez jasne alternativne etiologije; med njimi so bili hudi neželeni učinki na kožo, na primer Stevens-Johnsonov sindrom (SJS) in toksična epidermalna nekroliza (TEN) (v nekaterih primerih s smrtnim izidom), in druge 
kožne reakcije, na primer izpuščaj, multiformni eritem in pemfigoid. Imunsko pogojeni nefritis: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni nefritis, opredeljen s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije. 
Drugi imunsko pogojeni neželeni učinki: Pri bolnikih, ki so prejemali cemiplimab, so opažali še druge življenjsko nevarne in smrtne imunsko pogojene neželene učinke, med njimi paraneoplastični encefalomielitis, meningitis in miozitis. Zdravljenje s 
cemiplimabom lahko pri prejemnikih presadkov parenhimskih organov poveča tveganje za zavrnitev. V obdobju po prihodu na trg so pri bolnikih, ki so prejemali druge zaviralce PD-1/PD-L1 obenem z alogensko presaditvijo hematopoetskih matičnih celic, poročali 
o primerih bolezni presadka proti gostitelju. Z infundiranjem povezane reakcije: Cemiplimab lahko povzroči resne ali življenjsko nevarne z infundiranjem povezane reakcije. Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Uporabi 
sistemskih kortikosteroidov ali imunosupresivov pred uvedbo cemiplimaba se je treba izogibati, razen fizioloških odmerkov sistemskih kortikosteroidov (≤ 10 mg/dan prednizolona ali enakovredno), ker lahko motijo farmakodinamično aktivnost in učinkovitost 
cemiplimaba. Vendar pa je kortikosteroide ali druge imunosupresive mogoče uporabiti po začetku zdravljenja s cemiplimabom za zdravljenje imunsko pogojenih neželenih učinkov. Plodnost, nosečnost in dojenje: Ženske v rodni dobi morajo med zdravljenjem 
s cemiplimabom in vsaj še 4 mesece po zadnjem odmerku cemiplimaba uporabljati učinkovito kontracepcijo. Cemiplimab ni priporočljiv med nosečnostjo in za ženske v rodni dobi, ki ne uporabljajo učinkovite kontracepcije, razen če klinična korist odtehta možno 
tveganje. Če se ženska odloči za zdravljenje s cemiplimabom, ji je treba svetovati, da med zdravljenjem s cemiplimabom in vsaj še 4 mesece po zadnjem odmerku ne sme dojiti. Vpliv na sposobnost vožnje in upravljanja strojev: Po zdravljenju s 
cemiplimabom so poročali o utrujenosti. Neželeni učinki: Zelo pogosti: okužba zgornjih dihal, anemija, zmanjšan apetit, kašelj, slabost, driska, zaprtje, izpuščaj, pruritus, mišično-skeletna bolečina, utrujenost. Pogosti: okužba sečil, z infundiranjem povezane 
reakcije, hipotiroidizem, hipertiroidizem, glavobol, periferna nevropatija, hipertenzija, dispneja, pnevmonitis, bolečina v trebuhu, bruhanje, stomatitis, kolitis, hepatitis, artritis, nefritis, zvišana aspartat-aminotransferaza, zvišana alanin-aminotransferaza, zvišana 
alkalna fosfataza v krvi, zvišan kreatinin v krvi. Občasni: sjögrenov sindrom, imunsko pogojena trombocitopenična purpura, nadledvična insuficienca, tiroiditis, sladkorna bolezen tipa 1, hipofizitis, meningitis, encefalitis, miastenija gravis, praneoplastični 
encefalomielitis, kronična vnetna demielinizirajoča poliradikulonevropatija, keratitis, miokarditis, perikarditis, šibkost mišic, miozitis, revmatska polimialgija, zvišan ščitnični hormon v krvi, zvišane transaminase, zvišan bilirubin v krvi, znižan ščitnični hormon 
v krvi. Preveliko odmerjanje: V primeru prevelikega odmerjanja naj se bolnike natančno kontrolira glede znakov in simptomov neželenih učinkov in uvede ustrezno simptomatsko zdravljenje. Način in režim izdaje zdravila: H-Predpisovanje in izdaja zdravila 
je le na recept, zdravilo pa se uporablja samo v bolnišnicah. Imetnik dovoljenja za promet z zdravilom: Regeneron Ireland Designated Activity Company (DAC), One Warrington Place, Dublin 2, D02 HH27, Irska. Datum zadnje revizije besedila: 21.06.2021
SAMO ZA STROKOVNO JAVNOST
MAT-SI-2000079-5.0-09/2021
Pred predpisovanjem prosimo preberite celoten povzetek glavnih značilnosti zdravila.
Pfizer Luxembourg SARL, GRAND DUCHY OF LUXEMBOURG,  
51, Avenue J. F. Kennedy, L-1855
Pfizer, podružnica Ljubljana, Letališka cesta 29a, Ljubljana
BISTVENI PODATKI IZ POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA
IIBRANCE 75 mg, 100 mg, 125 mg trde kapsule(1)
IBRANCE 75 mg, 100 mg, 125 mg filmsko obložene tablete(2)
Sestava in oblika zdravila: (1) Ena trda kapsula vsebuje 75 mg, 100 mg ali 125 mg palbocikliba in 56 mg, 74 mg ali 93 mg laktoze (v obliki monohidrata). (2) Ena filmsko obložena tableta 
vsebuje 75 mg, 100 mg ali 125 mg palbocikliba. Indikacije: Zdravljenje lokalno napredovalega ali metastatskega na hormonske receptorje (HR – Hormone Receptors) pozitivnega in na 
receptorje humanega epidermalnega rastnega faktorja 2 (HER2 – Human Epidermal growth factor Receptor 2) negativnega raka dojk: v kombinaciji z zaviralcem aromataze ali v kombinaciji 
s fulvestrantom pri ženskah, ki so prejele predhodno endokrino zdravljenje. Pri ženskah v pred- in perimenopavzi je treba endokrino zdravljenje kombinirati z agonistom gonadoliberina. 
Odmerjanje in način uporabe: Zdravljenje mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje rakavih bolezni. Priporočeni odmerek je 125 mg enkrat na dan 
21 zaporednih dni, sledi 7 dni brez zdravljenja (shema 3/1), celotni cikel traja 28 dni. Zdravljenje je treba nadaljevati, dokler ima bolnik od zdravljenja klinično korist ali dokler se ne pojavi 
nesprejemljiva toksičnost. Pri sočasnem dajanju s palbociklibom je treba zaviralec aromataze dajati v skladu s shemo odmerjanja, ki je navedena v Povzetku glavnih značilnosti zdravila 
(PGZZ). Pri sočasnem dajanju s palbociklibom je priporočeni odmerek fulvestranta 500 mg intramuskularno 1., 15. in 29. dan ter nato enkrat na mesec, glejte PGZZ za fulvestrant. Prilagajanja 
odmerkov: Za prilagajanja odmerkov zaradi hematološke toksičnosti glejte preglednico 2, zaradi nehematološke toksičnosti pa preglednico 3 v PGZZ-ju. Pri bolnikih s hudo intersticijsko 
boleznijo pljuč (ILD)/pnevmonitisom je treba zdravljenje trajno prekiniti. Posebne skupine bolnikov: Starejši: Prilagajanje odmerka ni potrebno. Okvara jeter ali ledvic: Pri bolnikih z blago 
ali zmerno okvaro jeter ali blago, zmerno ali hudo okvaro ledvic prilagajanje odmerka ni potrebno. Pri bolnikih s hudo okvaro jeter je priporočeni odmerek 75 mg enkrat na dan po shemi 
3/1. Pediatrična populacija: Varnost in učinkovitost pri otrocih in mladostnikih, starih < 18 let, nista bili dokazani. Način uporabe: Peroralna uporaba. (1) Jemanje s hrano, priporočljivo z 
obrokom. (2) Tablete se lahko jemlje s hrano ali brez nje. (1, 2) Ne smemo jemati z grenivko ali grenivkinim sokom. Kapsule oz. tablete zdravila je treba pogoltniti cele. Kontraindikacije: 
Preobčutljivost na učinkovino ali katerokoli pomožno snov. Uporaba pripravkov s šentjanževko. Posebna opozorila in previdnostni ukrepi: Ženske v pred- in perimenopavzi: Kadar 
zdravilo uporabljamo v kombinaciji z zaviralcem aromataze je obvezna ovarijska ablacija ali supresija z agonistom gonadoliberina. Hematološke bolezni: Pri nevtropeniji stopnje 3 ali 4 je 
priporočljiva prekinitev odmerjanja, zmanjšanje odmerka ali odložitev začetka ciklov zdravljenja, bolnike pa je treba ustrezno spremljati. ILD/pnevmonitis: Pri bolnikih se lahko pojavita huda, 
življenjsko ogrožajoča ali smrtna ILD in/ali pnevmonitis, kadar zdravilo jemljejo v kombinaciji z endokrinim zdravljenjem. Bolnike je treba spremljati glede pljučnih simptomov, ki kažejo 
na ILD/pnevmonitis (npr. hipoksija, kašelj, dispneja), in pri pojavu novih ali poslabšanju respiratornih simptomov oz. sumu na ILD/pnevmonitis zdravljenje prekiniti. Okužbe: Zdravilo lahko 
poveča nagnjenost k okužbam, zato je bolnike treba spremljati glede znakov in simptomov okužbe ter jih ustrezno zdraviti. Okvara jeter ali ledvic: Pri bolnikih z zmerno ali hudo okvaro 
jeter ali ledvic je treba zdravilo uporabljati previdno in skrbno spremljati znake toksičnosti. (1) Laktoza: Vsebuje laktozo. Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima 
laktaze ali malabsorpcijo glukoze-galaktoze ne smejo jemati tega zdravila. Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Učinki drugih zdravil na farmakokinetiko 
palbocikliba: Zaviralci CYP3A: Sočasni uporabi močnih zaviralcev CYP3A, med drugim klaritromicina, indinavirja, itrakonazola, ketokonazola, lopinavirja/ritonavirja, nefazodona, nelfinavirja, 
posakonazola, sakvinavirja, telaprevirja, telitromicina, vorikonazola in grenivke ali grenivkinega soka, se je treba izogibati. Induktorji CYP3A: Sočasni uporabi močnih induktorjev CYP3A, 
med drugim karbamazepina, enzalutamida, fenitoina, rifampicina in šentjanževke, se je treba izogibati. Učinek zdravil za zmanjševanje kisline: (1) Če palbociklib zaužijemo s hrano, klinično 
pomembnega učinka na izpostavljenost palbociklibu ni pričakovati. (2) Klinično pomembnega učinka na izpostavljenost palbociklibu ni pričakovati. Učinki palbocikliba na farmakokinetiko 
drugih zdravil: Pri sočasni uporabi bo morda treba zmanjšati odmerek občutljivih substratov CYP3A z ozkim terapevtskim indeksom (npr. alfentanil, ciklosporin, dihidroergotamin, 
ergotamin, everolimus, fentanil, pimozid, kinidin, sirolimus in takrolimus), saj IBRANCE lahko poveča izpostavljenost tem zdravilom. Študije in vitro s prenašalci: Palbociklib lahko zavira 
prenos, posredovan s P-gp v prebavilih in beljakovino odpornosti pri raku dojk (BCRP). Uporaba palbocikliba z zdravili, ki so substrati P-gp (npr. digoksin, dabigatran, kolhicin) ali BCRP 
(npr. pravastatin, rosuvastatin, sulfasalazin) lahko poveča njihov terapevtski učinek in neželene učinke. Palbociklib lahko zavira privzemni prenašalec organskih kationov OCT1. Plodnost, 
nosečnost in dojenje: Med zdravljenjem in vsaj 3 tedne (ženske) oziroma 14 tednov (moški) po koncu zdravljenja je treba uporabljati ustrezne kontracepcijske metode. Zdravila ne 
uporabljajte pri nosečnicah in ženskah v rodni dobi, ki ne uporabljajo kontracepcije. Bolnice, ki prejemajo palbociklib, ne smejo dojiti. Zdravljenje s palbociklibom lahko ogrozi plodnost 
pri moških. Pred začetkom zdravljenja naj moški zato razmislijo o hrambi sperme. Vpliv na sposobnost vožnje in upravljanja s stroji: Ima blag vpliv na sposobnost vožnje in upravljanja 
strojev. Potrebna je previdnost. Neželeni učinki: Zelo pogosti: okužbe, nevtropenija, levkopenija, anemija, trombocitopenija, pomanjkanje teka, stomatitis, navzea, diareja, bruhanje, izpuščaj, 
alopecija, suha koža, utrujenost, astenija, pireksija, povečane vrednosti ALT/AST. Način in režim izdaje: Rp/Spec - Predpisovanje in izdaja zdravila je le na recept zdravnika specialista 
ustreznega področja medicine ali od njega pooblaščenega zdravnika. Imetnik dovoljenja za promet: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgija. Datum zadnje 
revizije besedila: 16.07.2021
Pred predpisovanjem se seznanite s celotnim povzetkom glavnih značilnosti zdravila.
PP-IBR-EEP-0236  Datum priprave: avgust 2021. Samo za strokovno javnost.
HR+/HER2- = pozitiven na hormonske receptorje in negativen na receptorje humanega epidermalnega rastnega faktorja 2.
Literatura: Povzetek glavnih značilnosti zdravila Ibrance, 16.7.2021.




•  v kombinaciji z zaviralcem aromataze,
•  v kombinaciji s fulvestrantom pri 
ženskah, ki so prejele  
predhodno endokrino zdravljenje.
Pri ženskah v pred- in perimenopavzi je 
treba endokrino zdravljenje kombinirati 





Več kot stoletje postavljamo nove standarde v diagnostiki in zdravljenju 
številnih bolezni. Danes nam novi viri podatkov in napredna analitika 
omogočajo, da zagotovimo pravo zdravljenje za pravega bolnika ob pravem 
času. Zato se povezujemo s tistimi, ki stremijo k istemu cilju in razumejo, da 
nova znanja služijo ne samo znanosti, temveč predvsem človeštvu.  
Revolucije
zahtevajo strast.  
Informacija pripravljena: september 2020.












KO PRI VAŠIH BOLNIKIH Z 
MELANOMOM STADIJA III ALI 





Dosežite podaljšano preživetje pri 
bolnikih z BRAF+ melanomom stadija IV 
ali možnost ozdravitve pri bolnikih s 
stadijem III s kombinacijo zdravil 
TAFINLAR + MEKINIST. 3, 4 * # †
*  V študiji COMBI-AD je bila po medianem času spremljanja 60 mesecev (dabrafenib in 
trametinib), oz. 58 mesecev (placebo) ocenjena stopnja ozdravitve 52 % (95-% IZ, 48 %-58 %; 
dabrafenib in trametinib), in 36 % (95-% IZ, 32 %-41 %; placebo).
#  V združeni populaciji bolnikov iz študij COMBI-d in COMBI-v je bila stopnja celokupnega preživetja bolnikov 
v skupini zdravljeni s kombinacijo zdravil dabrafenib in trametinib po 5 letih 34 % (95-% IZ, 30 %-38 %)  
v primerjavi s 27% (dabrafenib+placebo) in 23 % (vemurafenib).
†  Zdravili TAFINLAR in MEKINIST sta v kombinaciji indicirani za zdravljenje odraslih bolnikov z inoperabilnim ali metastatskim 
melanomom z mutacijo BRAF V600 in adjuvantno zdravljenje odraslih bolnikov po totalni resekciji melanoma stadija III  
z mutacijo BRAF V600.1,2
SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA ZA ZDRAVILI TAFINLAR IN MEKINIST
Novartis Pharma Services Inc., Podružnica v Sloveniji 
Verovškova ulica 57, 1000 Ljubljana, tel.: 01 300 75 50 Samo za strokovno javnostDatum priprave materiala: februar 2021 SI-2021-MEK-014
Viri in literatura: 1. Povzetek glavnih značilnosti zdravila Tafinlar. Januar 2021. 2. Povzetek glavnih značilnosti zdravila Mekinist. Januar 2021. 3. Dummer R, Hauschild A, Santinami M, et al. 
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020;383:1139-48. 4. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib 
plus Trametinib in Metastatic Melanoma. N Engl J Med 2019;381:626-36.
Imena zdravil: Tafinlar 50 mg trde kapsule, Tafinlar 75 mg trde kapsule, Mekinist 0,5 mg filmsko obložene tablete, Mekinist 2 mg filmsko obložene tablete. Sestava: Ena trda kapsula zdravila Tafinlar 
vsebuje dabrafenibijev mesilat, ki ustreza 50  mg dabrafeniba ali 75 mg dabrafeniba. Ena filmsko obložena tableta zdravila Mekinist vsebuje 0,5 mg trametiniba ali 2  mg trametiniba v obliki 
trametinibijevega dimetilsulfoksida. Indikacija: Melanom: Dabrafenib in trametinib sta v kombinaciji indicirana za zdravljenje odraslih bolnikov z inoperabilnim ali metastatskim melanomom 
z mutacijo BRAF V600. Dabrafenib in trametinib sta oba tudi v monoterapiji indicirana za zdravljenje odraslih bolnikov z inoperabilnim ali metastatskim melanomom z mutacijo BRAF V600. Trametinib 
v monoterapiji ni izkazal klinične aktivnosti pri bolnikih, ki jim je bolezen napredovala med predhodnim zdravljenjem z zaviralcem BRAF. Adjuvantno zdravljenje melanoma: Dabrafenib in trametinib 
sta v kombinaciji indicirana za adjuvantno zdravljenje odraslih bolnikov po totalni resekciji melanoma stadija III z mutacijo BRAF V600. Nedrobnocelični pljučni rak (NDCPR): Dabrafenib 
in trametinib sta v kombinaciji indicirana za zdravljenje odraslih bolnikov z napredovalim nedrobnoceličnim pljučnim rakom z mutacijo BRAF V600. Odmerjanje: Zdravljenje mora uvesti in 
nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil proti raku. Pred uporabo dabrafeniba in/ali trametiniba mora biti z validirano preiskavo potrjeno, da ima bolnik mutacijo BRAF V600. Kombinirano 
zdravljenje: 150 mg dabrafeniba 2x/dan in 2 mg trametiniba 1x/dan. Dabrafenib v monoterapiji (melanom): 150 mg dabrafeniba 2x/dan. Trametinib v monoterapiji (melanom): 2 mg trametiniba 1x/dan. 
Če bolnik pozabi vzeti odmerek trametiniba, naj ga vzame samo, če je do naslednjega rednega odmerka več kot 12 ur, pozabljenega odmerka dabrafeniba ne sme vzeti, če je do naslednjega odmerka 
po razporedu manj kot 6 ur. Zdravljenje je priporočljivo nadaljevati, dokler bolniku koristi oz. do pojava nesprejemljivih toksičnih učinkov. Pri adjuvantnem zdravljenju melanoma je treba bolnike zdraviti 
12 mesecev, razen če pride do ponovitve bolezni ali nesprejemljivih toksičnih učinkov. Obvladovanje neželenih učinkov lahko zahteva znižanje odmerka, prekinitev zdravljenja ali prenehanje zdravljenja. 
Prilagoditve odmerka ali prekinitve zdravljenja niso priporočljive v primeru neželenih učinkov ploščatoceličnega karcinoma kože ali novega primarnega melanoma. Če pri uporabi kombinacije 
dabrafeniba in trametiniba pride do toksičnih učinkov zdravljenja, je treba sočasno znižati odmerek obeh zdravil oz. sočasno začasno prekiniti ali dokončno ukiniti obe zdravljenji. Izjeme, pri katerih je 
treba odmerek prilagajati samo pri enem od obeh zdravil, so pojav zvišane telesne temperature (dabrafenib), uveitisa (dabrafenib), nekožnih malignomov z mutacijo RAS (dabrafenib), zmanjšanja 
iztisnega deleža levega prekata (LVEF) (trametinib), zapore mrežnične vene (RVO) ali odstopa mrežničnega pigmentnega epitelija (RPED) (trametinib) in intersticijske bolezni pljuč (IBP)/pnevmonitisa 
(trametinib). Za natančnejša navodila glede prilagajanja odmerkov glejte povzetka glavnih značilnosti zdravil Tafinlar in Mekinist. Bolnikom z blago ali zmerno okvaro ledvic ali z blago okvaro jeter 
odmerkov dabrafeniba in trametiniba ni treba prilagoditi. Pri bolnikih s hudo okvaro ledvic ali z zmerno ali hudo okvaro jeter je treba dabrafenib in trametinib, bodisi v monoterapiji ali v kombinaciji, 
uporabljati previdno. Bolnikom, starim > 65 let, začetnega odmerka dabrafeniba in trametiniba ni treba prilagoditi, je pa pri teh bolnikih lahko potrebno pogostejše prilagajanje odmerka trametiniba. Pri 
bolnikih azijske rase ni potrebno prilagajati odmerkov dabrafeniba. Varnost in učinkovitost trametiniba nista ugotovljeni pri bolnikih, ki niso belci. Varnost in učinkovitost dabrafeniba in trametiniba pri 
otrocih in mladostnikih (< 18 let) nista bili dokazani.  Način uporabe: Zdravilo Tafinlar: Kapsule je treba zaužiti cele z vodo najmanj 1 uro pred jedjo oz. najmanj 2 uri po jedi. Ne sme se jih zgristi ali 
odpreti. Če bolnik po zaužitju dabrafeniba ali trametiniba bruha, odmerka ne sme vzeti ponovno, temveč mora vzeti naslednji odmerek ob običajnem času. Zdravilo Mekinist: Tablete je treba zaužiti s 
polnim kozarcem vode vsaj 1 uro pred jedjo ali vsaj 2 uri po jedi. Ne sme se jih gristi ali drobiti. Kontraindikacije: Preobčutljivost na učinkovini ali katero koli pomožno snov. Posebna opozorila in 
previdnostni ukrepi: Dabrafeniba se ne sme uporabljati pri bolnikih z melanomom in pri bolnikih z NDCPR z divjim tipom BRAF. O uporabi kombinacije dabrafeniba in trametiniba pri bolnikih z 
melanomom, pri katerih je bolezen napredovala med predhodnim zdravljenjem z zaviralcem BRAF, je na voljo malo podatkov, ki pa kažejo, da je učinkovitost kombinacije pri teh bolnikih manjša. 
Ploščatocelični karcinom kože (dabrafenib ali kombinirano zdravljenje): Opisani so primeri ploščatoceličnega karcinoma kože. Priporočljivo je opraviti pregled kože pred uvedbo dabrafeniba, vsak mesec 
med zdravljenjem in še do 6 mesecev po zdravljenju ploščatoceličnega karcinoma kože. Bolnika se mora spremljati še 6 mesecev po prenehanju zdravljenja z dabrafenibom ali do uvedbe drugega 
antineoplastičnega zdravljenja. Primere ploščatoceličnega karcinoma kože je treba zdraviti z dermatološko ekscizijo, z dabrafenibom oz. kombinacijo pa nadaljevati brez prilagoditve odmerka. Bolnikom 
je treba naročiti, naj nemudoma obvestijo zdravnika, če se jim pojavi kakšna nova sprememba. Nov primarni melanom (dabrafenib ali kombinirano zdravljenje): Bolnika je mogoče zdraviti z ekscizijo, 
spremembe v zdravljenju niso potrebne. Nadzor kot pri ploščatoceličnem karcinomu kože. Nekožni malignomi (dabrafenib ali kombinirano zdravljenje): Dabrafenib lahko poveča tveganje za razvoj 
nekožnih malignomov, če so prisotne mutacije RAS. Bolnikom je treba pred uvedbo zdravljenja pregledati glavo in vrat (najmanj ogled ustne sluznice in palpacijo bezgavk), opraviti morajo CT prsnega 
koša/trebuha. Med zdravljenjem jih je treba nadzirati, kot je klinično primerno; to lahko vključuje pregled glave in vratu na 3 mesece in CT prsnega koša/trebuha na 6 mesecev. Pred zdravljenjem in na 
koncu zdravljenja (ter kadar koli je klinično indicirano) sta priporočljiva analni in ginekološki pregled. Opraviti je treba pregled celotne krvne slike in biokemične preiskave krvi, kot je klinično indicirano. 
Krvavitev (trametinib ali kombinirano zdravljenje): Prihajalo je do krvavitev, med katerimi so bile tudi večje krvavitve in krvavitve, zaradi katerih so bolniki umrli. Tveganje se lahko poveča v primeru 
sočasne uporabe antiagregacijskih ali antikoagulantnih zdravil. Če pride do krvavitve, je treba bolnika zdraviti v skladu s kliničnimi indikacijami. LVEF (trametinib ali kombinirano zdravljenje): Poročali 
so, da trametinib zmanjša LVEF. Vsem bolnikom je treba LVEF oceniti pred uvedbo trametiniba, 1 mesec po uvedbi in nato na približno 3 mesece med zdravljenjem. Pri jemanju trametiniba v kombinaciji 
z dabrafenibom, so poročali o akutni hudi disfunkciji levega prekata zaradi miokarditisa. Zdravniki naj bodo pozorni na možnost miokarditisa pri bolnikih, pri katerih se znaki ali simptomi težav s srcem 
pojavijo na novo oziroma se poslabšajo. Zvišana telesna temperatura (dabrafenib, trametinib ali kombinirano zdravljenje): Poročali so o zvišanju telesne temperature. Pri kombiniranem zdravljenju sta 
pogostnost in izraženost večji. Zdravljenje z dabrafenibom je treba prekiniti, če je bolnikova telesna temperatura ≥ 38,5 °C in bolnike oceniti glede znakov in simptomov okužbe. Ko mine, je mogoče 
zdravljenje z dabrafenibom znova začeti ob ustrezni profilaksi z uporabo nesteroidnih protivnetnih zdravil ali paracetamola. Če antipiretiki ne zadoščajo, je treba razmisliti o uporabi peroralnih 
kortikosteroidov. Če je zvišana telesna temperatura povezana z drugimi hudimi znaki ali simptomi, je treba zdravljenje z dabrafenibom znova začeti z nižjim odmerkom, ko zvišana telesna temperatura 
mine in kot je klinično primerno. Hipertenzija (trametinib ali kombinirano zdravljenje): Opisana so zvišanja krvnega tlaka tako pri bolnikih, ki so že prej imeli hipertenzijo, kot pri tistih, ki je prej niso imeli. 
Krvni tlak je treba izmeriti izhodiščno in med zdravljenjem; hipertenzijo je treba obvladovati s standardnim zdravljenjem. IBP (trametinib ali kombinirano zdravljenje): V primeru suma na IBP ali 
pnevmonitis je treba zdravljenje s trametinibom prekiniti; tudi pri bolnikih z novonastalimi ali napredujočimi pljučnimi simptomi ali izvidi, vključno s kašljem, dispnejo, hipoksijo, plevralnim izlivom ali 
infiltrati, dokler niso opravljene klinične preiskave. Pri bolnikih, ki imajo diagnosticirano z zdravljenjem povezano IBP ali pnevmonitis, je treba zdravljenje s trametinibom trajno končati. Okvara vida 
(trametinib ali kombinirano zdravljenje): Lahko pride do težav, povezanih z motnjami vida, vključno z RPED in RVO. Uporaba trametiniba ni priporočljiva pri bolnikih, ki so v preteklosti že imeli RVO. Če 
se pojavijo novonastale motnje vida, npr. poslabšanje centralnega vida, zamegljen vid ali izguba vida, je priporočljiva takojšnja oftalmološka ocena. Pri bolnikih z diagnozo RVO, je treba trametinib trajno 
ukiniti. Okvara vida (dabrafenib ali kombinirano zdravljenje): Opisovali so oftalmološke reakcije, vključno z uveitisom, iridociklitisom in/ali iritisom. Bolnike je treba redno kontrolirati glede znakov in 
simptomov s strani vida (npr. sprememb vida, fotofobije in bolečin v očesu). Prilagajanje odmerka ni potrebno, dokler je očesno vnetje mogoče obvladati z učinkovitimi lokalnimi zdravili. Če se uveitis 
ne odziva na lokalna očesna zdravila, je treba zdravljenje z dabrafenibom prekiniti, dokler očesno vnetje ni odpravljeno, nato pa ga ponovno uvesti v odmerku, ki je za eno odmerno raven nižji. Odpoved 
ledvic (dabrafenib ali kombinirano zdravljenje): Med zdravljenjem je treba rutinsko določati vrednost kreatinina v serumu. Če se vrednost zviša, je morda treba začasno prekiniti uporabo dabrafeniba, 
če je to klinično primerno. Uporabe dabrafeniba niso preučili pri bolnikih z insuficienco ledvic (kreatinin > 1,5 x ZMN), zato ga je treba v takšnih okoliščinah uporabljati previdno. Pankreatitis (dabrafenib 
ali kombinirano zdravljenje): Poročali so o primerih pankreatitisa. Nepojasnjene bolečine v trebuhu je treba nemudoma raziskati, vključno z meritvijo amilaze in lipaze v serumu. Ob ponovnem začetku 
uporabe dabrafeniba po pankreatitisu je treba bolnike skrbno kontrolirati. Jetrni dogodki (trametinib ali kombinirano zdravljenje): Prvih 6 mesecev po začetku zdravljenja s trametinibom je delovanje 
jeter priporočljivo kontrolirati na 4 tedne in nato kot je klinično indicirano. Globoka venska tromboza/pljučna embolija (trametinib ali kombinirano zdravljenje): Če se pri bolniku pojavijo znaki pljučne 
embolije ali globoke venske tromboze, kot so zadihanost, bolečine v prsnem košu ali zatekanje rok ali nog, mora takoj poiskati zdravniško pomoč. Če gre za življenjsko nevarno pljučno embolijo, je treba 
bolniku dokončno ukiniti zdravljenje s trametinibom in dabrafenibom. Hude kožne neželene reakcije: Pred uvedbo zdravljenja je treba bolnike opozoriti na znake in simptome kožnih reakcij in jih skrbno 
spremljati. Če se pojavijo znaki in simptomi, ki lahko pomenijo, da gre za hudo kožno neželeno reakcijo, mora bolnik prekiniti zdravljenje z dabrafenibom in trametinibom. Bolezni prebavil (trametinib 
ali kombinirano zdravljenje): Poročali so o kolitisu in perforaciji prebavil, vključno s primeri, ki so se končali s smrtjo. Previdnost je potrebna pri uporabi trametiniba pri bolnikih z dejavniki tveganja za 
perforacijo prebavil, kot so divertikulitis v anamnezi, metastaze v prebavnem traktu ali sočasna uporaba zdravil z znanim tveganjem za perforacijo prebavil. Sarkoidoza: Ob diagnozi sarkoidoze je treba 
razmisliti o ustreznem zdravljenju. Pomembno je, da se sarkoidoza ne interpretira kot napredovanje bolezni. Plodnost, nosečnost in dojenje: Ženske v rodni dobi morajo uporabljati učinkovite 
kontracepcijske metode med zdravljenjem in še 2 tedna po prenehanju zdravljenja z dabrafenibom ter še 16 tednov po zadnjem odmerku trametiniba. Dabrafenib lahko zmanjša učinkovitost peroralnih 
oz. katerihkoli hormonskih kontraceptivov, zato je treba uporabiti drug učinkovit način kontracepcije. Trenutno ni znano, ali trametinib vpliva na hormonske kontraceptive. Za preprečitev nosečnosti se 
bolnicam, ki jemljejo hormonske kontraceptive svetuje, da uporabijo dodaten ali drug način kontracepcije med zdravljenjem in še 16 tednov po prekinitvi zdravljenja s trametinibom. Nosečnice in doječe 
matere ne smejo dobivati trametiniba. Nosečnice naj ne bi prejemale dabrafeniba, razen če možna korist za mater odtehta možno tveganje za plod. Odločiti se je treba bodisi za prenehanje dojenja 
bodisi za prenehanje zdravljenja z dabrafenibom, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko. Dabrafenib in trametinib lahko prizadeneta plodnost moških in žensk. Moške 
bolnike, ki jemljejo dabrafenib in/ali trametinib, je treba seznaniti z možnim tveganjem za motnje spermatogeneze, ki so lahko ireverzibilne. Dabrafenib in trametinib imata blag vpliv na sposobnost 
vožnje in upravljanja strojev. Bolnika je treba seznaniti z možnostjo za utrujenost, omotico in težave z očmi, ki lahko vplivajo na takšne dejavnosti. Medsebojno delovanje z drugimi zdravili: Zdravilo 
Tafinlar: Verjetno je, da zdravila, ki močno zavirajo ali inducirajo CYP2C8 ali CYP3A4, povečajo oz. zmanjšajo koncentracijo dabrafeniba. Če je mogoče, je treba med uporabo dabrafeniba uporabiti druga 
zdravila. V primeru uporabe dabrafeniba z močnimi zaviralci (npr. ketokonazolom, gemfibrozilom, nefazodonom, klaritromicinom, ritonavirjem, sakvinavirjem, telitromicinom, itrakonazolom, 
vorikonazolom, posakonazolom, atazanavirjem) je potrebna previdnost. Izogibajte se sočasni uporabi dabrafeniba z močnimi induktorji (npr. rifampicinom, fenitoinom, karbamazepinom, fenobarbitalom 
ali šentjanževko (Hypericum perforatum)) CYP2C8 ali CYP3A4. Ne pričakuje se, da bi zdravila, ki spreminjajo pH zgornjega gastrointestinalnega trakta (npr. zaviralci protonske črpalke, antagonisti 
histaminskih receptorjev H2, antacidi), zmanjšala biološko uporabnost dabrafeniba. Dabrafenib je induktor encimov in poveča sintezo encimov, ki presnavljajo zdravila. Posledica je manjša plazemska 
koncentracija zdravil, ki se presnavljajo s temi encimi, kar lahko povzroči izgubo ali zmanjšanje kliničnega učinka teh zdravil. Pričakovati je mogoče medsebojna delovanja s številnimi zdravili, ki se 
izločajo s presnavljanjem ali aktivnim transportom, a velikost medsebojnega delovanja se razlikuje. To lahko velja za, vendar ni omejeno na naštete skupine zdravil: analgetiki (npr. fentanil, metadon), 
antibiotiki (npr. klaritromicin, doksiciklin), zdravila proti raku (npr. kabazitaksel), antikoagulansi (npr. acenokumarol, varfarin), antiepileptiki (npr. karbamazepin, fenitoin, primidon, valprojska kislina), 
antipsihotiki (npr. haloperidol), zaviralci kalcijevih kanalčkov (npr. diltiazem, felodipin, nikardipin, nifedipin, verapamil), srčni glikozidi (npr. digoksin), kortikosteroidi (npr. deksametazon, metilprednizolon), 
protivirusna zdravila proti HIV (npr. amprenavir, atazanavir, darunavir, delavirdin, efavirenz, fosamprenavir, indinavir, lopinavir, nelfinavir, sakvinavir, tipranavir), hormonski kontraceptivi, hipnotiki (npr. 
diazepam, midazolam, zolpidem), imunosupresivi (npr. ciklosporin, takrolimus, sirolimus), statini, ki se presnavljajo s CYP3A4 (npr. atorvastatin, simvastatin). Če je njihov terapevtski učinek za bolnika 
zelo pomemben in če odmerka ni mogoče zlahka prilagoditi glede na kontrolo učinkovitosti ali koncentracije v plazmi, se je tem zdravilom treba izogniti ali jih je treba uporabljati previdno. Tveganje za 
okvaro jeter po uporabi paracetamola je domnevno večje pri bolnikih, ki sočasno prejemajo induktorje encimov. Pojav indukcije je verjeten po 3 dneh ponavljajočega se odmerjanja dabrafeniba. Po 
prenehanju uporabe dabrafeniba indukcija mine postopoma. Bolnike je treba spremljati glede toksičnih učinkov; potrebna je lahko prilagoditev odmerjanja navedenih zdravil. Zdravilo Mekinist: Zaradi 
možnosti zvišanja koncentracije trametiniba, je priporočena previdnost pri sočasnem odmerjanju trametiniba in zdravil, ki so močni zaviralci P-gp (na primer verapamila, ciklosporina, ritonavirja, 
kinidina, itrakonazola). Trametinib lahko povzroči prehodno zavrtje substratov BCRP (npr. pitavastatina) v črevesu; to je mogoče omejiti na najmanjšo mero tako, da se ta zdravila in trametinib uporablja 
z medsebojnim zamikom (zamik 2 ur). Neželeni učinki: Dabrafenib v monoterapiji: Zelo pogosti (≥ 1/10): papilom, zmanjšan apetit, glavobol, kašelj, navzea, bruhanje, driska, hiperkeratoza, alopecija, 
izpuščaj, sindrom palmarno-plantarne eritrodisestezije, artralgija, mialgija, bolečine v okončini, pireksija, utrujenost, mrzlica, astenija. Pogosti (≥ 1/100 do < 1/10): ploščatocelični karcinom kože, 
seboroična keratoza, akrohordon (kožni izrastki), bazalnocelični karcinom, hipofosfatemija, hiperglikemija, zaprtost, suha koža, srbenje, aktinična keratoza, kožne lezije, eritem, fotosenzitivnost, gripi 
podobna bolezen. Občasni (≥ 1/1.000 do < 1/100): nov primarni melanom, preobčutljivost, uveitis, pankreatitis, panikulitis, odpoved ledvic, akutna odpoved ledvic, nefritis. Trametinib v monoterapiji: 
Zelo pogosti: hipertenzija, krvavitev, kašelj, dispneja, driska, navzea, bruhanje, zaprtost, bolečine v trebuhu, suha usta, izpuščaj, akneiformni dermatitis, suha koža, srbenje, alopecija, utrujenost, periferni 
edemi, zvišana telesna temperatura, zvišana aspartat-aminotransferaza. Pogosti: folikulitis, paronihija, celulitis, pustulozen izpuščaj, anemija, preobčutljivost, dehidracija, zamegljen vid, periorbitalni 
edem, okvara vida, disfunkcija levega prekata, zmanjšanje iztisnega deleža, bradikardija, limfedem, pnevmonitis, stomatitis, eritem, sindrom palmarno-plantarne eritrodisestezije, fisure na koži, 
razpokana koža, edem obraza, vnetje sluznice, astenija, zvišana alanin-aminotransferaza, zvišana alkalna fosfataza v krvi, zvišana kreatin-fosfokinaza v krvi. Občasni: horioretinopatija, papiledem, 
odstop mrežnice, zapora mrežnične vene, srčno popuščanje, intersticijska bolezen pljuč, perforacija prebavil, kolitis, rabdomioliza. Kombinirano zdravljenje z dabrafenibom in trametinibom: Zelo 
pogosti:nazofaringitis, zmanjšan apetit, glavobol, omotica, hipertenzija, krvavitev, kašelj, bolečine v trebuhu, zaprtost, diareja, navzea, bruhanje, suha koža, srbenje, izpuščaj, eritem, artralgija, mialgija, 
bolečine v okončini, mišični krči, utrujenost, mrzlica, astenija, periferni edemi, zvišana telesna temperatura, gripi podobna bolezen, zvišana vrednost alanin aminotransferaze, zvišana vrednost aspartat 
aminotransferaze. Pogosti: okužba sečil, celulitis, folikulitis, paronihija, pustulozen izpuščaj, ploščatocelični karcinom kože, papilom, seboroična keratoza, nevtropenija, anemija, trombocitopenija, 
levkopenija, dehidracija, hiponatriemija, hipofosfatemija, hiperglikemija, zamegljen vid, okvara vida, uveitis, zmanjšanje iztisnega deleža, limfedem, hipotenzija, dispneja, suha usta, stomatitis, 
akneiformni dermatitis, aktinična keratoza, nočno znojenje, hiperkeratoza, alopecija, sindrom palmarno-plantarne eritrodisestezije, kožne spremembe, čezmerno znojenje, panikulitis, fisure na koži, 
fotosenzitivnost, vnetje sluznice, edem obraza, zvišana vrednost alkalne fosfataze v krvi, zvišana vrednost gama-glutamiltransferaze, zvišana vrednost kreatin-fosfokinaze v krvi. Občasni: nov primarni 
melanom, akrohordon (pecljati fibrom), preobčutljivost, sarkoidoza, horioretinopatija, odstop mrežnice, periorbitalni edem, bradikardija, pnevmonitis, pankreatitis, kolitis, odpoved ledvic, nefritis. Redki: 
perforacija prebavil. Neznana pogostnost: miokarditis, Stevens-Johnsonov sindrom, reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS sindrom), generaliziran eksfoliativni dermatitis. 
Imetnik dovoljenja za promet z zdravilom: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Irska Dodatne informacije in literatura: Novartis Pharma Services Inc., 
Podružnica v Sloveniji, Verovškova ulica 57, 1000 Ljubljana. Način/režim izdajanja zdravil Tafinlar in Mekinist: Rp/Spec. Pred predpisovanjem natančno preberite zadnji odobreni povzetek 
glavnih značilnosti zdravila. Datum zadnje revizije skrajšanega povzetka glavnih značilnosti zdravila: januar 2021.
© 2020 Amgen Inc. All rights reserved. Amgen zdravila d.o.o., Ameriška ulica 2, Ljubljana 




Decades of innovation in targeted 
therapies is helping people with 
lung cancer live longer 
EDINI
zaviralec CDK4 & 6,
ki se jemlje
NEPREKINJENO VSAK DAN,
2x NA DAN1, 2, 3
SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo hitreje na voljo nove informacije o njegovi varnosti. Zdravstvene delavce naprošamo, da 
poročajo o katerem koli domnevnem neželenem učinku zdravila. Glejte poglavje 4.8, kako poročati o neželenih učinkih. 
IME ZDRAVILA: Verzenios 50 mg/100 mg/150 mg filmsko obložene tablete KAKOVOSTNA IN KOLIČINSKA SESTAVA: Ena filmsko obložena tableta vsebuje 50 mg/100 mg/150 
mg abemacikliba. Ena filmsko obložena tableta vsebuje 14 mg/28 mg/42 mg laktoze (v obliki monohidrata). Terapevtske indikacije: Zdravilo Verzenios je indicirano za zdravljenje 
žensk z lokalno napredovalim ali metastatskim, na hormonske receptorje (HR – Hormone Receptor) pozitivnim in na receptorje humanega epidermalnega rastnega faktorja 2 
(HER2 – Human Epidermal Growth Factor Receptor 2) negativnim rakom dojk v kombinaciji z zaviralcem aromataze ali s fulvestrantom kot začetnim endokrinim zdravljenjem 
ali pri ženskah, ki so prejele predhodno endokrino zdravljenje. Pri ženskah v pred- in perimenopavzi je treba endokrino zdravljenje kombinirati z agonistom gonadoliberina 
(LHRH – Luteinizing Hormone–Releasing Hormone). Odmerjanje in način uporabe: Zdravljenje z zdravilom Verzenios mora uvesti in nadzorovati zdravnik, ki ima izkušnje 
z uporabo zdravil za zdravljenje rakavih bolezni. Zdravilo Verzenios v kombinaciji z endokrinim zdravljenjem: Priporočeni odmerek abemacikliba je 150 mg dvakrat na dan, 
kadar se uporablja v kombinaciji z endokrinim zdravljenjem. Zdravilo Verzenios je treba jemati, dokler ima bolnica od zdravljenja klinično korist ali do pojava nesprejemljive 
toksičnosti. Če bolnica bruha ali izpusti odmerek zdravila Verzenios, ji je treba naročiti, da naj naslednji odmerek vzame ob predvidenem času; dodatnega odmerka ne sme 
vzeti. Obvladovanje nekaterih neželenih učinkov lahko zahteva prekinitev in/ali zmanjšanje odmerka. Zdravljenje z abemaciklibom prekinite v primeru povišanja vrednosti AST 
in/ali ALT >3 x ZMN SKUPAJ s celokupnim bilirubinom > 2,0 x ZMN v odsotnosti holestaze ter pri bolnicah z intersticijsko pljučno boleznijo (ILD)/pnevmonitis stopnje 3 ali 4. 
Sočasni uporabi močnih zaviralcev CYP3A4 se je treba izogibati. Če se uporabi močnih zaviralcev CYP3A4 ni mogoče izogniti, je treba odmerek abemacikliba znižati na 100 
mg dvakrat na dan. Pri bolnicah, pri katerih je bil odmerek znižan na 100 mg abemacikliba dvakrat na dan in pri katerih se sočasnemu dajanju močnega zaviralca CYP3A4 ni 
mogoče izogniti, je treba odmerek abemacikliba dodatno znižati na 50 mg dvakrat na dan. Pri bolnicah, pri katerih je bil odmerek znižan na 50 mg abemacikliba dvakrat na 
dan in pri katerih se sočasnemu dajanju močnega zaviralca CYP3A4 ni mogoče izogniti, je mogoče z odmerkom abemacikliba nadaljevati ob natančnem spremljanju znakov 
toksičnosti. Alternativno je mogoče odmerek abemacikliba znižati na 50 mg enkrat na dan ali prekiniti dajanje abemacikliba. Če je uporaba zaviralca CYP3A4 prekinjena, je 
treba odmerek abemacikliba povečati na odmerek, kakršen je bil pred uvedbo zaviralca CYP3A4 (po 3–5 razpolovnih časih zaviralca CYP3A4). Prilagajanje odmerka glede 
na starost in pri bolnicah z blago ali zmerno ledvično okvaro ter z blago (Child Pugh A) ali zmerno (Child Pugh B) jetrno okvaro ni potrebno. Pri dajanju abemacikliba bolnicam 
s hudo ledvično okvaro sta potrebna previdnost in skrbno spremljanje glede znakov toksičnosti. Način uporabe: Zdravilo Verzenios je namenjeno za peroralno uporabo. Od-
merek se lahko vzame s hrano ali brez nje. Zdravilo se ne sme jemati z grenivko ali grenivkinim sokom. Bolnice naj odmerke vzamejo vsak dan ob približno istem času. Tableto 
je treba zaužiti celo (bolnice je pred zaužitjem ne smejo gristi, drobiti ali deliti). Kontraindikacije: Preobčutljivost na učinkovino ali katero koli pomožno snov. Posebna opozorila 
in previdnostni ukrepi: Pri bolnicah, ki so prejemale abemaciklib, so poročali o nevtropeniji, o večji pogostnosti okužb kot pri bolnicah, zdravljenih s placebom in endokrinim 
zdravljenjem, o povečanih vrednostih ALT in AST. Pri bolnicah, pri katerih se pojavi nevtropenija stopnje 3 ali 4, je priporočljivo prilagoditi odmerek. Bolnice je treba spremljati 
za znake in simptome globoke venske tromboze in pljučne embolije ter jih zdraviti, kot je medicinsko utemeljeno. Glede na povečanje vrednosti ALT ali AST je mogoče pot-
rebna prilagoditev odmerka. Driska je najpogostejši neželeni učinek. Bolnice je treba ob prvem znaku tekočega blata začeti zdraviti z antidiaroiki, kot je loperamid, povečati 
vnos peroralnih tekočin in obvestiti zdravnika. Sočasni uporabi induktorjev CYP3A4 se je treba izogibati zaradi tveganja za zmanjšano učinkovitost abemacikliba. Bolnice z 
redkimi dednimi motnjami, kot so intoleranca za galaktozo, popolno pomanjkanje laktaze ali malapsorpcija glukoze/galaktoze, tega zdravila ne smejo jemati. Bolnice spremljajte 
glede pljučnih simptomov, ki kažejo na ILD/pnevmonitis, in jih ustrezno zdravite. Glede na stopnjo ILD/pnevmonitisa je morda potrebno prilagajanje odmerka abemacikliba. 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Abemaciklib se primarno presnavlja s CYP3A4. Sočasna uporaba abemacikliba in zaviralcev CYP3A4 
lahko poveča plazemsko koncentracijo abemacikliba. Uporabi močnih zaviralcev CYP3A4 sočasno z abemaciklibom se je treba izogibati. Če je močne zaviralce CYP3A4 treba 
dajati sočasno, je treba odmerek abemacikliba zmanjšati, nato pa bolnico skrbno spremljati glede toksičnosti. Pri bolnicah, zdravljenih z zmernimi ali šibkimi zaviralci CYP3A4, 
ni potrebno prilagajanje odmerka, vendar jih je treba skrbno spremljati za znake toksičnosti. Sočasni uporabi močnih induktorjev CYP3A4 (vključno, vendar ne omejeno na: 
karbamazepin, fenitoin, rifampicin in šentjanževko) se je treba izogibati zaradi tveganja za zmanjšano učinkovitost abemacikliba. Abemaciklib in njegovi glavni aktivni presnovki 
zavirajo prenašalce v ledvicah, in sicer kationski organski prenašalec 2 (OCT2) ter prenašalca MATE1. In vivo lahko pride do medsebojnega delovanja abemacikliba in klinično 
pomembnih substratov teh prenašalcev, kot je dofelitid ali kreatinin. Trenutno ni znano, ali lahko abemaciklib zmanjša učinkovitost sistemskih hormonskih kontraceptivov, zato 
se ženskam, ki uporabljajo sistemske hormonske kontraceptive, svetuje, da hkrati uporabljajo tudi mehansko metodo. Neželeni učinki: Najpogostejši neželeni učinki so driska, 
okužbe, nevtropenija, anemija, utrujenost, navzea, bruhanje in zmanjšanje apetita. Zelo pogosti: okužbe, nevtropenija, levkopenija, anemija, trombocitopenija, driska, bruhanje, 
navzea, zmanjšanje apetita, disgevzija, omotica, alopecija, pruritus, izpuščaj, utrujenost, pireksija, povečana vrednost alanin-aminotransferaze, povečana vrednost aspartat-a-
minotransferaze Pogosti: limfopenija, povečano solzenje, venska trombembolija, intersticijska pljučna bolezen (ILD)/pnevmonitis, suha koža, mišična šibkost Občasni: febrilna 
nevtropenija Rok uporabnosti: 3 leta Posebna navodila za shranjevanje: Za shranjevanje zdravila niso potrebna posebna navodila. Imetnik dovoljenja za promet z zdravilom: 
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528BJ, Utrecht, Nizozemska. Datum prve odobritve dovoljenja za promet: 27. september 2018 Datum zadnje revizije 
besedila: 19.7.2021 Režim izdaje: Rp/Spec - Predpisovanje in izdaja zdravila je le na recept zdravnika specialista ustreznega področja medicine ali od njega pooblaščenega 
zdravnika. 
Reference: 
1. Povzetek glavnih značilnosti zdravila Verzenios. Datum zadnje revizije besedila: 19.7.2021. 2. Povzetek glavnih značilnosti zdravila Ibrance. Dostop preverjen 
10.4.2020. 3. Povzetek glavnih značilnosti zdravila Kisqali. Dostop preverjen 10.4.2020.
Pomembno: Predpisovanje in izdaja zdravila je le na recept zdravnika specialista ustreznega področja medicine ali od njega pooblaščenega zdravnika. Pred 
predpisovanjem zdravila Verzenios si preberite zadnji veljavni Povzetek glavnih značilnosti zdravil. Podrobne informacije o zdravilu so objavljene na spletni 
strani Evropske agencije za zdravila http://www.ema.europa.eu
Eli Lilly farmacevtska družba, d.o.o., Dunajska cesta 167, 1000 Ljubljana, telefon 01 / 580 00 10, faks 01 / 569 17 05















Bolniki morajo imeti 
dostop do zdravil, 
ki jih potrebujejo.
S K R B I M O  Z A  V A S
Družba Viatris po celem svetu 
zdravnikom in bolnikom zagotavlja 
dostop do visokokakovostnih 
bioloških zdravil.
Slednjega zagotavljajo 
zavezanost h kontinuiranemu 
razvoju, kakovostnim raziskavam, 
nadzoru kakovosti in logistični 
odličnosti. To je naš svet. Naš 
svet je svet, ki mu je mar za vas.









8 čitalniških mest 
5.300 knjig
6.000 e-revij
vsak delovni dan od 8. do 15. ure
www.onko-i.si/strokovna_knjiznica
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